<!DOCTYPE html><html  lang="en" data-capo=""><head><meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>Frontiers | Assessing the effectiveness and safety of Patisiran and Vutrisiran in ATTRv amyloidosis with polyneuropathy: a systematic review</title>
<link rel="stylesheet" href="/ap-2024/_nuxt/entry.CWBB-NGm.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/vue-core.B-WA3Vg5.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/explainer.CMppEa5M.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleDetails.B93eTAmx.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleLayoutHeader.CKWUz2Al.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/AnnouncementCard.Db7nmstV.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/FloatingButtons.xuP8gC33.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleEvent.D0PaxIW7.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/SimilarArticles.BMee4Fk4.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleTemplateBanner.CXmOJ7NH.css">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/v1IBIWh4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/B674Mi_H.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BXedFy5e.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/eQMj-Fph.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Y8NTh2i4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUyL5Z_3.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/m8mdd2tc.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DHv8pTSw.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BHPWSuhB.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/x5HZk7Le.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CNJXQ6ZR.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dss5ciUI.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Do5q9QoL.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BhVAcJSK.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/y69VltF1.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Bw-bWKkJ.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/sQBxgu5L.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/D5YKKJGW.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CSLdjdGS.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUN89Jk2.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CCeQzihV.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DVDwh0-U.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dw4ta0fP.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CYv-CzHi.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/U-mJlaMn.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/NhyIC1F3.js">
<link rel="prefetch" as="style" crossorigin href="/ap-2024/_nuxt/ArticleHubLayout.q6CU8_bN.css">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/CKQJuUlk.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/D3plh7Cs.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/GWtHKqLR.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/DS3EY-DL.js">
<meta name="theme-color" content="#0C4DED">
<meta name="mobile-web-app-capable" content="yes">
<meta name="apple-mobile-web-app-capable" content="yes">
<script type="text/javascript" data-hid="4cd079c">window.NREUM||(NREUM={});NREUM.info = {"agent":"","beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","licenseKey":"598a124f17","applicationID":"586843029","agentToken":null,"applicationTime":3.581048,"transactionName":"MQcDMkECCkNSW0YMWghNLwlBDgVcWkJXAWAUC04MXBYWXlJUQUpbAxcTCV8MA0kcWUARXAUOBBUcSUtWXV1HFxtUUlNSHVJQBgYPBlIaABcNCg==","queueTime":0,"ttGuid":"ace0b98ff26a3e2d"}; (window.NREUM||(NREUM={})).init={privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]},feature_flags:["soft_nav"],distributed_tracing:{enabled:true}};(window.NREUM||(NREUM={})).loader_config={agentID:"594460232",accountID:"230385",trustKey:"230385",xpid:"VgUHUl5WGwYIUllWBAEFXw==",licenseKey:"598a124f17",applicationID:"586843029",browserID:"594460232"};;/*! For license information please see nr-loader-spa-1.303.0.min.js.LICENSE.txt */
(()=>{var e,t,r={384:(e,t,r)=>{"use strict";r.d(t,{NT:()=>s,US:()=>d,Zm:()=>a,bQ:()=>u,dV:()=>c,pV:()=>l});var n=r(6154),i=r(1863),o=r(1910);const s={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return n.gm.NREUM||(n.gm.NREUM={}),void 0===n.gm.newrelic&&(n.gm.newrelic=n.gm.NREUM),n.gm.NREUM}function c(){let e=a();return e.o||(e.o={ST:n.gm.setTimeout,SI:n.gm.setImmediate||n.gm.setInterval,CT:n.gm.clearTimeout,XHR:n.gm.XMLHttpRequest,REQ:n.gm.Request,EV:n.gm.Event,PR:n.gm.Promise,MO:n.gm.MutationObserver,FETCH:n.gm.fetch,WS:n.gm.WebSocket},(0,o.i)(...Object.values(e.o))),e}function u(e,t){let r=a();r.initializedAgents??={},t.initializedAt={ms:(0,i.t)(),date:new Date},r.initializedAgents[e]=t}function d(e,t){a()[e]=t}function l(){return function(){let e=a();const t=e.info||{};e.info={beacon:s.beacon,errorBeacon:s.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),c(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},782:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewTiming},860:(e,t,r)=>{"use strict";r.d(t,{$J:()=>d,K7:()=>c,P3:()=>u,XX:()=>i,Yy:()=>a,df:()=>o,qY:()=>n,v4:()=>s});const n="events",i="jserrors",o="browser/blobs",s="rum",a="browser/logs",c={ajax:"ajax",genericEvents:"generic_events",jserrors:i,logging:"logging",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",softNav:"soft_navigations",spa:"spa"},u={[c.pageViewEvent]:1,[c.pageViewTiming]:2,[c.metrics]:3,[c.jserrors]:4,[c.spa]:5,[c.ajax]:6,[c.sessionTrace]:7,[c.softNav]:8,[c.sessionReplay]:9,[c.logging]:10,[c.genericEvents]:11},d={[c.pageViewEvent]:s,[c.pageViewTiming]:n,[c.ajax]:n,[c.spa]:n,[c.softNav]:n,[c.metrics]:i,[c.jserrors]:i,[c.sessionTrace]:o,[c.sessionReplay]:o,[c.logging]:a,[c.genericEvents]:"ins"}},944:(e,t,r)=>{"use strict";r.d(t,{R:()=>i});var n=r(3241);function i(e,t){"function"==typeof console.debug&&(console.debug("New Relic Warning: https://github.com/newrelic/newrelic-browser-agent/blob/main/docs/warning-codes.md#".concat(e),t),(0,n.W)({agentIdentifier:null,drained:null,type:"data",name:"warn",feature:"warn",data:{code:e,secondary:t}}))}},993:(e,t,r)=>{"use strict";r.d(t,{A$:()=>o,ET:()=>s,TZ:()=>a,p_:()=>i});var n=r(860);const i={ERROR:"ERROR",WARN:"WARN",INFO:"INFO",DEBUG:"DEBUG",TRACE:"TRACE"},o={OFF:0,ERROR:1,WARN:2,INFO:3,DEBUG:4,TRACE:5},s="log",a=n.K7.logging},1687:(e,t,r)=>{"use strict";r.d(t,{Ak:()=>u,Ze:()=>f,x3:()=>d});var n=r(3241),i=r(7836),o=r(3606),s=r(860),a=r(2646);const c={};function u(e,t){const r={staged:!1,priority:s.P3[t]||0};l(e),c[e].get(t)||c[e].set(t,r)}function d(e,t){e&&c[e]&&(c[e].get(t)&&c[e].delete(t),p(e,t,!1),c[e].size&&h(e))}function l(e){if(!e)throw new Error("agentIdentifier required");c[e]||(c[e]=new Map)}function f(e="",t="feature",r=!1){if(l(e),!e||!c[e].get(t)||r)return p(e,t);c[e].get(t).staged=!0,h(e)}function h(e){const t=Array.from(c[e]);t.every(([e,t])=>t.staged)&&(t.sort((e,t)=>e[1].priority-t[1].priority),t.forEach(([t])=>{c[e].delete(t),p(e,t)}))}function p(e,t,r=!0){const s=e?i.ee.get(e):i.ee,c=o.i.handlers;if(!s.aborted&&s.backlog&&c){if((0,n.W)({agentIdentifier:e,type:"lifecycle",name:"drain",feature:t}),r){const e=s.backlog[t],r=c[t];if(r){for(let t=0;e&&t<e.length;++t)g(e[t],r);Object.entries(r).forEach(([e,t])=>{Object.values(t||{}).forEach(t=>{t[0]?.on&&t[0]?.context()instanceof a.y&&t[0].on(e,t[1])})})}}s.isolatedBacklog||delete c[t],s.backlog[t]=null,s.emit("drain-"+t,[])}}function g(e,t){var r=e[1];Object.values(t[r]||{}).forEach(t=>{var r=e[0];if(t[0]===r){var n=t[1],i=e[3],o=e[2];n.apply(i,o)}})}},1741:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(944),i=r(4261);class o{#e(e,...t){if(this[e]!==o.prototype[e])return this[e](...t);(0,n.R)(35,e)}addPageAction(e,t){return this.#e(i.hG,e,t)}register(e){return this.#e(i.eY,e)}recordCustomEvent(e,t){return this.#e(i.fF,e,t)}setPageViewName(e,t){return this.#e(i.Fw,e,t)}setCustomAttribute(e,t,r){return this.#e(i.cD,e,t,r)}noticeError(e,t){return this.#e(i.o5,e,t)}setUserId(e){return this.#e(i.Dl,e)}setApplicationVersion(e){return this.#e(i.nb,e)}setErrorHandler(e){return this.#e(i.bt,e)}addRelease(e,t){return this.#e(i.k6,e,t)}log(e,t){return this.#e(i.$9,e,t)}start(){return this.#e(i.d3)}finished(e){return this.#e(i.BL,e)}recordReplay(){return this.#e(i.CH)}pauseReplay(){return this.#e(i.Tb)}addToTrace(e){return this.#e(i.U2,e)}setCurrentRouteName(e){return this.#e(i.PA,e)}interaction(e){return this.#e(i.dT,e)}wrapLogger(e,t,r){return this.#e(i.Wb,e,t,r)}measure(e,t){return this.#e(i.V1,e,t)}consent(e){return this.#e(i.Pv,e)}}},1863:(e,t,r)=>{"use strict";function n(){return Math.floor(performance.now())}r.d(t,{t:()=>n})},1910:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(944);const i=new Map;function o(...e){return e.every(e=>{if(i.has(e))return i.get(e);const t="function"==typeof e&&e.toString().includes("[native code]");return t||(0,n.R)(64,e?.name||e?.toString()),i.set(e,t),t})}},2555:(e,t,r)=>{"use strict";r.d(t,{D:()=>a,f:()=>s});var n=r(384),i=r(8122);const o={beacon:n.NT.beacon,errorBeacon:n.NT.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0};function s(e){try{return!!e.licenseKey&&!!e.errorBeacon&&!!e.applicationID}catch(e){return!1}}const a=e=>(0,i.a)(e,o)},2614:(e,t,r)=>{"use strict";r.d(t,{BB:()=>s,H3:()=>n,g:()=>u,iL:()=>c,tS:()=>a,uh:()=>i,wk:()=>o});const n="NRBA",i="SESSION",o=144e5,s=18e5,a={STARTED:"session-started",PAUSE:"session-pause",RESET:"session-reset",RESUME:"session-resume",UPDATE:"session-update"},c={SAME_TAB:"same-tab",CROSS_TAB:"cross-tab"},u={OFF:0,FULL:1,ERROR:2}},2646:(e,t,r)=>{"use strict";r.d(t,{y:()=>n});class n{constructor(e){this.contextId=e}}},2843:(e,t,r)=>{"use strict";r.d(t,{u:()=>i});var n=r(3878);function i(e,t=!1,r,i){(0,n.DD)("visibilitychange",function(){if(t)return void("hidden"===document.visibilityState&&e());e(document.visibilityState)},r,i)}},3241:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(6154);const i="newrelic";function o(e={}){try{n.gm.dispatchEvent(new CustomEvent(i,{detail:e}))}catch(e){}}},3304:(e,t,r)=>{"use strict";r.d(t,{A:()=>o});var n=r(7836);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())??""}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}return""}}},3333:(e,t,r)=>{"use strict";r.d(t,{$v:()=>d,TZ:()=>n,Xh:()=>c,Zp:()=>i,kd:()=>u,mq:()=>a,nf:()=>s,qN:()=>o});const n=r(860).K7.genericEvents,i=["auxclick","click","copy","keydown","paste","scrollend"],o=["focus","blur"],s=4,a=1e3,c=2e3,u=["PageAction","UserAction","BrowserPerformance"],d={RESOURCES:"experimental.resources",REGISTER:"register"}},3434:(e,t,r)=>{"use strict";r.d(t,{Jt:()=>o,YM:()=>u});var n=r(7836),i=r(5607);const o="nr@original:".concat(i.W),s=50;var a=Object.prototype.hasOwnProperty,c=!1;function u(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");const s="-"===n.charAt(0);for(let a=0;a<t.length;a++){const c=t[a],u=e[c];l(u)||(e[c]=r(u,s?c+n:n,i,c,o))}},r.flag=o,r;function r(t,r,n,c,u){return l(t)?t:(r||(r=""),nrWrapper[o]=t,function(e,t,r){if(Object.defineProperty&&Object.keys)try{return Object.keys(e).forEach(function(r){Object.defineProperty(t,r,{get:function(){return e[r]},set:function(t){return e[r]=t,t}})}),t}catch(e){d([e],r)}for(var n in e)a.call(e,n)&&(t[n]=e[n])}(t,nrWrapper,e),nrWrapper);function nrWrapper(){var o,a,l,f;let h;try{a=this,o=[...arguments],l="function"==typeof n?n(o,a):n||{}}catch(t){d([t,"",[o,a,c],l],e)}i(r+"start",[o,a,c],l,u);const p=performance.now();let g;try{return f=t.apply(a,o),g=performance.now(),f}catch(e){throw g=performance.now(),i(r+"err",[o,a,e],l,u),h=e,h}finally{const e=g-p,t={start:p,end:g,duration:e,isLongTask:e>=s,methodName:c,thrownError:h};t.isLongTask&&i("long-task",[t,a],l,u),i(r+"end",[o,a,f],l,u)}}}function i(r,n,i,o){if(!c||t){var s=c;c=!0;try{e.emit(r,n,i,t,o)}catch(t){d([t,r,n,i],e)}c=s}}}function d(e,t){t||(t=n.ee);try{t.emit("internal-error",e)}catch(e){}}function l(e){return!(e&&"function"==typeof e&&e.apply&&!e[o])}},3606:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(9908);o.on=s;var i=o.handlers={};function o(e,t,r,o){s(o||n.d,i,e,t,r)}function s(e,t,r,i,o){o||(o="feature"),e||(e=n.d);var s=t[o]=t[o]||{};(s[r]=s[r]||[]).push([e,i])}},3738:(e,t,r)=>{"use strict";r.d(t,{He:()=>i,Kp:()=>a,Lc:()=>u,Rz:()=>d,TZ:()=>n,bD:()=>o,d3:()=>s,jx:()=>l,sl:()=>f,uP:()=>c});const n=r(860).K7.sessionTrace,i="bstResource",o="resource",s="-start",a="-end",c="fn"+s,u="fn"+a,d="pushState",l=1e3,f=3e4},3785:(e,t,r)=>{"use strict";r.d(t,{R:()=>c,b:()=>u});var n=r(9908),i=r(1863),o=r(860),s=r(8154),a=r(993);function c(e,t,r={},c=a.p_.INFO,u,d=(0,i.t)()){(0,n.p)(s.xV,["API/logging/".concat(c.toLowerCase(),"/called")],void 0,o.K7.metrics,e),(0,n.p)(a.ET,[d,t,r,c,u],void 0,o.K7.logging,e)}function u(e){return"string"==typeof e&&Object.values(a.p_).some(t=>t===e.toUpperCase().trim())}},3878:(e,t,r)=>{"use strict";function n(e,t){return{capture:e,passive:!1,signal:t}}function i(e,t,r=!1,i){window.addEventListener(e,t,n(r,i))}function o(e,t,r=!1,i){document.addEventListener(e,t,n(r,i))}r.d(t,{DD:()=>o,jT:()=>n,sp:()=>i})},3962:(e,t,r)=>{"use strict";r.d(t,{AM:()=>s,O2:()=>l,OV:()=>o,Qu:()=>f,TZ:()=>c,ih:()=>h,pP:()=>a,t1:()=>d,tC:()=>i,wD:()=>u});var n=r(860);const i=["click","keydown","submit"],o="popstate",s="api",a="initialPageLoad",c=n.K7.softNav,u=5e3,d=500,l={INITIAL_PAGE_LOAD:"",ROUTE_CHANGE:1,UNSPECIFIED:2},f={INTERACTION:1,AJAX:2,CUSTOM_END:3,CUSTOM_TRACER:4},h={IP:"in progress",PF:"pending finish",FIN:"finished",CAN:"cancelled"}},4234:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(7836),i=r(1687);class o{constructor(e,t){this.agentIdentifier=e,this.ee=n.ee.get(e),this.featureName=t,this.blocked=!1}deregisterDrain(){(0,i.x3)(this.agentIdentifier,this.featureName)}}},4261:(e,t,r)=>{"use strict";r.d(t,{$9:()=>d,BL:()=>c,CH:()=>p,Dl:()=>R,Fw:()=>w,PA:()=>v,Pl:()=>n,Pv:()=>A,Tb:()=>f,U2:()=>s,V1:()=>E,Wb:()=>T,bt:()=>y,cD:()=>b,d3:()=>x,dT:()=>u,eY:()=>g,fF:()=>h,hG:()=>o,hw:()=>i,k6:()=>a,nb:()=>m,o5:()=>l});const n="api-",i=n+"ixn-",o="addPageAction",s="addToTrace",a="addRelease",c="finished",u="interaction",d="log",l="noticeError",f="pauseReplay",h="recordCustomEvent",p="recordReplay",g="register",m="setApplicationVersion",v="setCurrentRouteName",b="setCustomAttribute",y="setErrorHandler",w="setPageViewName",R="setUserId",x="start",T="wrapLogger",E="measure",A="consent"},4387:(e,t,r)=>{"use strict";function n(e={}){return!(!e.id||!e.name)}function i(e){return"string"==typeof e&&e.trim().length<501||"number"==typeof e}function o(e,t){if(2!==t?.harvestEndpointVersion)return{};const r=t.agentRef.runtime.appMetadata.agents[0].entityGuid;return n(e)?{"mfe.id":e.id,"mfe.name":e.name,eventSource:e.eventSource,"parent.id":e.parent?.id||r}:{"entity.guid":r,appId:t.agentRef.info.applicationID}}r.d(t,{Ux:()=>o,c7:()=>n,yo:()=>i})},5205:(e,t,r)=>{"use strict";r.d(t,{j:()=>_});var n=r(384),i=r(1741);var o=r(2555),s=r(3333);const a=e=>{if(!e||"string"!=typeof e)return!1;try{document.createDocumentFragment().querySelector(e)}catch{return!1}return!0};var c=r(2614),u=r(944),d=r(8122);const l="[data-nr-mask]",f=e=>(0,d.a)(e,(()=>{const e={feature_flags:[],experimental:{allow_registered_children:!1,resources:!1},mask_selector:"*",block_selector:"[data-nr-block]",mask_input_options:{color:!1,date:!1,"datetime-local":!1,email:!1,month:!1,number:!1,range:!1,search:!1,tel:!1,text:!1,time:!1,url:!1,week:!1,textarea:!1,select:!1,password:!0}};return{ajax:{deny_list:void 0,block_internal:!0,enabled:!0,autoStart:!0},api:{get allow_registered_children(){return e.feature_flags.includes(s.$v.REGISTER)||e.experimental.allow_registered_children},set allow_registered_children(t){e.experimental.allow_registered_children=t},duplicate_registered_data:!1},browser_consent_mode:{enabled:!1},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},get feature_flags(){return e.feature_flags},set feature_flags(t){e.feature_flags=t},generic_events:{enabled:!0,autoStart:!0},harvest:{interval:30},jserrors:{enabled:!0,autoStart:!0},logging:{enabled:!0,autoStart:!0},metrics:{enabled:!0,autoStart:!0},obfuscate:void 0,page_action:{enabled:!0},page_view_event:{enabled:!0,autoStart:!0},page_view_timing:{enabled:!0,autoStart:!0},performance:{capture_marks:!1,capture_measures:!1,capture_detail:!0,resources:{get enabled(){return e.feature_flags.includes(s.$v.RESOURCES)||e.experimental.resources},set enabled(t){e.experimental.resources=t},asset_types:[],first_party_domains:[],ignore_newrelic:!0}},privacy:{cookies_enabled:!0},proxy:{assets:void 0,beacon:void 0},session:{expiresMs:c.wk,inactiveMs:c.BB},session_replay:{autoStart:!0,enabled:!1,preload:!1,sampling_rate:10,error_sampling_rate:100,collect_fonts:!1,inline_images:!1,fix_stylesheets:!0,mask_all_inputs:!0,get mask_text_selector(){return e.mask_selector},set mask_text_selector(t){a(t)?e.mask_selector="".concat(t,",").concat(l):""===t||null===t?e.mask_selector=l:(0,u.R)(5,t)},get block_class(){return"nr-block"},get ignore_class(){return"nr-ignore"},get mask_text_class(){return"nr-mask"},get block_selector(){return e.block_selector},set block_selector(t){a(t)?e.block_selector+=",".concat(t):""!==t&&(0,u.R)(6,t)},get mask_input_options(){return e.mask_input_options},set mask_input_options(t){t&&"object"==typeof t?e.mask_input_options={...t,password:!0}:(0,u.R)(7,t)}},session_trace:{enabled:!0,autoStart:!0},soft_navigations:{enabled:!0,autoStart:!0},spa:{enabled:!0,autoStart:!0},ssl:void 0,user_actions:{enabled:!0,elementAttributes:["id","className","tagName","type"]}}})());var h=r(6154),p=r(9324);let g=0;const m={buildEnv:p.F3,distMethod:p.Xs,version:p.xv,originTime:h.WN},v={consented:!1},b={appMetadata:{},get consented(){return this.session?.state?.consent||v.consented},set consented(e){v.consented=e},customTransaction:void 0,denyList:void 0,disabled:!1,harvester:void 0,isolatedBacklog:!1,isRecording:!1,loaderType:void 0,maxBytes:3e4,obfuscator:void 0,onerror:void 0,ptid:void 0,releaseIds:{},session:void 0,timeKeeper:void 0,registeredEntities:[],jsAttributesMetadata:{bytes:0},get harvestCount(){return++g}},y=e=>{const t=(0,d.a)(e,b),r=Object.keys(m).reduce((e,t)=>(e[t]={value:m[t],writable:!1,configurable:!0,enumerable:!0},e),{});return Object.defineProperties(t,r)};var w=r(5701);const R=e=>{const t=e.startsWith("http");e+="/",r.p=t?e:"https://"+e};var x=r(7836),T=r(3241);const E={accountID:void 0,trustKey:void 0,agentID:void 0,licenseKey:void 0,applicationID:void 0,xpid:void 0},A=e=>(0,d.a)(e,E),S=new Set;function _(e,t={},r,s){let{init:a,info:c,loader_config:u,runtime:d={},exposed:l=!0}=t;if(!c){const e=(0,n.pV)();a=e.init,c=e.info,u=e.loader_config}e.init=f(a||{}),e.loader_config=A(u||{}),c.jsAttributes??={},h.bv&&(c.jsAttributes.isWorker=!0),e.info=(0,o.D)(c);const p=e.init,g=[c.beacon,c.errorBeacon];S.has(e.agentIdentifier)||(p.proxy.assets&&(R(p.proxy.assets),g.push(p.proxy.assets)),p.proxy.beacon&&g.push(p.proxy.beacon),e.beacons=[...g],function(e){const t=(0,n.pV)();Object.getOwnPropertyNames(i.W.prototype).forEach(r=>{const n=i.W.prototype[r];if("function"!=typeof n||"constructor"===n)return;let o=t[r];e[r]&&!1!==e.exposed&&"micro-agent"!==e.runtime?.loaderType&&(t[r]=(...t)=>{const n=e[r](...t);return o?o(...t):n})})}(e),(0,n.US)("activatedFeatures",w.B),e.runSoftNavOverSpa&&=!0===p.soft_navigations.enabled&&p.feature_flags.includes("soft_nav")),d.denyList=[...p.ajax.deny_list||[],...p.ajax.block_internal?g:[]],d.ptid=e.agentIdentifier,d.loaderType=r,e.runtime=y(d),S.has(e.agentIdentifier)||(e.ee=x.ee.get(e.agentIdentifier),e.exposed=l,(0,T.W)({agentIdentifier:e.agentIdentifier,drained:!!w.B?.[e.agentIdentifier],type:"lifecycle",name:"initialize",feature:void 0,data:e.config})),S.add(e.agentIdentifier)}},5270:(e,t,r)=>{"use strict";r.d(t,{Aw:()=>s,SR:()=>o,rF:()=>a});var n=r(384),i=r(7767);function o(e){return!!(0,n.dV)().o.MO&&(0,i.V)(e)&&!0===e?.session_trace.enabled}function s(e){return!0===e?.session_replay.preload&&o(e)}function a(e,t){try{if("string"==typeof t?.type){if("password"===t.type.toLowerCase())return"*".repeat(e?.length||0);if(void 0!==t?.dataset?.nrUnmask||t?.classList?.contains("nr-unmask"))return e}}catch(e){}return"string"==typeof e?e.replace(/[\S]/g,"*"):"*".repeat(e?.length||0)}},5289:(e,t,r)=>{"use strict";r.d(t,{GG:()=>o,Qr:()=>a,sB:()=>s});var n=r(3878);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.sp)("load",e,t)}function s(e){if(i())return e();(0,n.DD)("DOMContentLoaded",e)}function a(e){if(i())return e();(0,n.sp)("popstate",e)}},5607:(e,t,r)=>{"use strict";r.d(t,{W:()=>n});const n=(0,r(9566).bz)()},5701:(e,t,r)=>{"use strict";r.d(t,{B:()=>o,t:()=>s});var n=r(3241);const i=new Set,o={};function s(e,t){const r=t.agentIdentifier;o[r]??={},e&&"object"==typeof e&&(i.has(r)||(t.ee.emit("rumresp",[e]),o[r]=e,i.add(r),(0,n.W)({agentIdentifier:r,loaded:!0,drained:!0,type:"lifecycle",name:"load",feature:void 0,data:e})))}},6154:(e,t,r)=>{"use strict";r.d(t,{A4:()=>a,OF:()=>d,RI:()=>i,WN:()=>h,bv:()=>o,gm:()=>s,lR:()=>f,m:()=>u,mw:()=>c,sb:()=>l});var n=r(1863);const i="undefined"!=typeof window&&!!window.document,o="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),s=i?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a="complete"===s?.document?.readyState,c=Boolean("hidden"===s?.document?.visibilityState),u=""+s?.location,d=/iPad|iPhone|iPod/.test(s.navigator?.userAgent),l=d&&"undefined"==typeof SharedWorker,f=(()=>{const e=s.navigator?.userAgent?.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),h=Date.now()-(0,n.t)()},6344:(e,t,r)=>{"use strict";r.d(t,{BB:()=>d,Qb:()=>l,TZ:()=>i,Ug:()=>s,Vh:()=>o,_s:()=>a,bc:()=>u,yP:()=>c});var n=r(2614);const i=r(860).K7.sessionReplay,o="errorDuringReplay",s=.12,a={DomContentLoaded:0,Load:1,FullSnapshot:2,IncrementalSnapshot:3,Meta:4,Custom:5},c={[n.g.ERROR]:15e3,[n.g.FULL]:3e5,[n.g.OFF]:0},u={RESET:{message:"Session was reset",sm:"Reset"},IMPORT:{message:"Recorder failed to import",sm:"Import"},TOO_MANY:{message:"429: Too Many Requests",sm:"Too-Many"},TOO_BIG:{message:"Payload was too large",sm:"Too-Big"},CROSS_TAB:{message:"Session Entity was set to OFF on another tab",sm:"Cross-Tab"},ENTITLEMENTS:{message:"Session Replay is not allowed and will not be started",sm:"Entitlement"}},d=5e3,l={API:"api",RESUME:"resume",SWITCH_TO_FULL:"switchToFull",INITIALIZE:"initialize",PRELOAD:"preload"}},6389:(e,t,r)=>{"use strict";function n(e,t=500,r={}){const n=r?.leading||!1;let i;return(...r)=>{n&&void 0===i&&(e.apply(this,r),i=setTimeout(()=>{i=clearTimeout(i)},t)),n||(clearTimeout(i),i=setTimeout(()=>{e.apply(this,r)},t))}}function i(e){let t=!1;return(...r)=>{t||(t=!0,e.apply(this,r))}}r.d(t,{J:()=>i,s:()=>n})},6630:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewEvent},6774:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.jserrors},7295:(e,t,r)=>{"use strict";r.d(t,{Xv:()=>s,gX:()=>i,iW:()=>o});var n=[];function i(e){if(!e||o(e))return!1;if(0===n.length)return!0;for(var t=0;t<n.length;t++){var r=n[t];if("*"===r.hostname)return!1;if(a(r.hostname,e.hostname)&&c(r.pathname,e.pathname))return!1}return!0}function o(e){return void 0===e.hostname}function s(e){if(n=[],e&&e.length)for(var t=0;t<e.length;t++){let r=e[t];if(!r)continue;0===r.indexOf("http://")?r=r.substring(7):0===r.indexOf("https://")&&(r=r.substring(8));const i=r.indexOf("/");let o,s;i>0?(o=r.substring(0,i),s=r.substring(i)):(o=r,s="");let[a]=o.split(":");n.push({hostname:a,pathname:s})}}function a(e,t){return!(e.length>t.length)&&t.indexOf(e)===t.length-e.length}function c(e,t){return 0===e.indexOf("/")&&(e=e.substring(1)),0===t.indexOf("/")&&(t=t.substring(1)),""===e||e===t}},7378:(e,t,r)=>{"use strict";r.d(t,{$p:()=>x,BR:()=>b,Kp:()=>R,L3:()=>y,Lc:()=>c,NC:()=>o,SG:()=>d,TZ:()=>i,U6:()=>p,UT:()=>m,d3:()=>w,dT:()=>f,e5:()=>E,gx:()=>v,l9:()=>l,oW:()=>h,op:()=>g,rw:()=>u,tH:()=>A,uP:()=>a,wW:()=>T,xq:()=>s});var n=r(384);const i=r(860).K7.spa,o=["click","submit","keypress","keydown","keyup","change"],s=999,a="fn-start",c="fn-end",u="cb-start",d="api-ixn-",l="remaining",f="interaction",h="spaNode",p="jsonpNode",g="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=(0,n.dV)().o.ST,w="-start",R="-end",x="-body",T="cb"+R,E="jsTime",A="fetch"},7485:(e,t,r)=>{"use strict";r.d(t,{D:()=>i});var n=r(6154);function i(e){if(0===(e||"").indexOf("data:"))return{protocol:"data"};try{const t=new URL(e,location.href),r={port:t.port,hostname:t.hostname,pathname:t.pathname,search:t.search,protocol:t.protocol.slice(0,t.protocol.indexOf(":")),sameOrigin:t.protocol===n.gm?.location?.protocol&&t.host===n.gm?.location?.host};return r.port&&""!==r.port||("http:"===t.protocol&&(r.port="80"),"https:"===t.protocol&&(r.port="443")),r.pathname&&""!==r.pathname?r.pathname.startsWith("/")||(r.pathname="/".concat(r.pathname)):r.pathname="/",r}catch(e){return{}}}},7699:(e,t,r)=>{"use strict";r.d(t,{It:()=>o,KC:()=>a,No:()=>i,qh:()=>s});var n=r(860);const i=16e3,o=1e6,s="SESSION_ERROR",a={[n.K7.logging]:!0,[n.K7.genericEvents]:!1,[n.K7.jserrors]:!1,[n.K7.ajax]:!1}},7767:(e,t,r)=>{"use strict";r.d(t,{V:()=>i});var n=r(6154);const i=e=>n.RI&&!0===e?.privacy.cookies_enabled},7836:(e,t,r)=>{"use strict";r.d(t,{P:()=>a,ee:()=>c});var n=r(384),i=r(8990),o=r(2646),s=r(5607);const a="nr@context:".concat(s.W),c=function e(t,r){var n={},s={},d={},l=!1;try{l=16===r.length&&u.initializedAgents?.[r]?.runtime.isolatedBacklog}catch(e){}var f={on:p,addEventListener:p,removeEventListener:function(e,t){var r=n[e];if(!r)return;for(var i=0;i<r.length;i++)r[i]===t&&r.splice(i,1)},emit:function(e,r,n,i,o){!1!==o&&(o=!0);if(c.aborted&&!i)return;t&&o&&t.emit(e,r,n);var a=h(n);g(e).forEach(e=>{e.apply(a,r)});var u=v()[s[e]];u&&u.push([f,e,r,a]);return a},get:m,listeners:g,context:h,buffer:function(e,t){const r=v();if(t=t||"feature",f.aborted)return;Object.entries(e||{}).forEach(([e,n])=>{s[n]=t,t in r||(r[t]=[])})},abort:function(){f._aborted=!0,Object.keys(f.backlog).forEach(e=>{delete f.backlog[e]})},isBuffering:function(e){return!!v()[s[e]]},debugId:r,backlog:l?{}:t&&"object"==typeof t.backlog?t.backlog:{},isolatedBacklog:l};return Object.defineProperty(f,"aborted",{get:()=>{let e=f._aborted||!1;return e||(t&&(e=t.aborted),e)}}),f;function h(e){return e&&e instanceof o.y?e:e?(0,i.I)(e,a,()=>new o.y(a)):new o.y(a)}function p(e,t){n[e]=g(e).concat(t)}function g(e){return n[e]||[]}function m(t){return d[t]=d[t]||e(f,t)}function v(){return f.backlog}}(void 0,"globalEE"),u=(0,n.Zm)();u.ee||(u.ee=c)},8122:(e,t,r)=>{"use strict";r.d(t,{a:()=>i});var n=r(944);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.R)(3);if(!t||"object"!=typeof t)return(0,n.R)(4);const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let s in o)if(void 0!==e[s])try{if(null===e[s]){r[s]=null;continue}Array.isArray(e[s])&&Array.isArray(t[s])?r[s]=Array.from(new Set([...e[s],...t[s]])):"object"==typeof e[s]&&"object"==typeof t[s]?r[s]=i(e[s],t[s]):r[s]=e[s]}catch(e){r[s]||(0,n.R)(1,e)}return r}catch(e){(0,n.R)(2,e)}}},8139:(e,t,r)=>{"use strict";r.d(t,{u:()=>f});var n=r(7836),i=r(3434),o=r(8990),s=r(6154);const a={},c=s.gm.XMLHttpRequest,u="addEventListener",d="removeEventListener",l="nr@wrapped:".concat(n.P);function f(e){var t=function(e){return(e||n.ee).get("events")}(e);if(a[t.debugId]++)return t;a[t.debugId]=1;var r=(0,i.YM)(t,!0);function f(e){r.inPlace(e,[u,d],"-",p)}function p(e,t){return e[1]}return"getPrototypeOf"in Object&&(s.RI&&h(document,f),c&&h(c.prototype,f),h(s.gm,f)),t.on(u+"-start",function(e,t){var n=e[1];if(null!==n&&("function"==typeof n||"object"==typeof n)&&"newrelic"!==e[0]){var i=(0,o.I)(n,l,function(){var e={object:function(){if("function"!=typeof n.handleEvent)return;return n.handleEvent.apply(n,arguments)},function:n}[typeof n];return e?r(e,"fn-",null,e.name||"anonymous"):n});this.wrapped=e[1]=i}}),t.on(d+"-start",function(e){e[1]=this.wrapped||e[1]}),t}function h(e,t,...r){let n=e;for(;"object"==typeof n&&!Object.prototype.hasOwnProperty.call(n,u);)n=Object.getPrototypeOf(n);n&&t(n,...r)}},8154:(e,t,r)=>{"use strict";r.d(t,{z_:()=>o,XG:()=>a,TZ:()=>n,rs:()=>i,xV:()=>s});r(6154),r(9566),r(384);const n=r(860).K7.metrics,i="sm",o="cm",s="storeSupportabilityMetrics",a="storeEventMetrics"},8374:(e,t,r)=>{r.nc=(()=>{try{return document?.currentScript?.nonce}catch(e){}return""})()},8990:(e,t,r)=>{"use strict";r.d(t,{I:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},9300:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.ajax},9324:(e,t,r)=>{"use strict";r.d(t,{AJ:()=>s,F3:()=>i,Xs:()=>o,Yq:()=>a,xv:()=>n});const n="1.303.0",i="PROD",o="CDN",s="@newrelic/rrweb",a="1.0.1"},9566:(e,t,r)=>{"use strict";r.d(t,{LA:()=>a,ZF:()=>c,bz:()=>s,el:()=>u});var n=r(6154);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function s(){const e=n.gm?.crypto||n.gm?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(30))),i.split("").map(e=>"x"===e?o(t,r++).toString(16):"y"===e?(3&o()|8).toString(16):e).join("")}function a(e){const t=n.gm?.crypto||n.gm?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(e)));const s=[];for(var a=0;a<e;a++)s.push(o(r,i++).toString(16));return s.join("")}function c(){return a(16)}function u(){return a(32)}},9908:(e,t,r)=>{"use strict";r.d(t,{d:()=>n,p:()=>i});var n=r(7836).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce((t,r)=>(i.f[r](e,t),t),[])),i.u=e=>({212:"nr-spa-compressor",249:"nr-spa-recorder",478:"nr-spa"}[e]+"-1.303.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA-1.303.0.PROD:",i.l=(r,n,o,s)=>{if(e[r])e[r].push(n);else{var a,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d<u.length;d++){var l=u[d];if(l.getAttribute("src")==r||l.getAttribute("data-webpack")==t+o){a=l;break}}if(!a){c=!0;var f={478:"sha512-Q1pLqcoiNmLHv0rtq3wFkJBA3kofBdRJl0ExDl0mTuAoCBd0qe/1J0XWrDlQKuNlUryL6aZfVkAMPLmoikWIoQ==",249:"sha512-695ZzudsxlMtHKnpDNvkMlJd3tdMtY03IQKVCw9SX12tjUC+f7Nrx5tnWO72Vg9RFf6DSY6wVmM3cEkRM12kkQ==",212:"sha512-18Gx1wIBsppcn0AnKFhwgw4IciNgFxiw3J74W393Ape+wtg4hlg7t6SBKsIE/Dk/tfl2yltgcgBFvYRs283AFg=="};(a=document.createElement("script")).charset="utf-8",i.nc&&a.setAttribute("nonce",i.nc),a.setAttribute("data-webpack",t+o),a.src=r,0!==a.src.indexOf(window.location.origin+"/")&&(a.crossOrigin="anonymous"),f[s]&&(a.integrity=f[s])}e[r]=[n];var h=(t,n)=>{a.onerror=a.onload=null,clearTimeout(p);var i=e[r];if(delete e[r],a.parentNode&&a.parentNode.removeChild(a),i&&i.forEach(e=>e(n)),t)return t(n)},p=setTimeout(h.bind(null,void 0,{type:"timeout",target:a}),12e4);a.onerror=h.bind(null,a.onerror),a.onload=h.bind(null,a.onload),c&&document.head.appendChild(a)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.p="https://js-agent.newrelic.com/",(()=>{var e={38:0,788:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise((r,i)=>n=e[t]=[r,i]);r.push(n[2]=o);var s=i.p+i.u(t),a=new Error;i.l(s,r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),s=r&&r.target&&r.target.src;a.message="Loading chunk "+t+" failed.\n("+o+": "+s+")",a.name="ChunkLoadError",a.type=o,a.request=s,n[1](a)}},"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[s,a,c]=r,u=0;if(s.some(t=>0!==e[t])){for(n in a)i.o(a,n)&&(i.m[n]=a[n]);if(c)c(i)}for(t&&t(r);u<s.length;u++)o=s[u],i.o(e,o)&&e[o]&&e[o][0](),e[o]=0},r=self["webpackChunk:NRBA-1.303.0.PROD"]=self["webpackChunk:NRBA-1.303.0.PROD"]||[];r.forEach(t.bind(null,0)),r.push=t.bind(null,r.push.bind(r))})(),(()=>{"use strict";i(8374);var e=i(9566),t=i(1741);class r extends t.W{agentIdentifier=(0,e.LA)(16)}var n=i(860);const o=Object.values(n.K7);var s=i(5205);var a=i(9908),c=i(1863),u=i(4261),d=i(3241),l=i(944),f=i(5701),h=i(8154);function p(e,t,i,o){const s=o||i;!s||s[e]&&s[e]!==r.prototype[e]||(s[e]=function(){(0,a.p)(h.xV,["API/"+e+"/called"],void 0,n.K7.metrics,i.ee),(0,d.W)({agentIdentifier:i.agentIdentifier,drained:!!f.B?.[i.agentIdentifier],type:"data",name:"api",feature:u.Pl+e,data:{}});try{return t.apply(this,arguments)}catch(e){(0,l.R)(23,e)}})}function g(e,t,r,n,i){const o=e.info;null===r?delete o.jsAttributes[t]:o.jsAttributes[t]=r,(i||null===r)&&(0,a.p)(u.Pl+n,[(0,c.t)(),t,r],void 0,"session",e.ee)}var m=i(1687),v=i(4234),b=i(5289),y=i(6154),w=i(5270),R=i(7767),x=i(6389),T=i(7699);class E extends v.W{constructor(e,t){super(e.agentIdentifier,t),this.agentRef=e,this.abortHandler=void 0,this.featAggregate=void 0,this.loadedSuccessfully=void 0,this.onAggregateImported=new Promise(e=>{this.loadedSuccessfully=e}),this.deferred=Promise.resolve(),!1===e.init[this.featureName].autoStart?this.deferred=new Promise((t,r)=>{this.ee.on("manual-start-all",(0,x.J)(()=>{(0,m.Ak)(e.agentIdentifier,this.featureName),t()}))}):(0,m.Ak)(e.agentIdentifier,t)}importAggregator(e,t,r={}){if(this.featAggregate)return;const n=async()=>{let n;await this.deferred;try{if((0,R.V)(e.init)){const{setupAgentSession:t}=await i.e(478).then(i.bind(i,8766));n=t(e)}}catch(e){(0,l.R)(20,e),this.ee.emit("internal-error",[e]),(0,a.p)(T.qh,[e],void 0,this.featureName,this.ee)}try{if(!this.#t(this.featureName,n,e.init))return(0,m.Ze)(this.agentIdentifier,this.featureName),void this.loadedSuccessfully(!1);const{Aggregate:i}=await t();this.featAggregate=new i(e,r),e.runtime.harvester.initializedAggregates.push(this.featAggregate),this.loadedSuccessfully(!0)}catch(e){(0,l.R)(34,e),this.abortHandler?.(),(0,m.Ze)(this.agentIdentifier,this.featureName,!0),this.loadedSuccessfully(!1),this.ee&&this.ee.abort()}};y.RI?(0,b.GG)(()=>n(),!0):n()}#t(e,t,r){if(this.blocked)return!1;switch(e){case n.K7.sessionReplay:return(0,w.SR)(r)&&!!t;case n.K7.sessionTrace:return!!t;default:return!0}}}var A=i(6630),S=i(2614);class _ extends E{static featureName=A.T;constructor(e){var t;super(e,A.T),this.setupInspectionEvents(e.agentIdentifier),t=e,p(u.Fw,function(e,r){"string"==typeof e&&("/"!==e.charAt(0)&&(e="/"+e),t.runtime.customTransaction=(r||"http://custom.transaction")+e,(0,a.p)(u.Pl+u.Fw,[(0,c.t)()],void 0,void 0,t.ee))},t),this.importAggregator(e,()=>i.e(478).then(i.bind(i,1983)))}setupInspectionEvents(e){const t=(t,r)=>{t&&(0,d.W)({agentIdentifier:e,timeStamp:t.timeStamp,loaded:"complete"===t.target.readyState,type:"window",name:r,data:t.target.location+""})};(0,b.sB)(e=>{t(e,"DOMContentLoaded")}),(0,b.GG)(e=>{t(e,"load")}),(0,b.Qr)(e=>{t(e,"navigate")}),this.ee.on(S.tS.UPDATE,(t,r)=>{(0,d.W)({agentIdentifier:e,type:"lifecycle",name:"session",data:r})})}}var O=i(384);var N=i(2843),I=i(3878),P=i(782);class j extends E{static featureName=P.T;constructor(e){super(e,P.T),y.RI&&((0,N.u)(()=>(0,a.p)("docHidden",[(0,c.t)()],void 0,P.T,this.ee),!0),(0,I.sp)("pagehide",()=>(0,a.p)("winPagehide",[(0,c.t)()],void 0,P.T,this.ee)),this.importAggregator(e,()=>i.e(478).then(i.bind(i,9917))))}}class k extends E{static featureName=h.TZ;constructor(e){super(e,h.TZ),y.RI&&document.addEventListener("securitypolicyviolation",e=>{(0,a.p)(h.xV,["Generic/CSPViolation/Detected"],void 0,this.featureName,this.ee)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,6555)))}}var C=i(6774),L=i(3304);class H{constructor(e,t,r,n,i){this.name="UncaughtError",this.message="string"==typeof e?e:(0,L.A)(e),this.sourceURL=t,this.line=r,this.column=n,this.__newrelic=i}}function M(e){return U(e)?e:new H(void 0!==e?.message?e.message:e,e?.filename||e?.sourceURL,e?.lineno||e?.line,e?.colno||e?.col,e?.__newrelic,e?.cause)}function K(e){const t="Unhandled Promise Rejection: ";if(!e?.reason)return;if(U(e.reason)){try{e.reason.message.startsWith(t)||(e.reason.message=t+e.reason.message)}catch(e){}return M(e.reason)}const r=M(e.reason);return(r.message||"").startsWith(t)||(r.message=t+r.message),r}function D(e){if(e.error instanceof SyntaxError&&!/:\d+$/.test(e.error.stack?.trim())){const t=new H(e.message,e.filename,e.lineno,e.colno,e.error.__newrelic,e.cause);return t.name=SyntaxError.name,t}return U(e.error)?e.error:M(e)}function U(e){return e instanceof Error&&!!e.stack}function F(e,t,r,i,o=(0,c.t)()){"string"==typeof e&&(e=new Error(e)),(0,a.p)("err",[e,o,!1,t,r.runtime.isRecording,void 0,i],void 0,n.K7.jserrors,r.ee),(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,r.ee)}var W=i(4387),B=i(993),V=i(3785);function G(e,{customAttributes:t={},level:r=B.p_.INFO}={},n,i,o=(0,c.t)()){(0,V.R)(n.ee,e,t,r,i,o)}function z(e,t,r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.hG,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function Z(e,t,r,i,o=(0,c.t)()){const{start:s,end:d,customAttributes:f}=t||{},h={customAttributes:f||{}};if("object"!=typeof h.customAttributes||"string"!=typeof e||0===e.length)return void(0,l.R)(57);const p=(e,t)=>null==e?t:"number"==typeof e?e:e instanceof PerformanceMark?e.startTime:Number.NaN;if(h.start=p(s,0),h.end=p(d,o),Number.isNaN(h.start)||Number.isNaN(h.end))(0,l.R)(57);else{if(h.duration=h.end-h.start,!(h.duration<0))return(0,a.p)(u.Pl+u.V1,[h,e,i],void 0,n.K7.genericEvents,r.ee),h;(0,l.R)(58)}}function q(e,t={},r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.fF,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function X(e){p(u.eY,function(t){return Y(e,t)},e)}function Y(e,t,r){const i={};(0,l.R)(54,"newrelic.register"),t||={},t.eventSource="MicroFrontendBrowserAgent",t.licenseKey||=e.info.licenseKey,t.blocked=!1,t.parent=r||{};let o=()=>{};const s=e.runtime.registeredEntities,u=s.find(({metadata:{target:{id:e,name:r}}})=>e===t.id);if(u)return u.metadata.target.name!==t.name&&(u.metadata.target.name=t.name),u;const d=e=>{t.blocked=!0,o=e};e.init.api.allow_registered_children||d((0,x.J)(()=>(0,l.R)(55))),(0,W.c7)(t)||d((0,x.J)(()=>(0,l.R)(48,t))),(0,W.yo)(t.id)&&(0,W.yo)(t.name)||d((0,x.J)(()=>(0,l.R)(48,t)));const f={addPageAction:(r,n={})=>m(z,[r,{...i,...n},e],t),log:(r,n={})=>m(G,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),measure:(r,n={})=>m(Z,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),noticeError:(r,n={})=>m(F,[r,{...i,...n},e],t),register:(t={})=>m(Y,[e,t],f.metadata.target),recordCustomEvent:(r,n={})=>m(q,[r,{...i,...n},e],t),setApplicationVersion:e=>g("application.version",e),setCustomAttribute:(e,t)=>g(e,t),setUserId:e=>g("enduser.id",e),metadata:{customAttributes:i,target:t}},p=()=>(t.blocked&&o(),t.blocked);p()||s.push(f);const g=(e,t)=>{p()||(i[e]=t)},m=(t,r,i)=>{if(p())return;const o=(0,c.t)();(0,a.p)(h.xV,["API/register/".concat(t.name,"/called")],void 0,n.K7.metrics,e.ee);try{return e.init.api.duplicate_registered_data&&"register"!==t.name&&t(...r,void 0,o),t(...r,i,o)}catch(e){(0,l.R)(50,e)}};return f}class J extends E{static featureName=C.T;constructor(e){var t;super(e,C.T),t=e,p(u.o5,(e,r)=>F(e,r,t),t),function(e){p(u.bt,function(t){e.runtime.onerror=t},e)}(e),function(e){let t=0;p(u.k6,function(e,r){++t>10||(this.runtime.releaseIds[e.slice(-200)]=(""+r).slice(-200))},e)}(e),X(e);try{this.removeOnAbort=new AbortController}catch(e){}this.ee.on("internal-error",(t,r)=>{this.abortHandler&&(0,a.p)("ierr",[M(t),(0,c.t)(),!0,{},e.runtime.isRecording,r],void 0,this.featureName,this.ee)}),y.gm.addEventListener("unhandledrejection",t=>{this.abortHandler&&(0,a.p)("err",[K(t),(0,c.t)(),!1,{unhandledPromiseRejection:1},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),y.gm.addEventListener("error",t=>{this.abortHandler&&(0,a.p)("err",[D(t),(0,c.t)(),!1,{},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,2176)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var Q=i(8990);let ee=1;function te(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===y.gm?0:(0,Q.I)(e,"nr@id",function(){return ee++})}function re(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,L.A)(e).length}catch(e){return}}}var ne=i(8139),ie=i(7836),oe=i(3434);const se={},ae=["open","send"];function ce(e){var t=e||ie.ee;const r=function(e){return(e||ie.ee).get("xhr")}(t);if(void 0===y.gm.XMLHttpRequest)return r;if(se[r.debugId]++)return r;se[r.debugId]=1,(0,ne.u)(t);var n=(0,oe.YM)(r),i=y.gm.XMLHttpRequest,o=y.gm.MutationObserver,s=y.gm.Promise,a=y.gm.setInterval,c="readystatechange",u=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],d=[],f=y.gm.XMLHttpRequest=function(e){const t=new i(e),o=r.context(t);try{r.emit("new-xhr",[t],o),t.addEventListener(c,(s=o,function(){var e=this;e.readyState>3&&!s.resolved&&(s.resolved=!0,r.emit("xhr-resolved",[],e)),n.inPlace(e,u,"fn-",b)}),(0,I.jT)(!1))}catch(e){(0,l.R)(15,e);try{r.emit("internal-error",[e])}catch(e){}}var s;return t};function h(e,t){n.inPlace(t,["onreadystatechange"],"fn-",b)}if(function(e,t){for(var r in e)t[r]=e[r]}(i,f),f.prototype=i.prototype,n.inPlace(f.prototype,ae,"-xhr-",b),r.on("send-xhr-start",function(e,t){h(e,t),function(e){d.push(e),o&&(p?p.then(v):a?a(v):(g=-g,m.data=g))}(t)}),r.on("open-xhr-start",h),o){var p=s&&s.resolve();if(!a&&!s){var g=1,m=document.createTextNode(g);new o(v).observe(m,{characterData:!0})}}else t.on("fn-end",function(e){e[0]&&e[0].type===c||v()});function v(){for(var e=0;e<d.length;e++)h(0,d[e]);d.length&&(d=[])}function b(e,t){return t}return r}var ue="fetch-",de=ue+"body-",le=["arrayBuffer","blob","json","text","formData"],fe=y.gm.Request,he=y.gm.Response,pe="prototype";const ge={};function me(e){const t=function(e){return(e||ie.ee).get("fetch")}(e);if(!(fe&&he&&y.gm.fetch))return t;if(ge[t.debugId]++)return t;function r(e,r,n){var i=e[r];"function"==typeof i&&(e[r]=function(){var e,r=[...arguments],o={};t.emit(n+"before-start",[r],o),o[ie.P]&&o[ie.P].dt&&(e=o[ie.P].dt);var s=i.apply(this,r);return t.emit(n+"start",[r,e],s),s.then(function(e){return t.emit(n+"end",[null,e],s),e},function(e){throw t.emit(n+"end",[e],s),e})})}return ge[t.debugId]=1,le.forEach(e=>{r(fe[pe],e,de),r(he[pe],e,de)}),r(y.gm,"fetch",ue),t.on(ue+"end",function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(ue+"done",[null,r],n)}else t.emit(ue+"done",[e],n)}),t}var ve=i(7485);class be{constructor(e){this.agentRef=e}generateTracePayload(t){const r=this.agentRef.loader_config;if(!this.shouldGenerateTrace(t)||!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var s=(0,e.ZF)(),a=(0,e.el)(),c=Date.now(),u={spanId:s,traceId:a,timestamp:c};return(t.sameOrigin||this.isAllowedOrigin(t)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(s,a),u.traceContextStateHeader=this.generateTraceContextStateHeader(s,c,n,i,o)),(t.sameOrigin&&!this.excludeNewrelicHeader()||!t.sameOrigin&&this.isAllowedOrigin(t)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(s,a,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof y.gm?.btoa))return null;var s={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(s.d.tk=o),btoa((0,L.A)(s))}shouldGenerateTrace(e){return this.agentRef.init?.distributed_tracing?.enabled&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var t=!1;const r=this.agentRef.init?.distributed_tracing;if(e.sameOrigin)t=!0;else if(r?.allowed_origins instanceof Array)for(var n=0;n<r.allowed_origins.length;n++){var i=(0,ve.D)(r.allowed_origins[n]);if(e.hostname===i.hostname&&e.protocol===i.protocol&&e.port===i.port){t=!0;break}}return t}excludeNewrelicHeader(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.exclude_newrelic_header}useNewrelicHeaderForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!1!==e.cors_use_newrelic_header}useTraceContextHeadersForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.cors_use_tracecontext_headers}}var ye=i(9300),we=i(7295);function Re(e){return"string"==typeof e?e:e instanceof(0,O.dV)().o.REQ?e.url:y.gm?.URL&&e instanceof URL?e.href:void 0}var xe=["load","error","abort","timeout"],Te=xe.length,Ee=(0,O.dV)().o.REQ,Ae=(0,O.dV)().o.XHR;const Se="X-NewRelic-App-Data";class _e extends E{static featureName=ye.T;constructor(e){super(e,ye.T),this.dt=new be(e),this.handler=(e,t,r,n)=>(0,a.p)(e,t,r,n,this.ee);try{const e={xmlhttprequest:"xhr",fetch:"fetch",beacon:"beacon"};y.gm?.performance?.getEntriesByType("resource").forEach(t=>{if(t.initiatorType in e&&0!==t.responseStatus){const r={status:t.responseStatus},i={rxSize:t.transferSize,duration:Math.floor(t.duration),cbTime:0};Oe(r,t.name),this.handler("xhr",[r,i,t.startTime,t.responseEnd,e[t.initiatorType]],void 0,n.K7.ajax)}})}catch(e){}me(this.ee),ce(this.ee),function(e,t,r,i){function o(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},t.latestLongtaskEnd=0,e.addEventListener("load",function(r){A(t,e)},(0,I.jT)(!1)),y.lR||e.addEventListener("progress",function(e){t.lastSize=e.loaded},(0,I.jT)(!1))}function s(e){this.params={method:e[0]},Oe(this,e[1]),this.metrics={}}function u(t,r){e.loader_config.xpid&&this.sameOrigin&&r.setRequestHeader("X-NewRelic-ID",e.loader_config.xpid);var n=i.generateTracePayload(this.parsedOrigin);if(n){var o=!1;n.newrelicHeader&&(r.setRequestHeader("newrelic",n.newrelicHeader),o=!0),n.traceContextParentHeader&&(r.setRequestHeader("traceparent",n.traceContextParentHeader),n.traceContextStateHeader&&r.setRequestHeader("tracestate",n.traceContextStateHeader),o=!0),o&&(this.dt=n)}}function d(e,r){var n=this.metrics,i=e[0],o=this;if(n&&i){var s=re(i);s&&(n.txSize=s)}this.startTime=(0,c.t)(),this.body=i,this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof r.onload)&&"function"==typeof o.end)&&o.end(r)}catch(e){try{t.emit("internal-error",[e])}catch(e){}}};for(var a=0;a<Te;a++)r.addEventListener(xe[a],this.listener,(0,I.jT)(!1))}function l(e,t,r){this.cbTime+=e,t?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof r.onload||"function"!=typeof this.end||this.end(r)}function f(e,t){var r=""+te(e)+!!t;this.xhrGuids&&!this.xhrGuids[r]&&(this.xhrGuids[r]=!0,this.totalCbs+=1)}function p(e,t){var r=""+te(e)+!!t;this.xhrGuids&&this.xhrGuids[r]&&(delete this.xhrGuids[r],this.totalCbs-=1)}function g(){this.endTime=(0,c.t)()}function m(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-added",[e[1],e[2]],r)}function v(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-removed",[e[1],e[2]],r)}function b(e,t,r){t instanceof Ae&&("onload"===r&&(this.onload=!0),("load"===(e[0]&&e[0].type)||this.onload)&&(this.xhrCbStart=(0,c.t)()))}function w(e,r){this.xhrCbStart&&t.emit("xhr-cb-time",[(0,c.t)()-this.xhrCbStart,this.onload,r],r)}function R(e){var t,r=e[1]||{};if("string"==typeof e[0]?0===(t=e[0]).length&&y.RI&&(t=""+y.gm.location.href):e[0]&&e[0].url?t=e[0].url:y.gm?.URL&&e[0]&&e[0]instanceof URL?t=e[0].href:"function"==typeof e[0].toString&&(t=e[0].toString()),"string"==typeof t&&0!==t.length){t&&(this.parsedOrigin=(0,ve.D)(t),this.sameOrigin=this.parsedOrigin.sameOrigin);var n=i.generateTracePayload(this.parsedOrigin);if(n&&(n.newrelicHeader||n.traceContextParentHeader))if(e[0]&&e[0].headers)a(e[0].headers,n)&&(this.dt=n);else{var o={};for(var s in r)o[s]=r[s];o.headers=new Headers(r.headers||{}),a(o.headers,n)&&(this.dt=n),e.length>1?e[1]=o:e.push(o)}}function a(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,c.t)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r=this.opts||{},n=this.target;Oe(this,Re(n));var i=(""+(n&&n instanceof Ee&&n.method||r.method||"GET")).toUpperCase();this.params.method=i,this.body=r.body,this.txSize=re(r.body)||0}function T(e,t){if(this.endTime=(0,c.t)(),this.params||(this.params={}),(0,we.iW)(this.params))return;let i;this.params.status=t?t.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(i=+this.rxSize);const o={txSize:this.txSize,rxSize:i,duration:(0,c.t)()-this.startTime};r("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,n.K7.ajax)}function E(e){const t=this.params,i=this.metrics;if(!this.ended){this.ended=!0;for(let t=0;t<Te;t++)e.removeEventListener(xe[t],this.listener,!1);t.aborted||(0,we.iW)(t)||(i.duration=(0,c.t)()-this.startTime,this.loadCaptureCalled||4!==e.readyState?null==t.status&&(t.status=0):A(this,e),i.cbTime=this.cbTime,r("xhr",[t,i,this.startTime,this.endTime,"xhr"],this,n.K7.ajax))}}function A(e,r){e.params.status=r.status;var i=function(e,t){var r=e.responseType;return"json"===r&&null!==t?t:"arraybuffer"===r||"blob"===r||"json"===r?re(e.response):"text"===r||""===r||void 0===r?re(e.responseText):void 0}(r,e.lastSize);if(i&&(e.metrics.rxSize=i),e.sameOrigin&&r.getAllResponseHeaders().indexOf(Se)>=0){var o=r.getResponseHeader(Se);o&&((0,a.p)(h.rs,["Ajax/CrossApplicationTracing/Header/Seen"],void 0,n.K7.metrics,t),e.params.cat=o.split(", ").pop())}e.loadCaptureCalled=!0}t.on("new-xhr",o),t.on("open-xhr-start",s),t.on("open-xhr-end",u),t.on("send-xhr-start",d),t.on("xhr-cb-time",l),t.on("xhr-load-added",f),t.on("xhr-load-removed",p),t.on("xhr-resolved",g),t.on("addEventListener-end",m),t.on("removeEventListener-end",v),t.on("fn-end",w),t.on("fetch-before-start",R),t.on("fetch-start",x),t.on("fn-start",b),t.on("fetch-done",T)}(e,this.ee,this.handler,this.dt),this.importAggregator(e,()=>i.e(478).then(i.bind(i,3845)))}}function Oe(e,t){var r=(0,ve.D)(t),n=e.params||e;n.hostname=r.hostname,n.port=r.port,n.protocol=r.protocol,n.host=r.hostname+":"+r.port,n.pathname=r.pathname,e.parsedOrigin=r,e.sameOrigin=r.sameOrigin}const Ne={},Ie=["pushState","replaceState"];function Pe(e){const t=function(e){return(e||ie.ee).get("history")}(e);return!y.RI||Ne[t.debugId]++||(Ne[t.debugId]=1,(0,oe.YM)(t).inPlace(window.history,Ie,"-")),t}var je=i(3738);function ke(e){p(u.BL,function(t=Date.now()){const r=t-y.WN;r<0&&(0,l.R)(62,t),(0,a.p)(h.XG,[u.BL,{time:r}],void 0,n.K7.metrics,e.ee),e.addToTrace({name:u.BL,start:t,origin:"nr"}),(0,a.p)(u.Pl+u.hG,[r,u.BL],void 0,n.K7.genericEvents,e.ee)},e)}const{He:Ce,bD:Le,d3:He,Kp:Me,TZ:Ke,Lc:De,uP:Ue,Rz:Fe}=je;class We extends E{static featureName=Ke;constructor(e){var t;super(e,Ke),t=e,p(u.U2,function(e){if(!(e&&"object"==typeof e&&e.name&&e.start))return;const r={n:e.name,s:e.start-y.WN,e:(e.end||e.start)-y.WN,o:e.origin||"",t:"api"};r.s<0||r.e<0||r.e<r.s?(0,l.R)(61,{start:r.s,end:r.e}):(0,a.p)("bstApi",[r],void 0,n.K7.sessionTrace,t.ee)},t),ke(e);if(!(0,R.V)(e.init))return void this.deregisterDrain();const r=this.ee;let o;Pe(r),this.eventsEE=(0,ne.u)(r),this.eventsEE.on(Ue,function(e,t){this.bstStart=(0,c.t)()}),this.eventsEE.on(De,function(e,t){(0,a.p)("bst",[e[0],t,this.bstStart,(0,c.t)()],void 0,n.K7.sessionTrace,r)}),r.on(Fe+He,function(e){this.time=(0,c.t)(),this.startPath=location.pathname+location.hash}),r.on(Fe+Me,function(e){(0,a.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,n.K7.sessionTrace,r)});try{o=new PerformanceObserver(e=>{const t=e.getEntries();(0,a.p)(Ce,[t],void 0,n.K7.sessionTrace,r)}),o.observe({type:Le,buffered:!0})}catch(e){}this.importAggregator(e,()=>i.e(478).then(i.bind(i,6974)),{resourceObserver:o})}}var Be=i(6344);class Ve extends E{static featureName=Be.TZ;#n;recorder;constructor(e){var t;let r;super(e,Be.TZ),t=e,p(u.CH,function(){(0,a.p)(u.CH,[],void 0,n.K7.sessionReplay,t.ee)},t),function(e){p(u.Tb,function(){(0,a.p)(u.Tb,[],void 0,n.K7.sessionReplay,e.ee)},e)}(e);try{r=JSON.parse(localStorage.getItem("".concat(S.H3,"_").concat(S.uh)))}catch(e){}(0,w.SR)(e.init)&&this.ee.on(u.CH,()=>this.#i()),this.#o(r)&&this.importRecorder().then(e=>{e.startRecording(Be.Qb.PRELOAD,r?.sessionReplayMode)}),this.importAggregator(this.agentRef,()=>i.e(478).then(i.bind(i,6167)),this),this.ee.on("err",e=>{this.blocked||this.agentRef.runtime.isRecording&&(this.errorNoticed=!0,(0,a.p)(Be.Vh,[e],void 0,this.featureName,this.ee))})}#o(e){return e&&(e.sessionReplayMode===S.g.FULL||e.sessionReplayMode===S.g.ERROR)||(0,w.Aw)(this.agentRef.init)}importRecorder(){return this.recorder?Promise.resolve(this.recorder):(this.#n??=Promise.all([i.e(478),i.e(249)]).then(i.bind(i,4866)).then(({Recorder:e})=>(this.recorder=new e(this),this.recorder)).catch(e=>{throw this.ee.emit("internal-error",[e]),this.blocked=!0,e}),this.#n)}#i(){this.blocked||(this.featAggregate?this.featAggregate.mode!==S.g.FULL&&this.featAggregate.initializeRecording(S.g.FULL,!0,Be.Qb.API):this.importRecorder().then(()=>{this.recorder.startRecording(Be.Qb.API,S.g.FULL)}))}}var Ge=i(3962);function ze(e){const t=e.ee.get("tracer");function r(){}p(u.dT,function(e){return(new r).get("object"==typeof e?e:{})},e);const i=r.prototype={createTracer:function(r,i){var o={},s=this,d="function"==typeof i;return(0,a.p)(h.xV,["API/createTracer/called"],void 0,n.K7.metrics,e.ee),e.runSoftNavOverSpa||(0,a.p)(u.hw+"tracer",[(0,c.t)(),r,o],s,n.K7.spa,e.ee),function(){if(t.emit((d?"":"no-")+"fn-start",[(0,c.t)(),s,d],o),d)try{return i.apply(this,arguments)}catch(e){const r="string"==typeof e?new Error(e):e;throw t.emit("fn-err",[arguments,this,r],o),r}finally{t.emit("fn-end",[(0,c.t)()],o)}}}};["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach(t=>{p.apply(this,[t,function(){return(0,a.p)(u.hw+t,[(0,c.t)(),...arguments],this,e.runSoftNavOverSpa?n.K7.softNav:n.K7.spa,e.ee),this},e,i])}),p(u.PA,function(){e.runSoftNavOverSpa?(0,a.p)(u.hw+"routeName",[performance.now(),...arguments],void 0,n.K7.softNav,e.ee):(0,a.p)(u.Pl+"routeName",[(0,c.t)(),...arguments],this,n.K7.spa,e.ee)},e)}class Ze extends E{static featureName=Ge.TZ;constructor(e){if(super(e,Ge.TZ),ze(e),!y.RI||!(0,O.dV)().o.MO)return;const t=Pe(this.ee);try{this.removeOnAbort=new AbortController}catch(e){}Ge.tC.forEach(e=>{(0,I.sp)(e,e=>{s(e)},!0,this.removeOnAbort?.signal)});const r=()=>(0,a.p)("newURL",[(0,c.t)(),""+window.location],void 0,this.featureName,this.ee);t.on("pushState-end",r),t.on("replaceState-end",r),(0,I.sp)(Ge.OV,e=>{s(e),(0,a.p)("newURL",[e.timeStamp,""+window.location],void 0,this.featureName,this.ee)},!0,this.removeOnAbort?.signal);let n=!1;const o=new((0,O.dV)().o.MO)((e,t)=>{n||(n=!0,requestAnimationFrame(()=>{(0,a.p)("newDom",[(0,c.t)()],void 0,this.featureName,this.ee),n=!1}))}),s=(0,x.s)(e=>{(0,a.p)("newUIEvent",[e],void 0,this.featureName,this.ee),o.observe(document.body,{attributes:!0,childList:!0,subtree:!0,characterData:!0})},100,{leading:!0});this.abortHandler=function(){this.removeOnAbort?.abort(),o.disconnect(),this.abortHandler=void 0},this.importAggregator(e,()=>i.e(478).then(i.bind(i,4393)),{domObserver:o})}}var qe=i(7378);const Xe={},Ye=["appendChild","insertBefore","replaceChild"];function Je(e){const t=function(e){return(e||ie.ee).get("jsonp")}(e);if(!y.RI||Xe[t.debugId])return t;Xe[t.debugId]=!0;var r=(0,oe.YM)(t),n=/[?&](?:callback|cb)=([^&#]+)/,i=/(.*)\.([^.]+)/,o=/^(\w+)(\.|$)(.*)$/;function s(e,t){if(!e)return t;const r=e.match(o),n=r[1];return s(r[3],t[n])}return r.inPlace(Node.prototype,Ye,"dom-"),t.on("dom-start",function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var o=(a=e.src,c=a.match(n),c?c[1]:null);var a,c;if(!o)return;var u=function(e){var t=e.match(i);if(t&&t.length>=3)return{key:t[2],parent:s(t[1],window)};return{key:e,parent:window}}(o);if("function"!=typeof u.parent[u.key])return;var d={};function l(){t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}function f(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",l,(0,I.jT)(!1)),e.addEventListener("error",f,(0,I.jT)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])}),t}const $e={};function Qe(e){const t=function(e){return(e||ie.ee).get("promise")}(e);if($e[t.debugId])return t;$e[t.debugId]=!0;var r=t.context,n=(0,oe.YM)(t),i=y.gm.Promise;return i&&function(){function e(r){var o=t.context(),s=n(r,"executor-",o,null,!1);const a=Reflect.construct(i,[s],e);return t.context(a).getCtx=function(){return o},a}y.gm.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return i.toString()},Object.setPrototypeOf(e,i),["all","race"].forEach(function(r){const n=i[r];e[r]=function(e){let i=!1;[...e||[]].forEach(e=>{this.resolve(e).then(s("all"===r),s(!1))});const o=n.apply(this,arguments);return o;function s(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}}),["resolve","reject"].forEach(function(r){const n=i[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}}),e.prototype=i.prototype;const o=i.prototype.then;i.prototype.then=function(...e){var i=this,s=r(i);s.promise=i,e[0]=n(e[0],"cb-",s,null,!1),e[1]=n(e[1],"cb-",s,null,!1);const a=o.apply(this,e);return s.nextPromise=a,t.emit("propagate",[i,!0],a,!1,!1),a},i.prototype.then[oe.Jt]=o,t.on("executor-start",function(e){e[0]=n(e[0],"resolve-",this,null,!1),e[1]=n(e[1],"resolve-",this,null,!1)}),t.on("executor-err",function(e,t,r){e[1](r)}),t.on("cb-end",function(e,r,n){t.emit("propagate",[n,!0],this.nextPromise,!1,!1)}),t.on("propagate",function(e,r,n){if(!this.getCtx||r){const r=this,n=e instanceof Promise?t.context(e):null;let i;this.getCtx=function(){return i||(i=n&&n!==r?"function"==typeof n.getCtx?n.getCtx():n:r,i)}}})}(),t}const et={},tt="setTimeout",rt="setInterval",nt="clearTimeout",it="-start",ot=[tt,"setImmediate",rt,nt,"clearImmediate"];function st(e){const t=function(e){return(e||ie.ee).get("timer")}(e);if(et[t.debugId]++)return t;et[t.debugId]=1;var r=(0,oe.YM)(t);return r.inPlace(y.gm,ot.slice(0,2),tt+"-"),r.inPlace(y.gm,ot.slice(2,3),rt+"-"),r.inPlace(y.gm,ot.slice(3),nt+"-"),t.on(rt+it,function(e,t,n){e[0]=r(e[0],"fn-",null,n)}),t.on(tt+it,function(e,t,n){this.method=n,this.timerDuration=isNaN(e[1])?0:+e[1],e[0]=r(e[0],"fn-",this,n)}),t}const at={};function ct(e){const t=function(e){return(e||ie.ee).get("mutation")}(e);if(!y.RI||at[t.debugId])return t;at[t.debugId]=!0;var r=(0,oe.YM)(t),n=y.gm.MutationObserver;return n&&(window.MutationObserver=function(e){return this instanceof n?new n(r(e,"fn-")):n.apply(this,arguments)},MutationObserver.prototype=n.prototype),t}const{TZ:ut,d3:dt,Kp:lt,$p:ft,wW:ht,e5:pt,tH:gt,uP:mt,rw:vt,Lc:bt}=qe;class yt extends E{static featureName=ut;constructor(e){if(super(e,ut),ze(e),!y.RI)return;try{this.removeOnAbort=new AbortController}catch(e){}let t,r=0;const n=this.ee.get("tracer"),o=Je(this.ee),s=Qe(this.ee),u=st(this.ee),d=ce(this.ee),l=this.ee.get("events"),f=me(this.ee),h=Pe(this.ee),p=ct(this.ee);function g(e,t){h.emit("newURL",[""+window.location,t])}function m(){r++,t=window.location.hash,this[mt]=(0,c.t)()}function v(){r--,window.location.hash!==t&&g(0,!0);var e=(0,c.t)();this[pt]=~~this[pt]+e-this[mt],this[bt]=e}function b(e,t){e.on(t,function(){this[t]=(0,c.t)()})}this.ee.on(mt,m),s.on(vt,m),o.on(vt,m),this.ee.on(bt,v),s.on(ht,v),o.on(ht,v),this.ee.on("fn-err",(...t)=>{t[2]?.__newrelic?.[e.agentIdentifier]||(0,a.p)("function-err",[...t],void 0,this.featureName,this.ee)}),this.ee.buffer([mt,bt,"xhr-resolved"],this.featureName),l.buffer([mt],this.featureName),u.buffer(["setTimeout"+lt,"clearTimeout"+dt,mt],this.featureName),d.buffer([mt,"new-xhr","send-xhr"+dt],this.featureName),f.buffer([gt+dt,gt+"-done",gt+ft+dt,gt+ft+lt],this.featureName),h.buffer(["newURL"],this.featureName),p.buffer([mt],this.featureName),s.buffer(["propagate",vt,ht,"executor-err","resolve"+dt],this.featureName),n.buffer([mt,"no-"+mt],this.featureName),o.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),b(f,gt+dt),b(f,gt+"-done"),b(o,"new-jsonp"),b(o,"jsonp-end"),b(o,"cb-start"),h.on("pushState-end",g),h.on("replaceState-end",g),window.addEventListener("hashchange",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",function(){g(0,r>1)},(0,I.jT)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,5592)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var wt=i(3333);class Rt extends E{static featureName=wt.TZ;constructor(e){super(e,wt.TZ);const t=[e.init.page_action.enabled,e.init.performance.capture_marks,e.init.performance.capture_measures,e.init.user_actions.enabled,e.init.performance.resources.enabled];var r;r=e,p(u.hG,(e,t)=>z(e,t,r),r),function(e){p(u.fF,(t,r)=>q(t,r,e),e)}(e),ke(e),X(e),function(e){p(u.V1,(t,r)=>Z(t,r,e),e)}(e);const o=e.init.feature_flags.includes("user_frustrations");let s;if(y.RI&&o&&(me(this.ee),ce(this.ee),s=Pe(this.ee)),y.RI){if(e.init.user_actions.enabled&&(wt.Zp.forEach(e=>(0,I.sp)(e,e=>(0,a.p)("ua",[e],void 0,this.featureName,this.ee),!0)),wt.qN.forEach(e=>{const t=(0,x.s)(e=>{(0,a.p)("ua",[e],void 0,this.featureName,this.ee)},500,{leading:!0});(0,I.sp)(e,t)}),o)){function c(t){const r=(0,ve.D)(t);return e.beacons.includes(r.hostname+":"+r.port)}function d(){s.emit("navChange")}y.gm.addEventListener("error",()=>{(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.ee.on("open-xhr-start",(e,t)=>{c(e[1])||t.addEventListener("readystatechange",()=>{2===t.readyState&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)})}),this.ee.on("fetch-start",e=>{e.length>=1&&!c(Re(e[0]))&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)}),s.on("pushState-end",d),s.on("replaceState-end",d),window.addEventListener("hashchange",d,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",d,(0,I.jT)(!0,this.removeOnAbort?.signal))}if(e.init.performance.resources.enabled&&y.gm.PerformanceObserver?.supportedEntryTypes.includes("resource")){new PerformanceObserver(e=>{e.getEntries().forEach(e=>{(0,a.p)("browserPerformance.resource",[e],void 0,this.featureName,this.ee)})}).observe({type:"resource",buffered:!0})}}try{this.removeOnAbort=new AbortController}catch(l){}this.abortHandler=()=>{this.removeOnAbort?.abort(),this.abortHandler=void 0},t.some(e=>e)?this.importAggregator(e,()=>i.e(478).then(i.bind(i,8019))):this.deregisterDrain()}}var xt=i(2646);const Tt=new Map;function Et(e,t,r,n){if("object"!=typeof t||!t||"string"!=typeof r||!r||"function"!=typeof t[r])return(0,l.R)(29);const i=function(e){return(e||ie.ee).get("logger")}(e),o=(0,oe.YM)(i),s=new xt.y(ie.P);s.level=n.level,s.customAttributes=n.customAttributes;const a=t[r]?.[oe.Jt]||t[r];return Tt.set(a,s),o.inPlace(t,[r],"wrap-logger-",()=>Tt.get(a)),i}var At=i(1910);class St extends E{static featureName=B.TZ;constructor(e){var t;super(e,B.TZ),t=e,p(u.$9,(e,r)=>G(e,r,t),t),function(e){p(u.Wb,(t,r,{customAttributes:n={},level:i=B.p_.INFO}={})=>{Et(e.ee,t,r,{customAttributes:n,level:i})},e)}(e),X(e);const r=this.ee;["log","error","warn","info","debug","trace"].forEach(e=>{(0,At.i)(y.gm.console[e]),Et(r,y.gm.console,e,{level:"log"===e?"info":e})}),this.ee.on("wrap-logger-end",function([e]){const{level:t,customAttributes:n}=this;(0,V.R)(r,e,n,t)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,5288)))}}new class extends r{constructor(e){var t;(super(),y.gm)?(this.features={},(0,O.bQ)(this.agentIdentifier,this),this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(_),this.runSoftNavOverSpa=[...this.desiredFeatures].some(e=>e.featureName===n.K7.softNav),(0,s.j)(this,e,e.loaderType||"agent"),t=this,p(u.cD,function(e,r,n=!1){if("string"==typeof e){if(["string","number","boolean"].includes(typeof r)||null===r)return g(t,e,r,u.cD,n);(0,l.R)(40,typeof r)}else(0,l.R)(39,typeof e)},t),function(e){p(u.Dl,function(t){if("string"==typeof t||null===t)return g(e,"enduser.id",t,u.Dl,!0);(0,l.R)(41,typeof t)},e)}(this),function(e){p(u.nb,function(t){if("string"==typeof t||null===t)return g(e,"application.version",t,u.nb,!1);(0,l.R)(42,typeof t)},e)}(this),function(e){p(u.d3,function(){e.ee.emit("manual-start-all")},e)}(this),function(e){p(u.Pv,function(t=!0){if("boolean"==typeof t){if((0,a.p)(u.Pl+u.Pv,[t],void 0,"session",e.ee),e.runtime.consented=t,t){const t=e.features.page_view_event;t.onAggregateImported.then(e=>{const r=t.featAggregate;e&&!r.sentRum&&r.sendRum()})}}else(0,l.R)(65,typeof t)},e)}(this),this.run()):(0,l.R)(21)}get config(){return{info:this.info,init:this.init,loader_config:this.loader_config,runtime:this.runtime}}get api(){return this}run(){try{const e=function(e){const t={};return o.forEach(r=>{t[r]=!!e[r]?.enabled}),t}(this.init),t=[...this.desiredFeatures];t.sort((e,t)=>n.P3[e.featureName]-n.P3[t.featureName]),t.forEach(t=>{if(!e[t.featureName]&&t.featureName!==n.K7.pageViewEvent)return;if(this.runSoftNavOverSpa&&t.featureName===n.K7.spa)return;if(!this.runSoftNavOverSpa&&t.featureName===n.K7.softNav)return;const r=function(e){switch(e){case n.K7.ajax:return[n.K7.jserrors];case n.K7.sessionTrace:return[n.K7.ajax,n.K7.pageViewEvent];case n.K7.sessionReplay:return[n.K7.sessionTrace];case n.K7.pageViewTiming:return[n.K7.pageViewEvent];default:return[]}}(t.featureName).filter(e=>!(e in this.features));r.length>0&&(0,l.R)(36,{targetFeature:t.featureName,missingDependencies:r}),this.features[t.featureName]=new t(this)})}catch(e){(0,l.R)(22,e);for(const e in this.features)this.features[e].abortHandler?.();const t=(0,O.Zm)();delete t.initializedAgents[this.agentIdentifier]?.features,delete this.sharedAggregator;return t.ee.get(this.agentIdentifier).abort(),!1}}}({features:[_e,_,j,We,Ve,k,J,Rt,St,Ze,yt],loaderType:"spa"})})()})();</script>
<link rel="icon" type="image/png" sizes="16x16" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png">
<meta name="apple-mobile-web-app-title" content="Frontiers | Articles">
<link rel="manifest" href="/manifest.json">
<link rel="canonical" href="https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1465747/full">
<meta property="description" name="description" content="Background: Hereditary transthyretin (ATTRv) amyloidosis, a multifaceted disorder affecting multiple systems, substantially diminishes patients' physical cap...">
<meta property="og:title" name="title" content="Frontiers | Assessing the effectiveness and safety of Patisiran and Vutrisiran in ATTRv amyloidosis with polyneuropathy: a systematic review">
<meta property="og:description" name="description" content="Background: Hereditary transthyretin (ATTRv) amyloidosis, a multifaceted disorder affecting multiple systems, substantially diminishes patients' physical cap...">
<meta name="keywords" content="hereditary amyloidosis,Transthyretin-related amyloidosis,patisiran,Vutrisiran,polyneuropathy,cardiomyopathy,clinical trials">
<meta property="og:site_name" name="site_name" content="Frontiers">
<meta property="og:image" name="image" content="https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t001.jpg">
<meta property="og:type" name="type" content="article">
<meta property="og:url" name="url" content="https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1465747/full">
<meta name="twitter:card" content="summary_large_image">
<meta name="citation_volume" content="15">
<meta name="citation_journal_title" content="Frontiers in Neurology">
<meta name="citation_publisher" content="Frontiers">
<meta name="citation_journal_abbrev" content="Front. Neurol.">
<meta name="citation_issn" content="1664-2295">
<meta name="citation_doi" content="10.3389/fneur.2024.1465747">
<meta name="citation_firstpage" content="1465747">
<meta name="citation_language" content="English">
<meta name="citation_title" content="Assessing the effectiveness and safety of Patisiran and Vutrisiran in ATTRv amyloidosis with polyneuropathy: a systematic review">
<meta name="citation_keywords" content="hereditary amyloidosis; Transthyretin-related amyloidosis; patisiran; Vutrisiran; polyneuropathy; cardiomyopathy; clinical trials">
<meta name="citation_abstract" content="Background: Hereditary transthyretin (ATTRv) amyloidosis, a multifaceted disorder affecting multiple systems, substantially diminishes patients' physical capabilities and overall quality of life.Patisiran and Vutrisiran, two Ribonucleic acid (RNA) interference therapies, target reducing both pathogenic and wild-type transthyretin (TTR) protein levels. This systematic review assesses the effectiveness and safety of these treatments in managing ATTRv. Methods: A comprehensive, thorough literature search across databases including Embase, PubMed, Web of Science, Cochrane Central, and Google Scholar yielded 858 studies. Following removing duplicate and irrelevant articles, 676 distinct studies underwent review. These studies, conducted on a global scale, encompassed a range of methodologies, including clinical trials and indirect treatment comparisons. Results: Ten studies, spanning a total population of 756 patients, were selected for in-depth analysis. Patisiran and Vutrisiran consistently demonstrated significant improvements in primary and secondary endpoints related to neuropathy, quality of life, and cardiac function. Both medications were well-tolerated, with primarily mild to moderate adverse events. Indirect treatment comparison studies indicated Vutrisiran's superiority over Tafamidis in treating ATTRv amyloidosis. Conclusion: This systematic review recommends using Patisiran and Vutrisiran to treat ATTRv amyloidosis. The findings suggest that these RNA interference therapies improve neuropathy, quality of life, and cardiac symptoms. The results indicate sustained benefits over prolonged treatment, with satisfactory safety profiles. However, potential biases, conflicts of interest in the studies, and limited follow-up periods in some trials necessitate cautious interpretation. Future research should address these limitations and provide more robust evidence for the long-term efficacy and safety of Patisiran and Vutrisiran in ATTRv treatment.">
<meta name="citation_article_type" content="Systematic Review">
<meta name="citation_pdf_url" content="https://public-pages-files-2025.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1465747/pdf">
<meta name="citation_xml_url" content="https://public-pages-files-2025.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1465747/xml">
<meta name="citation_fulltext_world_readable" content="yes">
<meta name="citation_online_date" content="2024/08/16">
<meta name="citation_publication_date" content="2024/09/02">
<meta name="citation_author" content="Karimi, Mohammad Amin ">
<meta name="citation_author_institution" content="School of Medicine, Shahid Beheshti University of Medical Sciences, Iran">
<meta name="citation_author" content="Esmaeilpour Moallem, Fatemeh ">
<meta name="citation_author_institution" content="Student Research Committee, Golestan University of Medical Sciences, Iran">
<meta name="citation_author" content="Gholami Chahkand, Mohammad Sadra ">
<meta name="citation_author_institution" content="Student Research Committee, Golestan University of Medical Sciences, Iran">
<meta name="citation_author" content="Azarm, Eftekhar ">
<meta name="citation_author_institution" content="School of Medicine, Isfahan University of Medical Sciences, Iran">
<meta name="citation_author" content="Emami Kazemabad, Mohammad Javad ">
<meta name="citation_author_institution" content="Student Research Committee, School of Medicine, Qom University of Medical Sciences, Iran">
<meta name="citation_author" content="Dadkhah, Parisa Alsadat ">
<meta name="citation_author_institution" content="School of Medicine, Isfahan University of Medical Sciences, Iran">
<meta name="dc.identifier" content="doi:10.3389/fneur.2024.1465747">
<script type="application/ld+json">{"@context":"https://schema.org","@type":"ScholarlyArticle","headline":"Assessing the effectiveness and safety of Patisiran and Vutrisiran in ATTRv amyloidosis with polyneuropathy: a systematic review","author":[{"@type":"Person","name":"Mohammad Amin Karimi","affiliation":["School of Medicine, Shahid Beheshti University of Medical Sciences, Iran"]},{"@type":"Person","name":"Fatemeh Esmaeilpour Moallem","affiliation":["Student Research Committee, Golestan University of Medical Sciences, Iran"]},{"@type":"Person","name":"Mohammad Sadra Gholami Chahkand","affiliation":["Student Research Committee, Golestan University of Medical Sciences, Iran"]},{"@type":"Person","name":"Eftekhar Azarm","affiliation":["School of Medicine, Isfahan University of Medical Sciences, Iran"]},{"@type":"Person","name":"Mohammad Javad Emami Kazemabad","affiliation":["Student Research Committee, School of Medicine, Qom University of Medical Sciences, Iran"]},{"@type":"Person","name":"Parisa Alsadat Dadkhah","affiliation":["School of Medicine, Isfahan University of Medical Sciences, Iran"]}],"datePublished":"2024-09-02","dateModified":"2025-11-25","publisher":{"@type":"Organization","name":"Frontiers"},"isPartOf":{"@type":"PublicationIssue","datePublished":"2024","isPartOf":{"@type":"PublicationVolume","volumeNumber":"15","isPartOf":{"@type":"Periodical","name":"Frontiers in Neurology"}}},"citation":["https://doi.org/10.3389/fneur.2024.1465747"],"inLanguage":"en"}</script>
<script type="module" src="/ap-2024/_nuxt/v1IBIWh4.js" crossorigin></script>
<script id="unhead:payload" type="application/json">{"title":"Frontiers | Articles"}</script></head><body  class="body--v3"><div id="__nuxt"><!--[--><!----><div theme="cyan"><nav class="Ibar"><div class="Ibar__main"><div class="Ibar__wrapper"><button class="Ibar__burger" aria-label="Open Menu" data-event="iBar-btn-openMenu"></button><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/neurology" class="Ibar__journalName" data-event="iBar-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Neurology</span></div></div></a><div class="Ibar__dropdown--aboutUs" parent-data-event="iBar"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=54&amp;specialtyid=0&amp;entitytype=2&amp;entityid=141" data-event="iBar-a-submit">Submit your research</a><div class="Ibar__spacer"></div><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><div><div class="Ibar__menu Ibar__menu--journal"><div class="Ibar__menu__header"><div class="Ibar__logo"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div></div><button class="Ibar__close" aria-label="Close Menu" data-event="iBarMenu-btn-closeMenu"></button></div><div class="Ibar__menu__wrapper"><div class="Ibar__menu__journal"><a href="//www.frontiersin.org/journals/neurology" data-event="iBarMenu-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Neurology</span></div></div></a><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/applied-neuroimaging" data-event="iBarJournal-sections-a_id_156">Applied Neuroimaging</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/artificial-intelligence-in-neurology" data-event="iBarJournal-sections-a_id_3712">Artificial Intelligence in Neurology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/autonomic-disorders" data-event="iBarJournal-sections-a_id_3023">Autonomic Disorders</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/cognitive-and-behavioral-neurology" data-event="iBarJournal-sections-a_id_3740">Cognitive and Behavioral Neurology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/dementia-and-neurodegenerative-diseases" data-event="iBarJournal-sections-a_id_1439">Dementia and Neurodegenerative Diseases</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/diagnostic-neuropathology" data-event="iBarJournal-sections-a_id_2038">Diagnostic Neuropathology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/endovascular-and-interventional-neurology" data-event="iBarJournal-sections-a_id_143">Endovascular and Interventional Neurology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/epilepsy" data-event="iBarJournal-sections-a_id_144">Epilepsy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/experimental-therapeutics" data-event="iBarJournal-sections-a_id_1784">Experimental Therapeutics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/headache-and-neurogenic-pain" data-event="iBarJournal-sections-a_id_153">Headache and Neurogenic Pain</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/movement-disorders" data-event="iBarJournal-sections-a_id_145">Movement Disorders</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/multiple-sclerosis-and-neuroimmunology" data-event="iBarJournal-sections-a_id_147">Multiple Sclerosis and Neuroimmunology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neuro-oncology-and-neurosurgical-oncology" data-event="iBarJournal-sections-a_id_150">Neuro-Oncology and Neurosurgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neuro-ophthalmology" data-event="iBarJournal-sections-a_id_154">Neuro-Ophthalmology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neuro-otology" data-event="iBarJournal-sections-a_id_155">Neuro-Otology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neurocritical-and-neurohospitalist-care" data-event="iBarJournal-sections-a_id_159">Neurocritical and Neurohospitalist Care</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neuroepidemiology" data-event="iBarJournal-sections-a_id_1339">Neuroepidemiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neurogenetics" data-event="iBarJournal-sections-a_id_160">Neurogenetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neuroinfectious-diseases" data-event="iBarJournal-sections-a_id_1334">Neuroinfectious Diseases</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neurological-biomarkers" data-event="iBarJournal-sections-a_id_2345">Neurological Biomarkers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neuromuscular-disorders-and-peripheral-neuropathies" data-event="iBarJournal-sections-a_id_146">Neuromuscular Disorders and Peripheral Neuropathies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neurorehabilitation" data-event="iBarJournal-sections-a_id_547">Neurorehabilitation</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neurotechnology" data-event="iBarJournal-sections-a_id_3418">Neurotechnology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neurotrauma" data-event="iBarJournal-sections-a_id_163">Neurotrauma</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/pediatric-neurology" data-event="iBarJournal-sections-a_id_161">Pediatric Neurology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/sleep-disorders" data-event="iBarJournal-sections-a_id_151">Sleep Disorders</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/stroke" data-event="iBarJournal-sections-a_id_142">Stroke</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/neurology/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/neurology/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/neurology/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div></div><div class="Ibar__dropdown--aboutUs" parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><!----><!----><!----><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=54&amp;specialtyid=0&amp;entitytype=2&amp;entityid=141" data-event="iBarMenu-a-submit">Submit your research</a></div></div></div><!--[--><div class="Ibar__journal Ibar__journal--main"><div class="Ibar__wrapper Ibar__wrapper--journal"><a href="//www.frontiersin.org/journals/neurology" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Neurology</span></div></div></a><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/applied-neuroimaging" data-event="iBarJournal-sections-a_id_156">Applied Neuroimaging</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/artificial-intelligence-in-neurology" data-event="iBarJournal-sections-a_id_3712">Artificial Intelligence in Neurology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/autonomic-disorders" data-event="iBarJournal-sections-a_id_3023">Autonomic Disorders</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/cognitive-and-behavioral-neurology" data-event="iBarJournal-sections-a_id_3740">Cognitive and Behavioral Neurology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/dementia-and-neurodegenerative-diseases" data-event="iBarJournal-sections-a_id_1439">Dementia and Neurodegenerative Diseases</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/diagnostic-neuropathology" data-event="iBarJournal-sections-a_id_2038">Diagnostic Neuropathology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/endovascular-and-interventional-neurology" data-event="iBarJournal-sections-a_id_143">Endovascular and Interventional Neurology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/epilepsy" data-event="iBarJournal-sections-a_id_144">Epilepsy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/experimental-therapeutics" data-event="iBarJournal-sections-a_id_1784">Experimental Therapeutics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/headache-and-neurogenic-pain" data-event="iBarJournal-sections-a_id_153">Headache and Neurogenic Pain</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/movement-disorders" data-event="iBarJournal-sections-a_id_145">Movement Disorders</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/multiple-sclerosis-and-neuroimmunology" data-event="iBarJournal-sections-a_id_147">Multiple Sclerosis and Neuroimmunology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neuro-oncology-and-neurosurgical-oncology" data-event="iBarJournal-sections-a_id_150">Neuro-Oncology and Neurosurgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neuro-ophthalmology" data-event="iBarJournal-sections-a_id_154">Neuro-Ophthalmology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neuro-otology" data-event="iBarJournal-sections-a_id_155">Neuro-Otology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neurocritical-and-neurohospitalist-care" data-event="iBarJournal-sections-a_id_159">Neurocritical and Neurohospitalist Care</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neuroepidemiology" data-event="iBarJournal-sections-a_id_1339">Neuroepidemiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neurogenetics" data-event="iBarJournal-sections-a_id_160">Neurogenetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neuroinfectious-diseases" data-event="iBarJournal-sections-a_id_1334">Neuroinfectious Diseases</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neurological-biomarkers" data-event="iBarJournal-sections-a_id_2345">Neurological Biomarkers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neuromuscular-disorders-and-peripheral-neuropathies" data-event="iBarJournal-sections-a_id_146">Neuromuscular Disorders and Peripheral Neuropathies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neurorehabilitation" data-event="iBarJournal-sections-a_id_547">Neurorehabilitation</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neurotechnology" data-event="iBarJournal-sections-a_id_3418">Neurotechnology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neurotrauma" data-event="iBarJournal-sections-a_id_163">Neurotrauma</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/pediatric-neurology" data-event="iBarJournal-sections-a_id_161">Pediatric Neurology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/sleep-disorders" data-event="iBarJournal-sections-a_id_151">Sleep Disorders</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/stroke" data-event="iBarJournal-sections-a_id_142">Stroke</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/neurology/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/neurology/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/neurology/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div></div></div><div class="Ibar__journal Ibar__journal--mix"><div class="Ibar__wrapper Ibar__wrapper--journal"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/neurology" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Neurology</span></div></div></a><div class="Ibar__spacer"></div><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/applied-neuroimaging" data-event="iBarJournal-sections-a_id_156">Applied Neuroimaging</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/artificial-intelligence-in-neurology" data-event="iBarJournal-sections-a_id_3712">Artificial Intelligence in Neurology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/autonomic-disorders" data-event="iBarJournal-sections-a_id_3023">Autonomic Disorders</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/cognitive-and-behavioral-neurology" data-event="iBarJournal-sections-a_id_3740">Cognitive and Behavioral Neurology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/dementia-and-neurodegenerative-diseases" data-event="iBarJournal-sections-a_id_1439">Dementia and Neurodegenerative Diseases</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/diagnostic-neuropathology" data-event="iBarJournal-sections-a_id_2038">Diagnostic Neuropathology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/endovascular-and-interventional-neurology" data-event="iBarJournal-sections-a_id_143">Endovascular and Interventional Neurology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/epilepsy" data-event="iBarJournal-sections-a_id_144">Epilepsy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/experimental-therapeutics" data-event="iBarJournal-sections-a_id_1784">Experimental Therapeutics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/headache-and-neurogenic-pain" data-event="iBarJournal-sections-a_id_153">Headache and Neurogenic Pain</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/movement-disorders" data-event="iBarJournal-sections-a_id_145">Movement Disorders</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/multiple-sclerosis-and-neuroimmunology" data-event="iBarJournal-sections-a_id_147">Multiple Sclerosis and Neuroimmunology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neuro-oncology-and-neurosurgical-oncology" data-event="iBarJournal-sections-a_id_150">Neuro-Oncology and Neurosurgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neuro-ophthalmology" data-event="iBarJournal-sections-a_id_154">Neuro-Ophthalmology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neuro-otology" data-event="iBarJournal-sections-a_id_155">Neuro-Otology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neurocritical-and-neurohospitalist-care" data-event="iBarJournal-sections-a_id_159">Neurocritical and Neurohospitalist Care</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neuroepidemiology" data-event="iBarJournal-sections-a_id_1339">Neuroepidemiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neurogenetics" data-event="iBarJournal-sections-a_id_160">Neurogenetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neuroinfectious-diseases" data-event="iBarJournal-sections-a_id_1334">Neuroinfectious Diseases</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neurological-biomarkers" data-event="iBarJournal-sections-a_id_2345">Neurological Biomarkers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neuromuscular-disorders-and-peripheral-neuropathies" data-event="iBarJournal-sections-a_id_146">Neuromuscular Disorders and Peripheral Neuropathies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neurorehabilitation" data-event="iBarJournal-sections-a_id_547">Neurorehabilitation</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neurotechnology" data-event="iBarJournal-sections-a_id_3418">Neurotechnology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/neurotrauma" data-event="iBarJournal-sections-a_id_163">Neurotrauma</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/pediatric-neurology" data-event="iBarJournal-sections-a_id_161">Pediatric Neurology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/sleep-disorders" data-event="iBarJournal-sections-a_id_151">Sleep Disorders</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/neurology/sections/stroke" data-event="iBarJournal-sections-a_id_142">Stroke</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/neurology/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/neurology/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/neurology/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/neurology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=54&amp;specialtyid=0&amp;entitytype=2&amp;entityid=141" data-event="iBarJournal-a-submit"><span>Submit</span><span>your research</span></a><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><!--]--></nav><div class="ArticlePage"><!--[--><div class="Layout Layout--withAside Layout--withIbarMix"><div class="Alert Alert--info Alert--noInfo ArticleTemplateBanner"><div class="Alert__icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" width="24px" class="FeedbackIcon"><path fill="#fff" d="M10 10h28v28H10z"></path><path fill="var(--blue50)" d="M24 2.88a21.12 21.12 0 1 0 0 42.24 21.12 21.12 0 0 0 0-42.24ZM22.08 13.4a.96.96 0 0 1 .96-.96h1.92a.96.96 0 0 1 .96.96v1.92a.96.96 0 0 1-.96.96h-1.92a.96.96 0 0 1-.96-.96V13.4Zm5.76 21.2a.96.96 0 0 1-.96.97h-5.76a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h.96v-7.68h-.96a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h3.84a.96.96 0 0 1 .96.96v10.56h.96a.96.96 0 0 1 .96.96v1.92Z"></path></svg></div><div class="Alert__main"><p class="Alert__message">Your new experience awaits. Try the new design now and help us make it even better</p><!--[--><button type="button" class="Button Button--outline Button--grey80 Button--small ArticleTemplateBanner__switchButton" data-event="btn-action"><span>Switch to the new experience</span></button><!--]--><!----></div><ol class="Alert__info"><!--[--><!--]--></ol></div><!----><main class="Layout__main"><!----><div class="ArticleDetails"><div class="ArticleLayoutHeader"><div class="ArticleLayoutHeader__info"><p class="ArticleLayoutHeader__info__title">SYSTEMATIC REVIEW article</p><p class="ArticleLayoutHeader__info__journalDate"><span>Front. Neurol.</span><span>, 02 September 2024</span></p><p class="ArticleLayoutHeader__info__journalDate"> Sec. Neuromuscular Disorders and Peripheral Neuropathies</p><p class="ArticleLayoutHeader__info__doiVolume"><span>Volume 15 - 2024 | </span><a class="ArticleLayoutHeader__info__doi" href="https://doi.org/10.3389/fneur.2024.1465747">https://doi.org/10.3389/fneur.2024.1465747</a></p><!----></div><!----><!----></div><div class="ArticleDetails__main__content"><div class="ArticleDetails__main__content__main ArticleDetails__main__content__main--fullArticle"><div class="JournalAbstract"><div class="JournalAbstract__titleWrapper"><h1>Assessing the effectiveness and safety of Patisiran and Vutrisiran in ATTRv amyloidosis with polyneuropathy: a systematic review</h1><!----></div><!----></div><div class="JournalFullText"><div class="JournalAbstract"> <a id="h1" name="h1"></a>
 <div class="authors"><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1843942" class="user-id-1843942"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1843942/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Mohammad Amin Karimi
&#x;">Mohammad Amin Karimi</a><sup>1</sup><sup>
&#x2020;</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/2064986" class="user-id-2064986"><img class="pr5" src="https://loop.frontiersin.org/images/profile/2064986/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Fatemeh Esmaeilpour Moallem
&#x;">Fatemeh Esmaeilpour Moallem</a><sup>2</sup><sup>
&#x2020;</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/2158070" class="user-id-2158070"><img class="pr5" src="https://loop.frontiersin.org/images/profile/2158070/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Mohammad Sadra Gholami Chahkand">Mohammad Sadra Gholami Chahkand</a><sup>2</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/2802865" class="user-id-2802865"><img class="pr5" src="https://loop.frontiersin.org/images/profile/2802865/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Eftekhar Azarm">Eftekhar Azarm</a><sup>3</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1830091" class="user-id-1830091"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1830091/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Mohammad Javad Emami Kazemabad">Mohammad Javad Emami Kazemabad</a><sup>4</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/2614325" class="user-id-2614325"><img class="pr5" src="https://loop.frontiersin.org/images/profile/2614325/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Parisa Alsadat Dadkhah&#xA;">Parisa Alsadat Dadkhah</a><sup>3</sup><sup>&#x0002A;</sup></span></div> <ul class="notes"> <li><span><sup>1</sup></span>School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran</li> <li><span><sup>2</sup></span>Student Research Committee, Golestan University of Medical Sciences, Gorgan, Iran</li> <li><span><sup>3</sup></span>School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran</li> <li><span><sup>4</sup></span>Student Research Committee, School of Medicine, Qom University of Medical Sciences, Qom, Iran</li> </ul>
<p class="mb15"><b>Background:</b> Hereditary transthyretin (ATTRv) amyloidosis, a multifaceted disorder affecting multiple systems, substantially diminishes patients&#x2019; physical capabilities and overall quality of life. Patisiran and Vutrisiran, two Ribonucleic acid (RNA) interference therapies, target reducing both pathogenic and wild-type transthyretin (TTR) protein levels. This systematic review assesses the effectiveness and safety of these treatments in managing ATTRv.</p>
<p class="mb15"><b>Methods:</b> A comprehensive, thorough literature search across databases including Embase, PubMed, Web of Science, Cochrane Central, and Google Scholar yielded 858 studies. Following removing duplicate and irrelevant articles, 676 distinct studies underwent review. These studies, conducted on a global scale, encompassed a range of methodologies, including clinical trials and indirect treatment comparisons.</p>
<p class="mb15"><b>Results:</b> Ten studies, spanning a total population of 756 patients, were selected for in-depth analysis. Patisiran and Vutrisiran consistently demonstrated significant improvements in primary and secondary endpoints related to neuropathy, quality of life, and cardiac function. Both medications were well-tolerated, with primarily mild to moderate adverse events. Indirect treatment comparison studies indicated Vutrisiran&#x2019;s superiority over Tafamidis in treating ATTRv amyloidosis.</p>
<p class="mb0"><b>Conclusion:</b> This systematic review recommends using Patisiran and Vutrisiran to treat ATTRv amyloidosis. The findings suggest that these RNA interference therapies improve neuropathy, quality of life, and cardiac symptoms. The results indicate sustained benefits over prolonged treatment, with satisfactory safety profiles. However, potential biases, conflicts of interest in the studies, and limited follow-up periods in some trials necessitate cautious interpretation. Future research should address these limitations and provide more robust evidence for the long-term efficacy and safety of Patisiran and Vutrisiran in ATTRv treatment.</p> <div class="clear"></div> </div> <div class="JournalFullText"> <a id="h2" name="h2"></a>
<h2>Introduction</h2>
<p class="mb15">Hereditary transthyretin (ATTRv) amyloidosis is a disease typically manifesting in adulthood, subsequent to mutations within the transthyretin (TTR) gene. TTR protein constitutes a circulating tetramer serving as a carrier protein for thyroxine and retinol-binding proteins affiliated with vitamin A. TTR is detectable in both serum and cerebrospinal fluid, predominantly biosynthesized in hepatic tissue, with minor synthesis occurring in the eye and the brain (<a href="#ref1">1</a>). Genetic mutations within the TTR gene precipitate the destabilization of its tetrameric structure, resulting in the dissociation into misfolded monomers, which aggregate within extracellular spaces, forming oligomers that eventually coalesce into amyloid fibrils typified by cross &#x03B2;-sheets (<a href="#ref2">2</a>). Accumulation of mutated transthyretin primarily occurs in the heart and peripheral nervous system (PNS), with secondary involvement of various organs such as the brain, kidneys, skin, and muscles, rendering ATTRv a multisystemic disorder. Over 130 pathogenic mutations have been delineated, with the most common TTR variants being the valine-to-methionine substitution at amino acid 30 mutation (Val30Met) and the Val122Ile mutation. However, early-onset disease is not the typical phenotype in all endemic areas. Late-onset disease is more common in Sweden, and this phenotype is also present in Japan and Portugal (<a href="#ref3">3</a>). Other mutations, particularly non-Val30Met variants, predominantly present with delayed manifestation characteristics (<a href="#ref4">4</a>). Primary clinical manifestations of ATTRv predominantly affecting the PNS or cardiac system delineate distinct neurological or cardiac phenotypes. However, most mutations progressively manifest as a mixed phenotype involving both systems throughout the disease course (<a href="#ref1">1</a>).</p>
<p class="mb15">ATTRv polyneuropathy emerges due to the accumulation of TTR within the PNS, leading to the development of sensory-motor and autonomic neuropathies characterized by length-dependent patterns. Manifesting as a progressive and incapacitating condition, untreated ATTRv results in a worsening disability, ultimately culminating in wheelchair dependence, bedridden states, and eventual mortality (<a href="#ref5">5</a>). Therefore, early identification of individuals affected by ATTRv is imperative, and prompt initiation of treatment is vital to enhance their quality of life (QOL) and attain favorable clinical outcomes (<a href="#ref6">6</a>).</p>
<p class="mb15">Therapeutic modalities for ATTRv amyloidosis encompass a range of interventions, including transthyretin tetramer stabilizers such as Tafamidis, pharmacotherapies targeting transthyretin reduction like Patisiran, and surgical interventions such as liver transplantation (<a href="#ref7">7</a>, <a href="#ref8">8</a>). Patisiran and Vutrisiran represent two newly approved pharmaceutical agents designed to mitigate abnormal protein levels through mechanisms involving either stabilization of protein structure or inhibition of protein production. These medications are classified as RNA interference (RNAi) therapies, explicitly targeting the TTR gene and effectively diminishing its expression within the liver (<a href="#ref9">9</a>&#x2013;<a href="#ref12">12</a>). Both pharmaceutical compounds have demonstrated effectiveness and safety through clinical trials involving individuals afflicted with ATTRv accompanied by polyneuropathy. These medications have obtained regulatory approval from both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) (<a href="#ref13">13</a>&#x2013;<a href="#ref15">15</a>). However, these drugs have differences and discrepancies regarding their mode of action, pharmacokinetics, and clinical outcomes.</p>
<p class="mb15">Medications like Inotersen and Eplontersen are anti-sense oligonucleotides and mediate RNA cleavage (<a href="#ref16">16</a>, <a href="#ref17">17</a>). They target the mRNA of the transthyretin gene and reduce the production of abnormal proteins that are responsible for ATTRv amyloidosis (<a href="#ref17">17</a>, <a href="#ref18">18</a>). Activation of RNase H by Inotersen causes cleavage of the mRNA that is responsible for transthyretin coding (<a href="#ref18">18</a>). Eplontersen attaches to both normal and mutant TTR mRNA and causes their degradation. This process inhibits TTR protein production, preventing amyloid deposits (<a href="#ref17">17</a>). Both Inotersen and Eplontersen have been recently approved for the treatment of polyneuropathy in patients with hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis) (<a href="#ref17">17</a>, <a href="#ref18">18</a>).</p>
<p class="mb0">This systematic review aims to critically examine and compare the cardiologic, neurologic, and adverse events of Patisiran and Vutrisiran on ATTRv with polyneuropathy.</p> <a id="h3" name="h3"></a>
<h2>Methods</h2>
<h3>Study protocol</h3>
<p class="mb0">Our systematic review assessed the efficacy of novel drugs for polyneuropathy in ATTRv amyloidosis (Patisiran and Vutrisiran). The current investigation followed the guidelines specified within the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) framework to conduct a thorough systematic review and meta-analysis in accordance with established protocols (<a href="#ref19">19</a>). The design protocol for our study was appropriately registered in the Open Science Framework (OSF). The hyperlink supplied leads to the OSF database, which houses a unique identification number record.<sup id="footnotesuper1"><a id="xfn0001"></a><a class="footnoteanchor" href="#fn0001">1</a></sup></p>
<h3>Literature search</h3>
<p class="mb0">In the initial stage, relevant keywords were determined using Medical Subject Headings (MeSH) terminology. Subsequently, a thorough inquiry was conducted till September 16, 2023. The investigation utilized the following databases: PubMed, Google Scholar, Scopus, Web of Science, and Cochrane Central. The search strategy was executed by considering the title, abstract, and pertinent keywords and tags, utilizing sophisticated search functionalities for each search engine. To enhance the accuracy of the search, the search strategy involved three primary subgroups of keywords and MeSH. One subgroup encompassed terms associated with the generic, brand, and premarketing titles of Patisiran and Vutrisiran. The second subgroup included keywords and terminology of Amyloid Neuropathies. Finally, the subgroups were merged using the &#x2018;AND&#x2019; operator. No specific limitations or restrictions were placed on the date, type of publishing, or language. The search methodology utilized in this investigation is illustrated in <a href="#SM1">Supplementary Table 1</a>.</p>
<h3>Study selection</h3>
<p class="mb0">This research is dedicated to examining the criteria for inclusion and exclusion within the research framework. The investigators utilized specific parameters to identify suitable publications. The eligibility requirements for this study were delineated as follows:</p>
<p style="margin-left:1em;text-indent:-1em;margin-top:1em;margin-bottom:0em;text-align:left;">&#x02022; 1. The study design needed to encompass observational cohort studies (both retrospective and prospective), randomized controlled trials, or early-phase clinical trials. These studies must be published in peer-reviewed journals and comprehensively analyzed.</p>
<p style="margin-left:1em;text-indent:-1em;margin-top: 0em;margin-bottom:0em;text-align:left;">&#x02022; 2. The trials under investigation must have evaluated Patisiran and Vutrisiran as interventions for Amyloidosis.</p>
<p style="margin-left:1em;text-indent:-1em;margin-top: 0em;margin-bottom:0em;text-align:left;">&#x02022; 3. The current study incorporated research inquiries that delved into the comparative efficacy of Patisiran or Vutrisiran compared to placebo, active therapies, or no intervention among adults aged 18&#x2009;years or older.</p>
<p style="margin-left:1em;text-indent:-1em;margin-top:0em;margin-bottom:1em;text-align:left;">&#x02022; 4. Our study comprised investigations documenting at least one occurrence of neurological or cardiologic outcomes or adverse events.</p>
<p class="mb0">Conversely, the exclusion criteria were defined as follows:</p>
<p style="margin-left:1em;text-indent:-1em;margin-top:1em;margin-bottom:0em;text-align:left;">&#x02022; 1. The surveyed population was confined to patients with ATTRv, excluding those with other types of Amyloidosis.</p>
<p style="margin-left:1em;text-indent:-1em;margin-top: 0em;margin-bottom:0em;text-align:left;">&#x02022; 2. Studies evaluating outcomes deemed irrelevant were excluded from the analysis.</p>
<p style="margin-left:1em;text-indent:-1em;margin-top:0em;margin-bottom:1em;text-align:left;">&#x02022; 3. Only well-designed observational cohort studies (including retrospective and prospective), randomized controlled trials, or early-phase clinical trials were considered for inclusion. Studies employing alternative methods, conducted on animal models, displaying biases, or utilizing different study designs were excluded from this analysis.</p>
<h3>Data extraction</h3>
<p class="mb0">The present analysis focused exclusively on observational cohort studies, including retrospective and prospective designs and randomized controlled trials. Early-phase clinical trials published in peer-reviewed journals were also considered, and comprehensive evaluations were conducted. Our main aim was to thoroughly examine scholarly literature that explores the effects of Patisiran and Vutrisiran on the polyneuropathy associated with ATTRv. After an exhaustive search, eliminating duplicate entries, and retrieving relevant articles, two researchers meticulously reviewed the titles and abstracts of selected studies. In instances of inconsistencies, a third author was consulted to facilitate resolution through deliberation. Subsequently, the next phase involved thoroughly analyzing the full text of identified articles to ascertain their precise alignment with the established inclusion criteria. All studies meeting the predetermined inclusion criteria were incorporated into the analysis, and a third reviewer resolved any discrepancies. The two reviewers systematically gathered pertinent study data using a pre-established data collection table. This encompassed details such as the author&#x2019;s identification, study methodology, year of publication, sample size, duration, and characteristics of the patient groups. Additionally, the researchers collected various patient characteristics, including gender, age, dosage, follow-up duration, ethnicity, and outcomes. The screening procedure is illustrated in the 2020 PRISMA checklist, as shown in <a href="#SM1">Supplementary Figure 1</a>.</p>
<h3>Quality assessment</h3>
<p class="mb0">Three reviewers individually evaluated the full texts of the articles for suitability, employing critical appraisal instruments sourced from the website specified.<sup id="footnotesuper2"><a id="xfn0002"></a><a class="footnoteanchor" href="#fn0002">2</a></sup> They resolved any disagreements by discussion and consultation with the corresponding author. Three reviewers independently collected the data using a predetermined template. This template encompassed the subsequent information: study title, publication year, publication journal, study characteristics (study design, participants, mean age, administered dose, follow-up duration), and primary outcomes (neurologic and cardiologic parameters and adverse events).</p> <a id="h4" name="h4"></a>
<h2>Results</h2>
<h3>Study selection and characteristics</h3>
<p class="mb15">A comprehensive search of primary literature databases encompassing Embase, PubMed, Web of Science, Cochrane Central, and Google Scholar identified 858 studies relevant to the present analysis. After removing duplicate items, the dataset was narrowed down to 676 distinct research studies. Subsequently, a meticulous review of titles and abstracts excluded 577 articles considered irrelevant to the research. Consequent analysis was applied to 99 remaining records, involving a comprehensive examination of their complete texts. Out of this group, 89 papers were excluded because they contained irrelevant or unnecessary information, resulting in a final collection of relevant studies for thorough examination. Finally, 10 articles with a total population of 756 were reviewed.</p>
<p class="mb15">Coelho et al. (<a href="#ref20">20</a>) employed Phase 1 randomized, single-blind, placebo-controlled, dose-ranging trials to assess the safety and dosage response of two RNAi therapies, ALN-TTR01 and ALN-TTR02 (Patisiran). Several research centers across Portugal, Sweden, France, and the United Kingdom actively participated in this study. The recruitment process entailed including 32 patients for ALN-TTR01 and 17 patients for ALN-TTR02, with 56% being male in the former group and all participants being male in the latter group. The mean age recorded for participants in the ALN-TTR01 trial was 32&#x2009;years, whereas for those in the ALN-TTR02 trial, it was 27&#x2009;years. The dosage range for ALN-TTR01 was 0.01 to 1.0&#x2009;mg/kg, and for ALN-TTR02, it was 0.01 to 0.5&#x2009;mg/kg (<a href="#ref20">20</a>).</p>
<p class="mb15">The Phase 2 study by Coelho et al. (<a href="#ref21">21</a>) was conducted internationally across seven countries, including the United States, Brazil, France, Germany, Portugal, Spain, and Sweden. The research comprised a cohort of 27 individuals diagnosed with ATTRv, manifesting mild-to-moderate neuropathic symptoms. The median age of the participants was 64, with 18 being male. The participants received intravenous administration of Patisiran at a dosage of 0.3&#x2009;mg/kg every 3&#x2009;weeks (Q3W) for a duration of approximately 2&#x2009;years (<a href="#ref21">21</a>).</p>
<p class="mb15">The study conducted by Suhr et al. (<a href="#ref22">22</a>) was characterized by its multicenter and international nature, employing an open-label design focusing on multiple-dose escalation in a phase two clinical trial. A total of 29 individuals met the eligibility criteria for participation in the study. The cohort included patients from diverse nationalities, including Brazilian, French, German, Portuguese, Spanish, Swedish, and American. Notably, all enrolled patients identified as of Caucasian ethnicity, with 69% being male, and the average age of the participants was 55.6&#x2009;years. In the context of this phase 2 investigation, individuals diagnosed with familial amyloid polyneuropathy (FAP) were subjected to two intravenous infusions of Patisiran, each administered at varying doses: 0.01 (<i>n</i> =&#x2009;4), 0.05 (<i>n</i>&#x2009;=&#x2009;3), 0.15 (<i>n</i>&#x2009;=&#x2009;3), or 0.3 (<i>n</i>&#x2009;=&#x2009;7) mg/kg every 4&#x2009;weeks (Q4W). Additionally, a subset of patients received a dosage of 0.3&#x2009;mg/kg Q3W, amounting to a cohort of 12 participants (<a href="#ref22">22</a>).</p>
<p class="mb15">The HELIOS-A was a worldwide, open-label phase 3 clinical trial conducted by Adams et al. (<a href="#ref13">13</a>). In this study cohort, 122 individuals were designated for the Vutrisiran cohort, 42 for the Patisiran reference cohort, and 77 subjects for the external placebo cohort. Notably, there was a significant male predominance observed within the HELIOS-A cohort, comprising 64.6% (<i>n</i>&#x2009;=&#x2009;106), and within the APPOLO cohort (placebo), constituting 75.3% (<i>n</i>&#x2009;=&#x2009;58). The study encompassed participants aged 18 to 85, recruited from 57 different sites across 22 countries. They were randomly assigned to receive either Vutrisiran at a dosage of 25&#x2009;mg subcutaneously every 3&#x2009;months (Q3M) or Partisan at a dosage of 0.3&#x2009;mg/kg intravenously Q3W over a period of 18&#x2009;months (<a href="#ref13">13</a>).</p>
<p class="mb15">Merkel et al. (<a href="#ref23">23</a>) carried out a comparative study, utilizing data from phase three randomized controlled trials involving three distinct groups: the Fx-005, HELIOS-A trial, and APOLLO trial cohorts, comprising 125, 164, and 77 patients, respectively. The Fx-005 trial focused on transthyretin amyloidosis patients with polyneuropathy, and the Val30Met in the TTR variant was a multinational, multicenter, randomized, double-blinded, and placebo-controlled study. It enrolled 125 patients in an intention-to-treat (ITT) group, allocated in a 1:1 ratio to receive either 20&#x2009;mg of Tafamidis orally (<i>n</i>&#x2009;=&#x2009;64) or placebo (<i>n</i> =&#x2009;61) daily for 18&#x2009;months. The HELIOS-A trial, also a phase three study, was a randomized, worldwide, open-label investigation assessing the efficacy of Vutrisiran in patients with transthyretin amyloidosis and polyneuropathy. This trial involved 164 patients randomly assigned in a 3:1 ratio to receive either Vutrisiran (<i>n</i>&#x2009;=&#x2009;122; 25&#x2009;mg subcutaneously, Q3M) or Partisan (<i>n</i>&#x2009;=&#x2009;42; 0.3&#x2009;mg/kg intravenously, Q3W), which served as the reference comparator. The treatment duration was 18&#x2009;months, with data from the APOLLO trial, a phase 3 study of Patisiran, used as an external placebo in this investigation. The primary objectives of the study were to evaluate the improvement or stability of the Neuropathy Impairment Score in the Lower Limbs (NIS-LL) and changes in the Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN) total score following 18&#x2009;months of Fx-005 treatment. The HELIOS-A trial assessed changes in the modified Neuropathy Impairment Score&#x2009;+&#x2009;7 (mNIS +7) from the baseline measurement at either 9 or 18&#x2009;months, depending on jurisdictional requirements (<a href="#ref23">23</a>).</p>
<p class="mb15">The original study by Adams et al. (<a href="#ref24">24</a>) was a phase 3 study conducted across multiple international centers, employing randomization, a placebo control, and a double-blind methodology. It enrolled 225 participants from 44 sites situated in 19 different countries. The study cohort comprised 167 male participants, representing 74% of the total sample, with a median age of 62. These individuals were subjected to random assignment, wherein they were allocated to receive either Patisiran or a placebo as part of a meticulously controlled clinical trial. In this study, 148 individuals were administered Patisiran intravenously at 0.3&#x2009;mg/kg, with each infusion lasting about 80&#x2009;min. This treatment regimen was administered Q3W for a total duration of 18&#x2009;months. In contrast, the remaining 77 participants were subjected to a placebo intervention (<a href="#ref24">24</a>).</p>
<p class="mb15">In a Phase 3b study conducted by Schmidt et al. (<a href="#ref25">25</a>), 24 individuals with ATTRv amyloidosis and post-LT polyneuropathy were investigated. They were administered a 0.3&#x2009;mg/kg Patisiran intravenous infusion once every 3&#x2009;weeks for 12&#x2009;months. The multinational study encompassed participants from seven countries: France, Germany, Italy, Portugal, Spain, Sweden, and the United Kingdom. The participants had an average age of 58.1 and a mean BMI of 23.5. Males accounted for 56.5% (<i>n</i>&#x2009;=&#x2009;13) of the sample, with 95.7% identifying as white. Notably, the majority of participants identified as non-Hispanic or Latino (<a href="#ref25">25</a>).</p>
<p class="mb15">The original article by Bleecker et al. (<a href="#ref26">26</a>) is a retrospective study conducted across six Belgian neuromuscular reference centers. The study encompassed a cohort of nine patients, with a median age of 63, who underwent treatment with Patisiran. The Partisan administration was conducted via an 80-min intravenous infusion at 300&#x2009;&#x03BC;g/kg dosage, administered in Q3W intervals as part of an Expanded Access Program (EAP) (<a href="#ref26">26</a>).</p>
<p class="mb15">The original study by Fontana et al. (<a href="#ref27">27</a>) encompassed 32 participants diagnosed with transthyretin cardiomyopathy (ATTR-CM). The cohort was divided into two distinct groups: one designated as the treatment group consisting of 16 patients, and another identified as the control group with equal participants. The median age of subjects in the treatment group was 62&#x2009;years, with 13 male participants, while the control group exhibited a median age of 69&#x2009;years, encompassing 14 male participants. All patients were administered 0.3&#x2009;mg/kg Patisiran via infusion Q3W. Of the 16 patients, 12 were given Diflunisal, a TTR-stabilizing drug, orally at 250&#x2009;mg twice daily. The study participants underwent serial monitoring at 12&#x2009;months through cardiac magnetic resonance, cardiac biomarkers, bone scintigraphy, 6-min walk tests (6MWTs), and echocardiography (<a href="#ref27">27</a>).</p>
<p class="mb15">Adams et al. (<a href="#ref28">28</a>) conducted an international, open-label extension (OLE) study across 43 medical facilities spanning 19 countries. This investigation enrolled individuals who had successfully concluded either the phase 3 APOLLO trial or the phase 2 OLE parent trials and could tolerate the experimental medication. The eligible participants from both the APOLLO trial (including both the patisiran and placebo cohorts) and the phase 2 OLE trial (Patisiran cohort) were included in this global extension study, receiving intravenous Patisiran at a dosage of 0.3&#x2009;mg/kg Q3W, with a planned study period of up to 5&#x2009;years. Recruitment took place between July 13, 2015, and August 21, 2017, with 211 out of 212 eligible patients enrolled, comprising 137 from the APOLLO-Partisan group, 49 from the APOLLO-placebo group, and 25 from the phase 2 OLE partisan group. As of the data cutoff on September 24, 2018, completion rates for the 12-month assessments were 92% (126 out of 137) for the APOLLO-Partisan group, 78% (38 out of 49) for the APOLLO-placebo group, and 100% (25 out of 25) for the phase 2 OLE Patisiran group (<a href="#ref28">28</a>).</p>
<p class="mb0">The summary of the study&#x2019;s characteristics is presented in <a href="#tab1">Table 1</a>.</p>
<div class="DottedLine"></div> <div class="Imageheaders">Table 1</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t001.jpg" name="table1" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t001.jpg" alt="www.frontiersin.org" id="tab1" loading="lazy">
  </picture>
</a>
<p><b>Table 1</b>. Characteristics of studies.
</p></div> <div class="clear"></div> <div class="DottedLine"></div>
<h3>Main results</h3>
<p class="mb15">Coelho et al. (<a href="#ref20">20</a>) investigation focused on assessing the safety and efficacy of two RNAi therapies, ALN-TTR01 and ALN-TTR02 (Patisiran), focusing on TTR levels within individuals diagnosed with ATTRv and a control group of unaffected individuals. In the ALN-TTR01 trial involving 32 ATTRv patients, single doses of ALN-TTR01 (ranging from 0.01 to 1.0&#x2009;mg/kg) or placebo were administered. Notably, the 1.0&#x2009;mg/kg dose demonstrated a significant 38% mean TTR knockdown at day seven compared to the placebo, affecting both mutant and nonmutant TTR similarly. Infusion reactions of mild to moderate severity occurred in 20.8% of the ALN-TTR01 group. In the ALN-TTR02 Phase 1 trial with 17 healthy volunteers, single doses of ALN-TTR02 (ranging from 0.01 to 0.5&#x2009;mg/kg) or placebo were given. The study revealed potent, dose-dependent TTR lowering, with a mean 82&#x2013;87% TTR knockdown at nadir for 0.15 and 0.3&#x2009;mg/kg doses. Remarkably, a durable knockdown of 56&#x2013;67% persisted on day 28, with only one mild infusion reaction reported in the 0.5&#x2009;mg/kg group (<a href="#ref20">20</a>).</p>
<p class="mb15">In summary, ALN-TTR01 and ALN-TTR02 demonstrated a significant capacity to suppress TTR production via an RNAi mechanism, thereby establishing proof of concept. ALN-TTR02 exhibited notably enhanced potency compared to ALN-TTR01, and both RNAi therapies were generally well-tolerated. Additional research is crucial to assess these interventions&#x2019; clinical effectiveness and long-term safety thoroughly (<a href="#ref20">20</a>).</p>
<p class="mb15">Coelho et al. (<a href="#ref21">21</a>) conducted research that revealed that prolonged Patisiran administration was both safe and efficacious in arresting or facilitating the advancement of polyneuropathy in individuals with ATTRv. Patisiran reduced TTR levels by approximately 82% over 24&#x2009;months, resulting in an average improvement of 6.95 points in mNIS+7 compared to baseline among 19 out of 27 patients at the end of the 24&#x2009;months. Throughout the duration of the study, assessments of motor function, autonomic symptoms, disease progression, and quality of life showed no notable changes. Likewise, no significant variations were observed in echocardiographic evaluations or cardiac biomarkers among the subgroup of patients with cardiac involvement. Reported adverse events were mainly mild to moderate severity, and none necessitated treatment discontinuation. Flushes and infusion reactions were the most common drug-related incidents, each accounting for 22% of the reported adverse events (<a href="#ref21">21</a>).</p>
<p class="mb15">Suhr et al. (<a href="#ref22">22</a>) attempted to evaluate the tolerability, safety, pharmacokinetic (PK), and pharmacodynamic (PD) of Patisiran in patients with transthyretin-mediated FAP. The inclusion criteria for this study encompassed adult patients diagnosed with confirmed ATTRv. Baseline serum levels of TTR proteins exhibited uniformity across various dosage cohorts. TTR knockdown was identical between patients with the Val30Met and those with non-Val30Met genotypes. The reduction in TTR levels was strongly correlated with decreased circulating retinol-binding protein (RBP) and vitamin A. After the administration of Patisiran, the mean concentrations of the TTR small interfering RNAs (siRNAs) component decreased (<a href="#ref22">22</a>).</p>
<p class="mb15">Nevertheless, there was no buildup of siRNAs after administering the second dose. The C<sub>max</sub> and AUC0-last increased proportionally with the dose for both the first and second doses. Mild-to-moderate reaction during the infusion was the main side effect associated with their study. It is worthy of note that a few cases also experienced various adverse events, including back pain, asthenia, leukocytosis, neutrophilia, cellulitis, lymphangitis, polyuria, nausea/vomiting, facial erythema, dry mouth, pyrexia, dysphagia (<a href="#ref22">22</a>).</p>
<p class="mb15">The study HELIOS-A was conducted by Adams et al. (<a href="#ref13">13</a>), which lasted for 18&#x2009;months, and examined the safety and effectiveness of Vutrisiran for individuals with ATTRv and polyneuropathy. The investigation demonstrated that Vutrisiran exerted a favorable influence on the primary endpoint, specifically the alteration from baseline in the modified Neuropathy Impairment Score&#x2009;+&#x2009;7 (mNIS+7) at the nine-month mark (&#x02212;2.24 [Vutrisiran] and&#x2009;+&#x2009;14.76 [placebo] (<i>p</i>&#x2009;=&#x2009;3.54 &#x000D7; 10&#x2013;12)). Furthermore, the compound demonstrated favorable outcomes across various secondary efficacy measures. Vutrisiran exhibited notable advancements in Norfolk QOL-DN during the ninth month compared to the external placebo cohort. The Vutrisiran group demonstrated a 53.4% enhancement, surpassing the 23.4% improvement observed in the placebo group, as indicated by the Norfolk QOL-DN score. By the eighteenth month, these figures further accentuated the positive impact of Vutrisiran, with a 56.8% improvement observed in the Vutrisiran group, in contrast to a mere 10.4% improvement in the placebo group. The 10-meter walk test (10MWT) demonstrated significant improvements at both the nine and 18-month intervals (<a href="#ref13">13</a>).</p>
<p class="mb15">Additionally, the mNIS+7 results after 18&#x2009;months showed a notable difference, with a decrease of 0.46 for Vutrisiran and an increase of 28.1 for the placebo. Notably, 48.3% of Vutrisiran recipients exhibited improvement in mNIS+7, in contrast to only 3.9% in the external placebo cohort. Furthermore, favorable results were noted in the modified Body Mass Index (mBMI) and the Rasch-built Overall Disability Scale (R-ODS) after 18&#x2009;months. The majority of adverse occurrences documented exhibited mild to moderate severity and aligned with the expected course of ATTRv. Noteworthy is the absence of any occurrences necessitating cessation of drug treatment or resulting in fatalities. The research findings underscore that Vutrisiran demonstrated substantial improvements in various disease-related parameters for ATTRv compared to an external placebo while maintaining a commendable safety record (<a href="#ref13">13</a>).</p>
<p class="mb15">Merkel et al. (<a href="#ref23">23</a>) conducted an investigation employing Indirect Treatment Comparison (ITC) methodology to evaluate the therapeutic effectiveness of Vutrisiran and Tafamidis across diverse parameters such as NIS-LL, Norfolk QOL-DN score, NIS-LL Response, and mBMI. This investigation seeks to establish the effectiveness of both Vutrisiran and Tafamidis in treating ATTRv with polyneuropathy. The empirical basis for this study is derived from the analysis of data obtained from phase three randomized controlled trials, namely HELIOS-A, APOLLO, and Fx-005 studies. These trials systematically evaluated and compared the outcomes associated with Vutrisiran and Tafamidis interventions in the context of ATTRv with polyneuropathy. The primary analysis demonstrated a statistically significant superiority of Vutrisiran compared to Tafamidis in terms of the average change from baseline at the 18-month evaluation point for two crucial outcome metrics: the NIS-LL (mean difference: &#x02212;5.3, 95% CI: &#x02212;9.4 to &#x02212;1.2, <i>p</i>&#x2009;=&#x2009;0.011) and the Norfolk QOL-DN (mean difference: &#x02212;18.3, CI 95%: &#x02212;28.6 to &#x02212;8.0, <i>p</i>&#x2009;&#x0003C;&#x2009;0.001). Additionally, Vutrisiran exhibited superior efficacy in the NIS-LL Responder outcome at the 18-month mark compared to Tafamidis NIS-LL response (odds ratio: 1.7). This ITC study concluded that Vutrisiran has higher efficacy in enhancing multiple measures of polyneuropathy impairment and health-related quality of life (HRQOL) compared to Tafamidis in patients with ATTRv amyloidosis with polyneuropathy (<a href="#ref23">23</a>).</p>
<p class="mb15">Adams et al. (<a href="#ref24">24</a>) conducted a research study to examine the effectiveness of Patisiran in patients with ATTRv with polyneuropathy. All individuals involved in this research were of adult age and exhibited an NIS ranging from 5 to 130, along with a polyneuropathy disability score of 3b or below, and demonstrated sufficient liver and renal functionality. According to the research, Patisiran demonstrated significant enhancements in both the primary endpoint (mNIS+7) for 56% of the patients who received the treatment, as opposed to only 4% of those who received a placebo. Additionally, regarding the secondary endpoint, Norfolk QOL-DN score, 51% of the patients who received Patisiran displayed an improvement in their Norfolk QOL-DN score, compared to 10% of those who received a placebo. In the subset of individuals within the cardiac subpopulation, Patisiran demonstrated a superior impact on cardiac structural integrity and functionality compared to administering a placebo. It is noteworthy that both cohorts documented the occurrence of adverse events throughout the clinical trial (<a href="#ref24">24</a>).</p>
<p class="mb15">Schmidt et al. (<a href="#ref25">25</a>) conducted a Phase 3b open-label trial to evaluate the efficacy and safety of Patisiran in patients with ATTRv amyloidosis who experienced polyneuropathy progression following liver transplantation. The study involved mature individuals who had received a liver transplant as a treatment for ATTRv amyloidosis at least a year before the study and had encountered the advancement of polyneuropathy after the transplant. The research findings revealed that Patisiran led to an average reduction of approximately 91% in TTR levels between Months 6 and 12. Additionally, at Month 12, improvements in neuropathy, quality of life, and autonomic symptoms were observed, with mean changes from baseline of &#x02212;3.7 (SEM 2.7) in the NIS, &#x02212;6.5 (SEM 4.9) in the Norfolk QOL-DN score, and&#x2009;&#x02212;&#x2009;5.0 (SEM 2.6) in the Composite Autonomic Symptom Score-31 (COMPASS-31). Measures of disability, assessed using the R-ODS, and nutritional status, monitored through the mBMI, remained relatively stable with mean changes from baseline of &#x02212;0.1 (SEM 1.1) and&#x2009;+&#x2009;4.4 (SEM 21.8), respectively, over the 12-month treatment period. Adverse events reported during the trial were consistent with the known safety profile of Patisiran, including diarrhea and infusion-related reactions (<a href="#ref25">25</a>).</p>
<p class="mb15">After an 18-month retrospective study, Bleecker et al. (<a href="#ref26">26</a>) investigated 12 patients diagnosed with ATTRv who underwent Patisiran treatment. The comprehensive character of the disease is demonstrated through the manifestation of neurological and/or cardiological symptoms, as indicated by various metrics and assessments. The investigation revealed that 98.9% of the intended treatment regimens were successfully executed throughout the study (<a href="#ref26">26</a>). The median durations of treatment were 551.1&#x2009;days and 700&#x2009;days, respectively, spanning from 35 to 815&#x2009;days. Among the patients, seven exhibited stage 1 polyneuropathy, while the remaining five presented stage 2. The polyneuropathy disability (PND) score varied from 1 to 3b, with a median NIS-LL score of 31. Eleven patients had abnormal Electromyography (EMG) results. The median Functional Independence Measurements (FIM) score was 115, and six patients had cardiac symptoms. Six patients had abnormal electrocardiogram (ECG) and left ventricular ejection fraction (LVEF) findings (<a href="#ref26">26</a>).</p>
<p class="mb0">Fontana et al. (<a href="#ref27">27</a>) investigated for 12&#x2009;months and found that Patisiran was well tolerated. The median reduction in serum TTR levels among the cohort of treated patients amounted to 86% (interquartile range [IQR]: 82 to 90%). Furthermore, it is noteworthy that 82% of the cases exhibited a TTR knockdown exceeding 80%. The administration of Patisiran therapy showed a remarkable decrease in extracellular volume (ECV), as evidenced by the adjusted mean difference between groups amounting to &#x02212;6.2% (<i>p</i>&#x2009;=&#x2009;0.001). Furthermore, there was an evident reduction in levels of N-terminal pro&#x2013;B-type natriuretic peptide (NT-proBNP) linked with Patisiran treatment, as demonstrated by the adjusted mean difference between cohorts, which amounted to &#x02212;1,342&#x2009;ng/L (<i>p</i>&#x2009;=&#x2009;0.012). Moreover, Patisiran therapy was significantly associated with better distances in the 6MWT, as indicated by adjusted mean differences between groups of 169 meters (<i>p</i>&#x2009;=&#x2009;0.004). Additionally, a median reduction of 19.6% in cardiac uptake was observed, as determined through bone scintigraphy, and expressed with an IQR of 9.8 to 27.1%. In conclusion, the investigation postulated that reductions in ECV, as discerned through cardiac magnetic resonance, offered compelling evidence of regression in ATTRv affecting the heart in select patients undergoing Patisiran treatment (<a href="#ref27">27</a>). The cardiologic effects, neurologic consequences, and adverse events documented in the encompassed studies have been briefly presented in <a href="#tab2">Tables 2</a>&#x2013;<a href="#tab4">4</a>, respectively.</p>
<div class="DottedLine"></div> <div class="Imageheaders">Table 2</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t002.jpg" name="table2" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t002.jpg" alt="www.frontiersin.org" id="tab2" loading="lazy">
  </picture>
</a>
<p><b>Table 2</b>. Cardiological effects.
</p></div> <div class="clear"></div> <div class="DottedLine mb15"></div>
<div class="Imageheaders">Table 3</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t003.jpg" name="table3" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t003.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t003.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t003.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t003.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t003.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t003.jpg" alt="www.frontiersin.org" id="tab3" loading="lazy">
  </picture>
</a>
<p><b>Table 3</b>. Neurological effects.
</p></div> <div class="clear"></div> <div class="DottedLine mb15"></div>
<div class="Imageheaders">Table 4</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t004.jpg" name="table4" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t004.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t004.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t004.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t004.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t004.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t004.jpg" alt="www.frontiersin.org" id="tab4" loading="lazy">
  </picture>
</a>
<p><b>Table 4</b>. Adverse events.
</p></div> <div class="clear"></div> <div class="DottedLine"></div>
<p class="mb0">Adams et al. (<a href="#ref28">28</a>) extended the phase 3 open-label clinical trial over 12&#x2009;months. Data were collected systematically at regular intervals, revealing persistent enhancements in polyneuropathy measures following treatment with Patisiran. The analysis also revealed improved QOL, autonomic function, disability, and nutritional condition. Nevertheless, despite a consistent enhancement in polyneuropathy, it did not revert to the baseline levels observed in prior studies. The average alteration in autonomic function demonstrated a decrease of &#x02212;3.7 following 12&#x2009;months of treatment. Furthermore, the levels of TTR exhibited a significant reduction of 78% after 6&#x2009;months of treatment. The study&#x2019;s primary objective was to evaluate the safety and tolerability of prolonged Patisiran administration. Secondary objectives included investigating disease progression, assessing quality of life, and evaluating nutritional well-being (<a href="#ref28">28</a>).</p>
<h3>Risk of bias</h3>
<p class="mb15">These investigations offer noteworthy discoveries; nonetheless, it is essential to recognize the conceivable hazards linked to conflicts of interest and biases that could have influenced the research outcomes. An identifiable source of bias in these inquiries is the sponsorship received from specific pharmaceutical companies, introducing the potential for partiality in study design, execution, and reporting. Furthermore, researchers may be inclined to disclose positive results to ensure continued financial support from these entities. To alleviate the risk of bias and conflicts of interest, researchers ought to openly divulge potential conflicts and institute measures to ensure the objectivity and impartiality of the research. The sponsor of the trials is indeed a pharmaceutical company, but this is inevitable since a pharmaceutical company initiates most phase I-III trials.</p>
<p class="mb15">In the study by Schmidt et al. (<a href="#ref25">25</a>), the authors disclosed conflicts of interest, including employment and stock ownership with Alnylam Pharmaceuticals, as well as consulting fees, honoraria, and research funding from Alnylam Pharmaceuticals, Pfizer Inc., Akcea Therapeutics, Ionis Pharmaceuticals, and Eidos. Additionally, Alnylam Pharmaceuticals supported related research by Adams et al. (<a href="#ref13">13</a>, <a href="#ref24">24</a>, <a href="#ref28">28</a>), Merckle et al. (<a href="#ref23">23</a>), and Coelho et al. (<a href="#ref20">20</a>, <a href="#ref21">21</a>). Furthermore, Adams et al. (<a href="#ref28">28</a>) also reported financial support from Pfizer, while Coelho et al. (<a href="#ref20">20</a>) disclosed funding from the National Institute for Health Research (NIHR) Biomedical Research Center at Guy&#x2019;s and St. Thomas&#x2019; NHS Foundation Trust and King&#x2019;s College London, specifically allocated to Dr. Mant (<a href="#ref20">20</a>).</p>
<p class="mb15">The authors of the investigation by Suhr et al. (<a href="#ref22">22</a>) revealed financial affiliations with pharmaceutical enterprises among the involved parties. O Suhr is actively engaged in clinical investigations in collaboration with Pfizer and Alnylam Pharmaceuticals. T Coelho&#x2019;s medical institution has received remunerations from multiple corporate entities, and Coelho personally has received financial backing from Alnylam Pharmaceuticals and Pfizer. J Buades, J Pouget, and I Conceicao are affiliated with Alnylam Pharmaceuticals, whereas J Berk and M Waddington-Cruz have received financial support from pharmaceutical corporations.</p>
<p class="mb0">In a study by Bleeker et al. (<a href="#ref26">26</a>), various institutions such as Sanofi-Genzyme, CSL Behring, Pfizer, Alnylam, Biogen, Roche, and Alexion provided compensation between 2008 and 2021. On the other hand, the study by Fontana et al. (<a href="#ref27">27</a>) was financially supported by the British Heart Foundation, with reference number FS/18/21/33447. Furthermore, the authors reported consulting affiliations with Alnylam, Akcea, Eidos, Intellia, Pfizer, and Alexion.</p> <a id="h5" name="h5"></a>
<h2>Discussion</h2>
<p class="mb15">ATTRv causes multisystem dysfunction due to peripheral and autonomic neuropathy and/or cardiomyopathy. This significantly and progressively impacts physical functioning and QOL (<a href="#ref24">24</a>, <a href="#ref29">29</a>, <a href="#ref30">30</a>). Vutrisiran and Patisiran represent RNAi treatments aimed at diminishing the levels of pathogenic TTR protein by suppressing the expression of the TTR gene in individuals afflicted with ATTRv (<a href="#ref13">13</a>, <a href="#ref24">24</a>).</p>
<p class="mb15">This systematic review recommends using Vutrisiran and Patisiran in ATTRv. The recommendation is based on outcomes of the latest studies that showed notable enhancements across various disease-relevant parameters in individuals with ATTRv (<a href="#ref13">13</a>, <a href="#ref20">20</a>&#x2013;<a href="#ref24">24</a>, <a href="#ref26">26</a>&#x2013;<a href="#ref28">28</a>). The results indicate that Patisiran (<a href="#ref20">20</a>, <a href="#ref21">21</a>, <a href="#ref24">24</a>, <a href="#ref25">25</a>, <a href="#ref28">28</a>) and Vutrisiran (<a href="#ref13">13</a>) considerably enhanced the mNIS+7 and Norfolk QOL-DN results. Vutrisiran (<a href="#ref13">13</a>) also demonstrated significant enhancements in the 10MWT, mBMI, and R-ODS. At the same time, Patisiran showed substantial improvements in the NIS-LL Field (<a href="#ref25">25</a>, <a href="#ref26">26</a>), autonomic function, disability, and nutritional situation (<a href="#ref20">20</a>, <a href="#ref21">21</a>, <a href="#ref25">25</a>, <a href="#ref28">28</a>), as well as reduced neurofilament light (NfL) levels (<a href="#ref31">31</a>). Both pharmaceutical interventions were well-tolerated among the study participants, and most adverse incidents exhibited mild to moderate severity (<a href="#ref13">13</a>, <a href="#ref20">20</a>&#x2013;<a href="#ref24">24</a>, <a href="#ref28">28</a>).</p>
<p class="mb15">Merkel et al. (<a href="#ref23">23</a>) conducted an analysis using phase three randomized controlled trials. They used a Bucher analysis to compare the effects of Vutrisiran and Tafamidis&#x2019; treatment. The results indicated that Vutrisiran is more effective than Tafamidis in treating symptoms associated with polyneuropathy manifestations, HRQOL, nutritional status, NIS-LL, Norfolk QOL-DN, and mBMI in patients with a diagnosis of ATTRv amyloidosis. They observed disparity in efficacy holds clinical significance, suggesting Vutrisiran&#x2019;s potential as a preferable option for maintaining physical function and enhancing the QOL in this patient population (<a href="#ref23">23</a>).</p>
<p class="mb15">Schmidt et al. (<a href="#ref25">25</a>) demonstrated that 12&#x2009;months of Patisiran treatment led to a 91.0% median reduction in serum TTR levels. Significant improvements were observed in neuropathy (NIS), quality of life (Norfolk QOL-DN), and autonomic symptoms (COMPASS-31). Additionally, disability (R-ODS) and nutritional status (mBMI) remained stable throughout the study period. Patisiran demonstrated a favorable safety profile with no new safety concerns emerging. These findings underscore the efficacy of Patisiran in the management of polyneuropathy in patients with ATTRv following liver transplantation.</p>
<p class="mb15">Furthermore, the second interim analysis of the Global OLE study (<a href="#ref31">31</a>) provides empirical evidence regarding the long-term administration of Patisiran treatment spanning 48&#x2009;months. The results demonstrate sustained enhancements in mNIS+7 and Norfolk QOL-DN scores over an additional 24&#x2009;months of Patisiran treatment, accompanied by a safety profile deemed acceptable and consistent with previous reports spanning up to 12&#x2009;months (<a href="#ref28">28</a>). Additionally, analytical studies showed that, In the APOLLO and HELIOS-A trials, NfL levels significantly decreased at 4 and 18&#x2009;months in patients treated with Patisiran or Vutrisiran (<a href="#ref31">31</a>, <a href="#ref32">32</a>).</p>
<p class="mb15">The APOLLO and phase 2 OLE investigations have demonstrated that Patisiran therapy significantly diminishes NfL concentrations and enhances neuropathy outcomes as evaluated by mNIS+7 and QOL measures in contrast to initial assessments (<a href="#ref21">21</a>). The findings remained consistent throughout an additional 24-month treatment period in the Global OLE investigation, demonstrating a correlation between the impact of Patisiran on NfL levels and its clinical efficacy (<a href="#ref24">24</a>). After a nine-month treatment regimen, Patisiran demonstrated notable superiority over a placebo in enhancing the QOL. By the 18-month, enhancements were evident across all QOL metrics, particularly within the predetermined cardiac subgroup, as delineated in the APOLLO study. These findings underscore the advantageous impact of Patisiran on QOL among individuals afflicted with both polyneuropathy and cardiomyopathy, conditions known to diminish overall well-being substantially (<a href="#ref33">33</a>). Postural blood pressure (PBP) evaluations investigate the impact of RNAi medications such as Patisiran and Vutrisiran on autonomic functioning among individuals diagnosed with ATTRv accompanied by polyneuropathy. The observed elevation of PBP levels into symptomatic thresholds among untreated individuals underscores the importance of prompt intervention measures (<a href="#ref34">34</a>).</p>
<p class="mb15">Patisiran and Vutrisiran exert an influence on cardiac symptoms and findings as well. Notably, Vutrisiran therapy has demonstrated a beneficial effect on NT-ProBNP levels and echocardiographic parameters within the subset of patients with cardiac involvement. It also led to a reduction in cardiac uptake of 99mTc, suggesting a decrease in cardiac amyloid. Nevertheless, the clinical significance remains uncertain at present (<a href="#ref35">35</a>). Patisiran treatment has reduced NT-proBNP (<a href="#ref24">24</a>, <a href="#ref27">27</a>, <a href="#ref28">28</a>), TTR levels (<a href="#ref28">28</a>), cardiac uptake (<a href="#ref27">27</a>), and abnormal ECG (<a href="#ref26">26</a>). Additionally, it demonstrated enhanced cardiac morphology and performance, evidenced by notable variances in the average thickness of the left ventricular wall and longitudinal strain (<a href="#ref26">26</a>) and an increase in 6MWT distances (<a href="#ref27">27</a>). Cardiac magnetic resonance (CMR) is a superior alternative for assessing myocardial tissue and estimating cardiac amyloid burden (<a href="#ref27">27</a>).</p>
<p class="mb15">Depending on the phenotype and country regulations, Tafamidis, Diflunisal, Patisiran, Inotersen, Vutrisiran, and Eplontersen can be used for ATTRv amyloidosis. Patisiran is administered at 0.3&#x2009;mg/kg via intravenous infusion lasting 80&#x2009;min every 3&#x2009;weeks (<a href="#ref24">24</a>). In contrast, Vutrisiran is a novel therapeutic agent that operates through a similar mechanism and is administered at a dosage of 25&#x2009;mg via subcutaneous injection every 3&#x2009;months (Q3M) (<a href="#ref13">13</a>).</p>
<p class="mb15">Regarding cost, Vutrisiran is estimated to be more cost-effective than Patisiran due to its less frequent dosing schedule and lower administration costs. The cost savings for Vutrisiran depend on factors such as how long it takes to administer Patisiran and which healthcare professional distributes it. Considering these factors, a cost comparison suggests that Vutrisiran is more cost-effective than Patisiran and is therefore recommended (<a href="#ref36">36</a>).</p>
<p class="mb0">This systematic review article acknowledges several limitations that impede a comprehensive evaluation of Patisiran and Vutrisiran&#x2019;s effects on amyloidosis polyneuropathy and myocardiopathies. Firstly, the scarcity of studies available to the researchers limits the scope of the analysis. Secondly, heterogeneity in participant numbers across studies challenges comparing results. Thirdly, most studies were funded by Anylham, a drug manufacturer, which raises the possibility of publication bias. Finally, incomplete follow-up periods in a series of studies further complicate the interpretation of findings. Given these limitations, it is recommended that large-scale studies be conducted to provide a more robust understanding of the effects of Vutrisiran and Patrisiran on these conditions.</p> <a id="h6" name="h6"></a>
<h2>Conclusion</h2>
<p class="mb0">This comprehensive analysis evaluated the effectiveness and safety of RNA interference treatments, Patisiran and Vutrisiran, in managing ATTRv amyloidosis. The study consistently demonstrated favorable results, revealing that Patisiran and Vutrisiran significantly reduce pathogenic TTR protein levels. This reduction significantly improved neuropathy parameters, quality of life, and cardiac symptoms among patients with ATTRv amyloidosis. The findings strongly support using these RNA interference therapies for controlling the multisystem dysfunction associated with the disease. However, it is imperative to approach the interpretation of the results with caution due to potential biases stemming from funding sources and variations in study designs. Extended investigations with prolonged observation periods and diverse cohorts are essential to enhance our comprehensive understanding of these interventions&#x2019; enduring effectiveness and safety.</p> <a id="h7" name="h7"></a>
<h2>Data availability statement</h2>
<p class="mb0">The original contributions presented in the study are included in the article/<a href="#SM1">Supplementary material</a>, further inquiries can be directed to the corresponding author.</p> <a id="h8" name="h8"></a>
<h2>Author contributions</h2>
<p class="mb0">MK: Writing &#x2013; original draft, Writing &#x2013; review &#x00026; editing. FE: Writing &#x2013; original draft, Writing &#x2013; review &#x00026; editing. MG: Writing &#x2013; original draft, Writing &#x2013; review &#x00026; editing. EA: Writing &#x2013; original draft, Writing &#x2013; review &#x00026; editing. ME: Writing &#x2013; original draft, Writing &#x2013; review &#x00026; editing. PD: Writing &#x2013; original draft, Writing &#x2013; review &#x00026; editing.</p> <a id="h9" name="h9"></a>
<h2>Funding</h2>
<p class="mb0">The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.</p> <a id="h10" name="h10"></a>
<h2>Acknowledgments</h2>
<p class="mb0">The authors would like to appreciate all the researchers whose published articles were used in this study. No organizations or associations supported this work.</p> <a id="h11" name="h11"></a>
<h2>Conflict of interest</h2>
<p class="mb0">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p> <a id="h12" name="h12"></a>
<h2>Publisher&#x2019;s note</h2>
<p class="mb0">All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p> <a id="h13" name="h13"></a>
<h2>Supplementary material</h2>
<p class="mb0" id="SM1">The Supplementary material for this article can be found online at: <a href="https://www.frontiersin.org/articles/10.3389/fneur.2024.1465747/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fneur.2024.1465747/full#supplementary-material</a></p> <a id="h14" name="h14"></a>
<h2>Footnotes</h2> <div id="footnotetext" class="fulltextdescription">
<p style="margin-top:0em;margin-bottom:0em;margin-left:1em;text-indent:-1em;" id="fn0001">1. <a class="footnotetextanchor" href="#xfn0001" title="">^</a>
<a href="https://osf.io/evwtd">https://osf.io/evwtd</a>
</p>
<p style="margin-top:0em;margin-bottom:0em;margin-left:1em;text-indent:-1em;" id="fn0002">2. <a class="footnotetextanchor" href="#xfn0002" title="">^</a>
<a href="https://jbi.global/critical-appraisal-tools">https://jbi.global/critical-appraisal-tools</a>
</p>
</div> <a id="h15" name="h15"></a>
<h2>References</h2>
<div class="References">
<p class="ReferencesCopy1"><a name="ref1" id="ref1"></a>1. Adams, D, Koike, H, Slama, M, and Coelho, T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. <i>Nat Rev Neurol</i>. (2019) 15:387&#x2013;404. doi: 10.1038/s41582-019-0210-4 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/31209302" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s41582-019-0210-4" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=D+Adams&#x00026;author=H+Koike&#x00026;author=M+Slama&#x00026;author=T+Coelho&#x00026;publication_year=2019&#x00026;title=Hereditary+transthyretin+amyloidosis:+a+model+of+medical+progress+for+a+fatal+disease&#x00026;journal=Nat+Rev+Neurol&#x00026;volume=15&#x00026;pages=387-404" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref2" id="ref2"></a>2. Manganelli, F, Fabrizi, GM, Luigetti, M, Mandich, P, Mazzeo, A, and Pareyson, D. Hereditary transthyretin amyloidosis overview. <i>Neurol Sci</i>. (2022) 43:595&#x2013;604. doi: 10.1007/s10072-020-04889-2
</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1007/s10072-020-04889-2" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=F+Manganelli&#x00026;author=GM+Fabrizi&#x00026;author=M+Luigetti&#x00026;author=P+Mandich&#x00026;author=A+Mazzeo&#x00026;author=D+Pareyson&#x00026;publication_year=2022&#x00026;title=Hereditary+transthyretin+amyloidosis+overview&#x00026;journal=Neurol+Sci&#x00026;volume=43&#x00026;pages=595-604" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref3" id="ref3"></a>3. Koike, H, Misu, K-i, Ikeda, S-i, Ando, Y, Nakazato, M, Ando, E, et al. Type I (transthyretin met 30) familial amyloid polyneuropathy in Japan: early-vs late-onset form. <i>Arch Neurol</i>. (2002) 59:1771&#x2013;6. doi: 10.1001/archneur.59.11.1771
</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1001/archneur.59.11.1771" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H+Koike&#x00026;author=K-i+Misu&#x00026;author=S-i+Ikeda&#x00026;author=Y+Ando&#x00026;author=M+Nakazato&#x00026;author=E+Ando&#x00026;publication_year=2002&#x00026;title=Type+I+(transthyretin+met+30)+familial+amyloid+polyneuropathy+in+Japan:+early-vs+late-onset+form&#x00026;journal=Arch+Neurol&#x00026;volume=59&#x00026;pages=1771-6" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref4" id="ref4"></a>4. Carroll, A, Dyck, PJ, de Carvalho, M, Kennerson, M, Reilly, MM, Kiernan, MC, et al. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. <i>J Neurol Neurosurg Psychiatry</i>. (2022) 93:668&#x2013;78. doi: 10.1136/jnnp-2021-327909 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/35256455" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1136/jnnp-2021-327909" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Carroll&#x00026;author=PJ+Dyck&#x00026;author=M+de+Carvalho&#x00026;author=M+Kennerson&#x00026;author=MM+Reilly&#x00026;author=MC+Kiernan&#x00026;publication_year=2022&#x00026;title=Novel+approaches+to+diagnosis+and+management+of+hereditary+transthyretin+amyloidosis&#x00026;journal=J+Neurol+Neurosurg+Psychiatry&#x00026;volume=93&#x00026;pages=668-78" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref5" id="ref5"></a>5. Tozza, S, Severi, D, Spina, E, Iovino, A, Aruta, F, Ruggiero, L, et al. The neuropathy in hereditary transthyretin amyloidosis: a narrative review. <i>J Peripher Nerv Syst</i>. (2021) 26:155&#x2013;9. doi: 10.1111/jns.12451 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/33960565" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/jns.12451" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S+Tozza&#x00026;author=D+Severi&#x00026;author=E+Spina&#x00026;author=A+Iovino&#x00026;author=F+Aruta&#x00026;author=L+Ruggiero&#x00026;publication_year=2021&#x00026;title=The+neuropathy+in+hereditary+transthyretin+amyloidosis:+a+narrative+review&#x00026;journal=J+Peripher+Nerv+Syst&#x00026;volume=26&#x00026;pages=155-9" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref6" id="ref6"></a>6. Plant&#x000E9;-Bordeneuve, V, Gorram, F, Salhi, H, Nordine, T, Ayache, SS, Le Corvoisier, P, et al. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study. <i>J Neurol</i>. (2017) 264:268&#x2013;76. doi: 10.1007/s00415-016-8337-3 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/27878441" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s00415-016-8337-3" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=V+Plant&#x000E9;-Bordeneuve&#x00026;author=F+Gorram&#x00026;author=H+Salhi&#x00026;author=T+Nordine&#x00026;author=SS+Ayache&#x00026;author=P+Le+Corvoisier&#x00026;publication_year=2017&#x00026;title=Long-term+treatment+of+transthyretin+familial+amyloid+polyneuropathy+with+tafamidis:+a+clinical+and+neurophysiological+study&#x00026;journal=J+Neurol&#x00026;volume=264&#x00026;pages=268-76" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref7" id="ref7"></a>7. Hawkins, PN, Ando, Y, Dispenzeri, A, Gonzalez-Duarte, A, Adams, D, and Suhr, OB. Evolving landscape in the management of transthyretin amyloidosis. <i>Ann Med</i>. (2015) 47:625&#x2013;38. doi: 10.3109/07853890.2015.1068949 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/26611723" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3109/07853890.2015.1068949" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=PN+Hawkins&#x00026;author=Y+Ando&#x00026;author=A+Dispenzeri&#x00026;author=A+Gonzalez-Duarte&#x00026;author=D+Adams&#x00026;author=OB+Suhr&#x00026;publication_year=2015&#x00026;title=Evolving+landscape+in+the+management+of+transthyretin+amyloidosis&#x00026;journal=Ann+Med&#x00026;volume=47&#x00026;pages=625-38" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref8" id="ref8"></a>8. Aimo, A, Castiglione, V, Rapezzi, C, Franzini, M, Panichella, G, Vergaro, G, et al. RNA-targeting and gene editing therapies for transthyretin amyloidosis. <i>Nat Rev Cardiol</i>. (2022) 19:655&#x2013;67. doi: 10.1038/s41569-022-00683-z </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/35322226" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s41569-022-00683-z" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Aimo&#x00026;author=V+Castiglione&#x00026;author=C+Rapezzi&#x00026;author=M+Franzini&#x00026;author=G+Panichella&#x00026;author=G+Vergaro&#x00026;publication_year=2022&#x00026;title=RNA-targeting+and+gene+editing+therapies+for+transthyretin+amyloidosis&#x00026;journal=Nat+Rev+Cardiol&#x00026;volume=19&#x00026;pages=655-67" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref9" id="ref9"></a>9. Soprano, DR, Herbert, J, Soprano, K, Schon, E, and Goodman, D. Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat. <i>J Biol Chem</i>. (1985) 260:11793&#x2013;8.
</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/4044580" target="_blank">PubMed Abstract</a> | <a href="http://scholar.google.com/scholar_lookup?author=DR+Soprano&#x00026;author=J+Herbert&#x00026;author=K+Soprano&#x00026;author=E+Schon&#x00026;author=D+Goodman&#x00026;publication_year=1985&#x00026;title=Demonstration+of+transthyretin+mRNA+in+the+brain+and+other+extrahepatic+tissues+in+the+rat&#x00026;journal=J+Biol+Chem&#x00026;volume=260&#x00026;pages=11793-8" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref10" id="ref10"></a>10. Holmgren, G, Steen, L, Ekstedt, J, Groth, CG, Ericzon, BG, Eriksson, S, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met 30). <i>Clin Genet</i>. (1991) 40:242&#x2013;6.
</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/1685359" target="_blank">PubMed Abstract</a> | <a href="http://scholar.google.com/scholar_lookup?author=G+Holmgren&#x00026;author=L+Steen&#x00026;author=J+Ekstedt&#x00026;author=CG+Groth&#x00026;author=BG+Ericzon&#x00026;author=S+Eriksson&#x00026;publication_year=1991&#x00026;title=Biochemical+effect+of+liver+transplantation+in+two+Swedish+patients+with+familial+amyloidotic+polyneuropathy+(FAP-met+30)&#x00026;journal=Clin+Genet&#x00026;volume=40&#x00026;pages=242-6" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref11" id="ref11"></a>11. Nair, JK, Willoughby, JL, Chan, A, Charisse, K, Alam, MR, Wang, Q, et al. Multivalent N-acetylgalactosamine-conjugated si RNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. <i>J Am Chem Soc</i>. (2014) 136:16958&#x2013;61. doi: 10.1021/ja505986a </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/25434769" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1021/ja505986a" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=JK+Nair&#x00026;author=JL+Willoughby&#x00026;author=A+Chan&#x00026;author=K+Charisse&#x00026;author=MR+Alam&#x00026;author=Q+Wang&#x00026;publication_year=2014&#x00026;title=Multivalent+N-acetylgalactosamine-conjugated+si+RNA+localizes+in+hepatocytes+and+elicits+robust+RNAi-mediated+gene+silencing&#x00026;journal=J+Am+Chem+Soc&#x00026;volume=136&#x00026;pages=16958-61" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref12" id="ref12"></a>12. Habtemariam, BA, Karsten, V, Attarwala, H, Goel, V, Melch, M, Clausen, VA, et al. Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine&#x2013;small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects. <i>Clinical Pharmacol Therapeutics</i>. (2021) 109:372&#x2013;82. doi: 10.1002/cpt.1974 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/32599652" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/cpt.1974" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=BA+Habtemariam&#x00026;author=V+Karsten&#x00026;author=H+Attarwala&#x00026;author=V+Goel&#x00026;author=M+Melch&#x00026;author=VA+Clausen&#x00026;publication_year=2021&#x00026;title=Single-dose+pharmacokinetics+and+pharmacodynamics+of+transthyretin+targeting+N-acetylgalactosamine&#x2013;small+interfering+ribonucleic+acid+conjugate+vutrisiran+in+healthy+subjects&#x00026;journal=Clinical+Pharmacol+Therapeutics&#x00026;volume=109&#x00026;pages=372-82" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref13" id="ref13"></a>13. Adams, D, Tournev, IL, Taylor, MS, Coelho, T, Plant&#x000E9;-Bordeneuve, V, Berk, JL, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. <i>Amyloid</i>. (2023) 30:18&#x2013;26. doi: 10.1080/13506129.2022.2091985
</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1080/13506129.2022.2091985" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=D+Adams&#x00026;author=IL+Tournev&#x00026;author=MS+Taylor&#x00026;author=T+Coelho&#x00026;author=V+Plant&#x000E9;-Bordeneuve&#x00026;author=JL+Berk&#x00026;publication_year=2023&#x00026;title=Efficacy+and+safety+of+vutrisiran+for+patients+with+hereditary+transthyretin-mediated+amyloidosis+with+polyneuropathy:+a+randomized+clinical+trial&#x00026;journal=Amyloid&#x00026;volume=30&#x00026;pages=18-26" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref14" id="ref14"></a>14. Center for Drug Evaluation and Research. Onpattro 2 mg/mL injectionfor intravenous use. (2023). Available from: <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210922Orig1s000Approv.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210922Orig1s000Approv.pdf</a> (Accessed February 25, 2024).
</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?publication_year=2023&#x00026;" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref15" id="ref15"></a>15. European Medicines Agency. Onpattro (patisiran): an overview of Onpattro and why it is authorised in the EU. (2023). Available from: <a href="https://www.ema.europa.eu/en/documents/overview/onpattro-epar-medicine-overview_en.pdf">https://www.ema.europa.eu/en/documents/overview/onpattro-epar-medicine-overview_en.pdf</a> (Accessed February 25, 2024).
</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?publication_year=2023&#x00026;" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref16" id="ref16"></a>16. Brannagan, TH 3rd, Berk, JL, Gillmore, JD, Maurer, MS, Waddington-Cruz, M, Fontana, M, et al. Liver-directed drugs for transthyretin-mediated amyloidosis. <i>J Peripher Nerv Syst: JPNS</i>. (2022) 27:228&#x2013;37. doi: 10.1111/jns.12519 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/36345805" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/jns.12519" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=TH+Brannagan&#x00026;author=JL+Berk&#x00026;author=JD+Gillmore&#x00026;author=MS+Maurer&#x00026;author=M+Waddington-Cruz&#x00026;author=M+Fontana&#x00026;publication_year=2022&#x00026;title=Liver-directed+drugs+for+transthyretin-mediated+amyloidosis&#x00026;journal=J+Peripher+Nerv+Syst:+JPNS&#x00026;volume=27&#x00026;pages=228-37" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref17" id="ref17"></a>17. Nie, T. Eplontersen: first approval. <i>Drugs</i>. (2024) 84:473&#x2013;8. doi: 10.1007/s40265-024-02008-5 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/38413492" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s40265-024-02008-5" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=T+Nie&#x00026;publication_year=2024&#x00026;title=Eplontersen:+first+approval&#x00026;journal=Drugs&#x00026;volume=84&#x00026;pages=473-8" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref18" id="ref18"></a>18. Collotta, D, Bertocchi, I, Chiapello, E, and Collino, M. Antisense oligonucleotides: a novel Frontier in pharmacological strategy. <i>Front. Pharmacol</i>. 14:1304342. (2023). doi: 10.3389/fphar.2023.1304342
</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.3389/fphar.2023.1304342" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=D+Collotta&#x00026;author=I+Bertocchi&#x00026;author=E+Chiapello&#x00026;author=M+Collino&#x00026;publication_year=2023&#x00026;title=Antisense+oligonucleotides:+a+novel+Frontier+in+pharmacological+strategy&#x00026;journal=Front.+Pharmacol&#x00026;volume=14&#x00026;pages=1304342" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref19" id="ref19"></a>19. Page, MJ, McKenzie, JE, Bossuyt, PM, Boutron, I, Hoffmann, TC, Mulrow, CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. <i>BMJ</i>. (2021) 372:n71. doi: 10.1136/bmj.n71
</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1136/bmj.n71" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=MJ+Page&#x00026;author=JE+McKenzie&#x00026;author=PM+Bossuyt&#x00026;author=I+Boutron&#x00026;author=TC+Hoffmann&#x00026;author=CD+Mulrow&#x00026;publication_year=2021&#x00026;title=The+PRISMA+2020+statement:+an+updated+guideline+for+reporting+systematic+reviews&#x00026;journal=BMJ&#x00026;volume=372&#x00026;pages=n71" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref20" id="ref20"></a>20. Coelho, T, Adams, D, Silva, A, Lozeron, P, Hawkins, PN, Mant, T, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. <i>N Engl J Med</i>. (2013) 369:819&#x2013;29. doi: 10.1056/NEJMoa1208760 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/23984729" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1056/NEJMoa1208760" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=T+Coelho&#x00026;author=D+Adams&#x00026;author=A+Silva&#x00026;author=P+Lozeron&#x00026;author=PN+Hawkins&#x00026;author=T+Mant&#x00026;publication_year=2013&#x00026;title=Safety+and+efficacy+of+RNAi+therapy+for+transthyretin+amyloidosis&#x00026;journal=N+Engl+J+Med&#x00026;volume=369&#x00026;pages=819-29" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref21" id="ref21"></a>21. Coelho, T, Adams, D, Concei&#x000E7;&#x000E3;o, I, Waddington-Cruz, M, Schmidt, HH, Buades, J, et al. A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis. <i>Orphanet J Rare Dis</i>. (2020) 15:1&#x2013;10. doi: 10.1186/s13023-020-01399-4
</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1186/s13023-020-01399-4" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=T+Coelho&#x00026;author=D+Adams&#x00026;author=I+Concei&#x000E7;&#x000E3;o&#x00026;author=M+Waddington-Cruz&#x00026;author=HH+Schmidt&#x00026;author=J+Buades&#x00026;publication_year=2020&#x00026;title=A+phase+II+open-label+extension+study+of+long-term+patisiran+treatment+in+patients+with+hereditary+transthyretin-mediated+(hATTR)+amyloidosis&#x00026;journal=Orphanet+J+Rare+Dis&#x00026;volume=15&#x00026;pages=1-10" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref22" id="ref22"></a>22. Suhr, O, Coelho, T, Buades Pouget, J, Conceicao, I, Berk, J, and Schmidt, H. Waddington-Cruz; Campistol JM; Bettencourt BR; Vaishnaw a; Gollob J; Adams D efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase ii multi-dose study. <i>Orphanet J Rare Dis</i>. (2015) 10:1&#x2013;9. doi: 10.1186/s13023-015-0326-6
</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1186/s13023-015-0326-6" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=O+Suhr&#x00026;author=T+Coelho&#x00026;author=J+Buades+Pouget&#x00026;author=I+Conceicao&#x00026;author=J+Berk&#x00026;author=H+Schmidt&#x00026;publication_year=2015&#x00026;title=Waddington-Cruz;+Campistol+JM;+Bettencourt+BR;+Vaishnaw+a;+Gollob+J;+Adams+D+efficacy+and+safety+of+patisiran+for+familial+amyloidotic+polyneuropathy:+a+phase+ii+multi-dose+study&#x00026;journal=Orphanet+J+Rare+Dis&#x00026;volume=10&#x00026;pages=1-9" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref23" id="ref23"></a>23. Merkel, M, Danese, D, Chen, C, Wang, J, Wu, A, Yang, H, et al. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy. <i>Expert Opin Pharmacother</i>. (2023) 24:1205&#x2013;14. doi: 10.1080/14656566.2023.2215925
</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1080/14656566.2023.2215925" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Merkel&#x00026;author=D+Danese&#x00026;author=C+Chen&#x00026;author=J+Wang&#x00026;author=A+Wu&#x00026;author=H+Yang&#x00026;publication_year=2023&#x00026;title=Indirect+treatment+comparison+(ITC)+of+the+efficacy+of+vutrisiran+and+tafamidis+for+hereditary+transthyretin-mediated+amyloidosis+with+polyneuropathy&#x00026;journal=Expert+Opin+Pharmacother&#x00026;volume=24&#x00026;pages=1205-14" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref24" id="ref24"></a>24. Adams, D, Gonzalez-Duarte, A, O&#x2019;Riordan, WD, Yang, C-C, Ueda, M, Kristen, AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. <i>N Engl J Med</i>. (2018) 379:11&#x2013;21. doi: 10.1056/NEJMoa1716153 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/29972753" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1056/NEJMoa1716153" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=D+Adams&#x00026;author=A+Gonzalez-Duarte&#x00026;author=WD+O&#x2019;Riordan&#x00026;author=C-C+Yang&#x00026;author=M+Ueda&#x00026;author=AV+Kristen&#x00026;publication_year=2018&#x00026;title=Patisiran+an+RNAi+therapeutic+for+hereditary+transthyretin+amyloidosis&#x00026;journal=N+Engl+J+Med&#x00026;volume=379&#x00026;pages=11-21" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref25" id="ref25"></a>25. Schmidt, HH, Wixner, J, Plant&#x000E9;-Bordeneuve, V, Mu&#x000F1;oz-Beamud, F, Llad&#x000F3;, L, Gillmore, JD, et al. Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation. <i>Am J Transplant</i>. (2022) 22:1646&#x2013;57. doi: 10.1111/ajt.17009 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/35213769" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/ajt.17009" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=HH+Schmidt&#x00026;author=J+Wixner&#x00026;author=V+Plant&#x000E9;-Bordeneuve&#x00026;author=F+Mu&#x000F1;oz-Beamud&#x00026;author=L+Llad&#x000F3;&#x00026;author=JD+Gillmore&#x00026;publication_year=2022&#x00026;title=Patisiran+treatment+in+patients+with+hereditary+transthyretin-mediated+amyloidosis+with+polyneuropathy+after+liver+transplantation&#x00026;journal=Am+J+Transplant&#x00026;volume=22&#x00026;pages=1646-57" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref26" id="ref26"></a>26. De Bleecker, JL, Claeys, KG, Delstanche, S, Van Parys, V, Baets, J, Tilleux, S, et al. A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium. <i>Acta Neurol Belg</i>. (2023). 1029&#x2013;37. doi: 10.1007/s13760-023-02188-z
</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1007/s13760-023-02188-z" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=JL+De+Bleecker&#x00026;author=KG+Claeys&#x00026;author=S+Delstanche&#x00026;author=V+Van+Parys&#x00026;author=J+Baets&#x00026;author=S+Tilleux&#x00026;publication_year=2023&#x00026;title=A+retrospective+survey+of+patients+with+hereditary+transthyretin-mediated+(hATTR)+amyloidosis+treated+with+patisiran+in+real-world+clinical+practice+in+Belgium&#x00026;journal=Acta+Neurol+Belg&#x00026;pages=1029-37" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref27" id="ref27"></a>27. Fontana, M, Martinez-Naharro, A, Chacko, L, Rowczenio, D, Gilbertson, JA, Whelan, CJ, et al. Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression. <i>Cardiovascular Imaging</i>. (2021) 14:189&#x2013;99. doi: 10.1016/j.jcmg.2020.07.043 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/33129740" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.jcmg.2020.07.043" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Fontana&#x00026;author=A+Martinez-Naharro&#x00026;author=L+Chacko&#x00026;author=D+Rowczenio&#x00026;author=JA+Gilbertson&#x00026;author=CJ+Whelan&#x00026;publication_year=2021&#x00026;title=Reduction+in+CMR+derived+extracellular+volume+with+patisiran+indicates+cardiac+amyloid+regression&#x00026;journal=Cardiovascular+Imaging&#x00026;volume=14&#x00026;pages=189-99" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref28" id="ref28"></a>28. Adams, D, Polydefkis, M, Gonz&#x000E1;lez-Duarte, A, Wixner, J, Kristen, AV, Schmidt, HH, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. <i>Lancet Neurol</i>. (2021) 20:49&#x2013;59. doi: 10.1016/S1474-4422(20)30368-9 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/33212063" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/S1474-4422(20)30368-9" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=D+Adams&#x00026;author=M+Polydefkis&#x00026;author=A+Gonz&#x000E1;lez-Duarte&#x00026;author=J+Wixner&#x00026;author=AV+Kristen&#x00026;author=HH+Schmidt&#x00026;publication_year=2021&#x00026;title=Long-term+safety+and+efficacy+of+patisiran+for+hereditary+transthyretin-mediated+amyloidosis+with+polyneuropathy:+12-month+results+of+an+open-label+extension+study&#x00026;journal=Lancet+Neurol&#x00026;volume=20&#x00026;pages=49-59" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref29" id="ref29"></a>29. Vinik, EJ, Vinik, AI, Paulson, JF, Merkies, IS, Packman, J, Grogan, DR, et al. Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy. <i>J Peripher Nerv Syst</i>. (2014) 19:104&#x2013;14. doi: 10.1111/jns5.12059 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/24738700" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/jns5.12059" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=EJ+Vinik&#x00026;author=AI+Vinik&#x00026;author=JF+Paulson&#x00026;author=IS+Merkies&#x00026;author=J+Packman&#x00026;author=DR+Grogan&#x00026;publication_year=2014&#x00026;title=Norfolk+QOL-DN:+validation+of+a+patient+reported+outcome+measure+in+transthyretin+familial+amyloid+polyneuropathy&#x00026;journal=J+Peripher+Nerv+Syst&#x00026;volume=19&#x00026;pages=104-14" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref30" id="ref30"></a>30. Coelho, T, Vinik, A, Vinik, EJ, Tripp, T, Packman, J, and Grogan, DR. Clinical measures in transthyretin familial amyloid polyneuropathy. <i>Muscle Nerve</i>. (2017) 55:323&#x2013;32. doi: 10.1002/mus.25257 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/27422379" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/mus.25257" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=T+Coelho&#x00026;author=A+Vinik&#x00026;author=EJ+Vinik&#x00026;author=T+Tripp&#x00026;author=J+Packman&#x00026;author=DR+Grogan&#x00026;publication_year=2017&#x00026;title=Clinical+measures+in+transthyretin+familial+amyloid+polyneuropathy&#x00026;journal=Muscle+Nerve&#x00026;volume=55&#x00026;pages=323-32" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref31" id="ref31"></a>31. Ticau, S, Aldinc, E, Polydefkis, M, Adams, D, Coelho, T, Ueda, M, et al. Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study. <i>Amyloid</i>. (2023) 1-11. doi: 10.1080/13506129.2023.2232520
</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1080/13506129.2023.2232520" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S+Ticau&#x00026;author=E+Aldinc&#x00026;author=M+Polydefkis&#x00026;author=D+Adams&#x00026;author=T+Coelho&#x00026;author=M+Ueda&#x00026;publication_year=2023&#x00026;title=Treatment+response+and+neurofilament+light+chain+levels+with+long-term+patisiran+in+hereditary+transthyretin-mediated+amyloidosis+with+polyneuropathy:+24-month+results+of+an+open-label+extension+study&#x00026;journal=Amyloid&#x00026;volume=1-11&#x00026;" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref32" id="ref32"></a>32. Polydefkis, M, Aldinc, E, Nienhuis, H, Karam, C, Ajroud-Driss, S, Sekijima, Y, et al. <i>NfL levels significantly decrease in response to treatment with Patisiran or Vutrisiran in hATTR amyloidosis with polyneuropathy (S14. 001)</i> Switzerland: AAN Enterprises (2023).
</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?author=M+Polydefkis&#x00026;author=E+Aldinc&#x00026;author=H+Nienhuis&#x00026;author=C+Karam&#x00026;author=S+Ajroud-Driss&#x00026;author=Y+Sekijima&#x00026;publication_year=2023&#x00026;journal=NfL+levels+significantly+decrease+in+response+to+treatment+with+Patisiran+or+Vutrisiran+in+hATTR+amyloidosis+with+polyneuropathy+(S14.+001)&#x00026;" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref33" id="ref33"></a>33. Obici, L, Berk, JL, Gonz&#x000E1;lez-Duarte, A, Coelho, T, Gillmore, J, Schmidt, HH-J, et al. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. <i>Amyloid</i>. (2020) 27:153&#x2013;62. doi: 10.1080/13506129.2020.1730790 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/32131641" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1080/13506129.2020.1730790" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=L+Obici&#x00026;author=JL+Berk&#x00026;author=A+Gonz&#x000E1;lez-Duarte&#x00026;author=T+Coelho&#x00026;author=J+Gillmore&#x00026;author=HH-J+Schmidt&#x00026;publication_year=2020&#x00026;title=Quality+of+life+outcomes+in+APOLLO+the+phase+3+trial+of+the+RNAi+therapeutic+patisiran+in+patients+with+hereditary+transthyretin-mediated+amyloidosis&#x00026;journal=Amyloid&#x00026;volume=27&#x00026;pages=153-62" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref34" id="ref34"></a>34. Algalarrondo, V, Obici, L, Okumura, T, Slama, M, Arum, S, Hale, C, et al. Effect of RNAi therapeutics patisiran and vutrisiran on orthostatic hypotension due to dysautonomia in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. <i>Archives of Cardiovas Dis Supplements</i>. (2023) 15:37. doi: 10.1016/j.acvdsp.2022.10.065
</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1016/j.acvdsp.2022.10.065" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=V+Algalarrondo&#x00026;author=L+Obici&#x00026;author=T+Okumura&#x00026;author=M+Slama&#x00026;author=S+Arum&#x00026;author=C+Hale&#x00026;publication_year=2023&#x00026;title=Effect+of+RNAi+therapeutics+patisiran+and+vutrisiran+on+orthostatic+hypotension+due+to+dysautonomia+in+patients+with+hereditary+transthyretin-mediated+amyloidosis+with+polyneuropathy&#x00026;journal=Archives+of+Cardiovas+Dis+Supplements&#x00026;volume=15&#x00026;pages=37" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref35" id="ref35"></a>35. Mussinelli, R, Garcia-pavia, P, Gillmore, JD, Kale, P, Berk, JL, Maurer, MS, et al. 77 HELIOS-a: 18-month exploratory cardiac results from the phase 3 study of VUTRISIRAN in patients with hereditary transthyretin-mediated amyloidosis. <i>European Heart J Supplements</i>. (2022) 24:654. doi: 10.1093/eurheartjsupp/suac121.654
</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1093/eurheartjsupp/suac121.654" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R+Mussinelli&#x00026;author=P+Garcia-pavia&#x00026;author=JD+Gillmore&#x00026;author=P+Kale&#x00026;author=JL+Berk&#x00026;author=MS+Maurer&#x00026;publication_year=2022&#x00026;title=77+HELIOS-a:+18-month+exploratory+cardiac+results+from+the+phase+3+study+of+VUTRISIRAN+in+patients+with+hereditary+transthyretin-mediated+amyloidosis&#x00026;journal=European+Heart+J+Supplements&#x00026;volume=24&#x00026;pages=654" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref36" id="ref36"></a>36. National Insitute for Health and care Excellence (NICE). Vutrisiran for treating hereditary transthyretin-related amyloidosis. (2023). Available from: <a href="https://www.nice.org.uk/guidance/ta868">https://www.nice.org.uk/guidance/ta868</a> (Accessed February 15, 2024).
</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?publication_year=2023&#x00026;" target="_blank">Google Scholar</a></p></div>
</div> <div class="thinLineM20"></div> <div class="AbstractSummary">
<p><span>Keywords:</span> hereditary amyloidosis, transthyretin-related amyloidosis, Patisiran, Vutrisiran, polyneuropathy, cardiomyopathy, clinical trials</p>
<p><span>Citation:</span> Karimi MA, Esmaeilpour Moallem F, Gholami Chahkand MS, Azarm E, Emami Kazemabad MJ and Dadkhah PA (2024) Assessing the effectiveness and safety of Patisiran and Vutrisiran in ATTRv amyloidosis with polyneuropathy: a systematic review. <i>Front. Neurol</i>. 15:1465747. doi: 10.3389/fneur.2024.1465747</p>
<p class="timestamps"><span>Received:</span> 17 July 2024; <span>Accepted:</span> 16 August 2024;<br> <span>Published:</span> 02 September 2024.</p> <div>
<p>Edited by:</p> <a href="https://loop.frontiersin.org/people/857342/overview">Vincenzo Di Stefano</a>, University of Studies G. d&#x2019;Annunzio Chieti and Pescara, Italy</div> <div>
<p>Reviewed by:</p> <a href="https://loop.frontiersin.org/people/756275/overview">Koike Haruki</a>, Saga University, Japan<br> <a href="https://loop.frontiersin.org/people/1662511/overview">Jonas Wixner</a>, Ume&#x00E5; University, Sweden</div>
<p><span>Copyright</span> &#x000A9; 2024 Karimi, Esmaeilpour Moallem, Gholami Chahkand, Azarm, Emami Kazemabad and Dadkhah. This is an open-access article distributed under the terms of the <a rel="license" href="http://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License (CC BY)</a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
<p><span>&#x0002A;Correspondence:</span> Parisa Alsadat Dadkhah, <a id="encmail">cGFyZGFkNzY5N0BnbWFpbC5jb20=</a></p>
<p><span><sup>&#x2020;</sup></span>These authors have contributed equally to this work</p> <div class="clear"></div> </div></div></div><p class="AbstractSummary__disclaimer"><span>Disclaimer: </span> All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. </p></div></div><!----></main><aside class="Layout__aside"><div class="ArticleDetails__wrapper"><div class="ArticleDetails__aside"><div class="ArticleDetails__aside__responsiveButtons"><div class="ActionsDropDown" id="FloatingButtonsEl"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--icon ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1465747/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fneur.2024.1465747" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1465747/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1465747/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="ArticleDetails__aside__responsiveButtons__items"><span></span><div class="ArticleDetailsShare__responsive"><button class="ArticleDetailsShare__trigger" aria-label="Open share options"></button><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1465747/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1465747/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1465747/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div></div><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeIconButton ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><!----></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Export citation</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1465747/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1465747/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1465747/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1465747/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div></div></div><div class="TotalViews"><div class="TotalViews__data"><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">5,8K</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Total views</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">2,1K</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Downloads</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">5</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Citations</div></div></div><div class="ImpactMetricsInfoPopover"><button aria-label="Open impact metrics info" class="ImpactMetricsInfoPopover__button"></button><div class="ImpactMetricsInfoPopover__tooltip"><button aria-label="Close impact metrics info" class="ImpactMetricsInfoPopover__tooltip__closeButton"></button><div class="ImpactMetricsInfoPopover__tooltip__text"> Citation numbers are available from Dimensions </div></div></div></div><div class="TotalViews__viewImpactLink"><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View article impact" href="http://loop-impact.frontiersin.org/impact/article/1465747#totalviews/views" target="_blank" data-event="customLink-link-a_viewArticleImpact"><span>View article impact</span></a></span></div><div class="TotalViews__altmetric"><div data-badge-popover="bottom" data-badge-type="donut" data-doi="10.3389/fneur.2024.1465747" data-condensed="true" data-link-target="new" class="altmetric-embed"></div><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View altmetric score" href="https://www.altmetric.com/details/doi/10.3389/fneur.2024.1465747" target="_blank" data-event="customLink-link-a_viewAltmetricScore"><span>View altmetric score</span></a></span></div></div><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1465747/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1465747/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1465747/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Edited by</div><!--[--><a href="https://loop.frontiersin.org/people/857342/overview" data-event="editorInfo-a-vincenzoDiStefano" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">V</span><span class="notranslate">D</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Vincenzo  Di Stefano</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, Italy</div></div></a><!--]--></div></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Reviewed by</div><!--[--><a href="https://loop.frontiersin.org/people/1662511/overview" data-event="editorInfo-a-jonasWixner" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">J</span><span class="notranslate">W</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Jonas  Wixner</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Faculty of Medicine, Ume University, Sweden</div></div></a><a href="https://loop.frontiersin.org/people/756275/overview" data-event="editorInfo-a-koikeHaruki" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">K</span><span class="notranslate">H</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Koike  Haruki</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Saga University, Japan</div></div></a><!--]--></div></div><div class="ArticleDetailsGlossary ArticleDetailsGlossary--open"><button class="ArticleDetailsGlossary__header"><div class="ArticleDetailsGlossary__header__title">Table of contents</div><div class="ArticleDetailsGlossary__header__arrow"></div></button><div class="ArticleDetailsGlossary__content"><ul class="flyoutJournal"> <li><a href="#h1">Abstract</a></li> <li><a href="#h2">Introduction</a></li> <li><a href="#h3">Methods</a></li> <li><a href="#h4">Results</a></li> <li><a href="#h5">Discussion</a></li> <li><a href="#h6">Conclusion</a></li> <li><a href="#h7">Data availability statement</a></li> <li><a href="#h8">Author contributions</a></li> <li><a href="#h9">Funding</a></li> <li><a href="#h10">Acknowledgments</a></li> <li><a href="#h11">Conflict of interest</a></li> <li><a href="#h12">Publisher&#x2019;s note</a></li> <li><a href="#h13">Supplementary material</a></li> <li><a href="#h14">Footnotes</a></li> <li><a href="#h15">References</a></li> </ul></div></div><span></span><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeOutline ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Export citation</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1465747/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1465747/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1465747/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1465747/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="CheckForUpdates"><button data-target="crossmark" class="CheckForUpdates__link" data-event="checkForUpdates-btn-openModal"><img class="CheckForUpdates__link__img" src="/ap-2024/images/crossmark.svg" alt="Crossmark icon"><div class="CheckForUpdates__link__text">Check for updates</div></button></div><div class="AnnouncementCard"><p class="AnnouncementCard__title">Frontiers&#39; impact</p><article class="CardA"><div class="CardA__wrapper CardA__wrapper--vertical"><figure class="FrontiersImage CardA__img"><picture class="FrontiersImage"><!--[--><source srcset="https://images-provider.frontiersin.org/api/ipx/w=440&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 563px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=320x400&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1024px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=268x280&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1441px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><!--]--><img src="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" class="is-inside-mask" alt loading="eager"></picture><!----></figure><div class="CardA__info"><!--[--><h2 class="CardA__title">Articles published with Frontiers have received 12 million total citations</h2><p class="CardA__text">Your research is the real superpower - learn how we maximise its impact through our leading community journals</p><br><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--small Link--icon Link--chevronRight Link--right" aria-label="Explore our impact metrics" href="https://www.frontiersin.org/about/impact" target="_self" data-event="customLink-linkType-a_exploreOurImpactMe"><span>Explore our impact metrics</span></a></span><!--]--></div></div></article></div><!----><!----></div><div><div class="Modal Modal--noFooter"><button aria-label="Close modal" class="Modal__overlay" data-event="modal-overlay-close"></button><div class="Modal__container"><div class="Modal__header"><p class="Modal__title">Supplementary Material</p><button aria-label="Close modal" class="Modal__close" data-event="modal-button-close"></button></div><div class="Modal__body"><!--[--><div class="SupplementalData"><ul class="SupplementalData__list"><!--[--><!--]--></ul></div><!--]--><!----></div><!----><!----></div></div></div><div><div class="FloatingButtons"><!----><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--iconDownload ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Download</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1465747/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fneur.2024.1465747" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1465747/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1465747/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><!----></div></div></div></aside></div><div class=""><!----></div><!--]--></div><!----><footer class="Footer"><div class="Footer__wrapper"><div class="Footer__sections"><ul class="Accordion"><!--[--><!--[--><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Guidelines</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/guidelines/author-guidelines" target="_self" data-event="footer-block_0-a_authorGuidelines">Author guidelines</a></li><li><a href="https://www.frontiersin.org/for-authors/author-services" target="_self" data-event="footer-block_0-a_servicesForAuthors">Services for authors</a></li><li><a href="https://www.frontiersin.org/guidelines/policies-and-publication-ethics" target="_self" data-event="footer-block_0-a_policiesAndPublicationE">Policies and publication ethics</a></li><li><a href="https://www.frontiersin.org/guidelines/editor-guidelines" target="_self" data-event="footer-block_0-a_editorGuidelines">Editor guidelines</a></li><li><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="footer-block_0-a_feePolicy">Fee policy</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Explore</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/articles" target="_self" data-event="footer-block_1-a_articles">Articles</a></li><li><a href="https://www.frontiersin.org/research-topics" target="_self" data-event="footer-block_1-a_researchTopics">Research Topics </a></li><li><a href="https://www.frontiersin.org/journals" target="_self" data-event="footer-block_1-a_journals">Journals</a></li><li><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="footer-block_1-a_howWePublish">How we publish</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Outreach</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://forum.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForum">Frontiers Forum </a></li><li><a href="https://policylabs.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersPolicyLabs">Frontiers Policy Labs </a></li><li><a href="https://kids.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForYoungMinds">Frontiers for Young Minds</a></li><li><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="footer-block_2-a_frontiersPlanetPrize">Frontiers Planet Prize</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Connect</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://helpcenter.frontiersin.org" target="_blank" data-event="footer-block_3-a_helpCenter">Help center</a></li><li><a href="https://subscription-management.frontiersin.org/emails/preferences#block0" target="_blank" data-event="footer-block_3-a_emailsAndAlerts">Emails and alerts </a></li><li><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="footer-block_3-a_contactUs">Contact us </a></li><li><a href="https://www.frontiersin.org/submission/submit" target="_self" data-event="footer-block_3-a_submit">Submit</a></li><li><a href="https://careers.frontiersin.org/" target="_blank" data-event="footer-block_3-a_careerOpportunities">Career opportunities</a></li><!--]--></ul><!--]--></div></li><!--]--><!--]--></ul><div class="Footer__socialLinks"><div class="Footer__socialLinks__title">Follow us</div><!--[--><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--facebook Link--right" aria-label="Frontiers Facebook" href="https://www.facebook.com/Frontiersin" target="_blank" data-event="footer-facebook-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--twitter Link--right" aria-label="Frontiers Twitter" href="https://twitter.com/frontiersin" target="_blank" data-event="footer-twitter-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--linkedin Link--right" aria-label="Frontiers LinkedIn" href="https://www.linkedin.com/company/frontiers" target="_blank" data-event="footer-linkedIn-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--instagram Link--right" aria-label="Frontiers Instagram" href="https://www.instagram.com/frontiersin_" target="_blank" data-event="footer-instagram-a_true"><span></span></a></span><!--]--></div></div><div class="Footer__copyright"><div><span> 2025 Frontiers Media SA. All rights reserved.</span></div><div><a href="https://www.frontiersin.org/legal/privacy-policy" target="_blank">Privacy policy</a><span>|</span><a href="https://www.frontiersin.org/legal/terms-and-conditions" target="_blank">Terms and conditions</a></div></div></div></footer><div class="SnackbarWrapper"><div class="SnackbarManager"><!--[--><!--]--></div></div></div><noscript><iframe
            src="https://tag-manager.frontiersin.org/ns.html?id=GTM-M322FV2&gtm_auth=owVbWxfaJr21yQv1fe1cAQ&gtm_preview=env-1&gtm_cookies_win=x"
            height="0"
            width="0"
            style="display: none; visibility: hidden">
          </iframe></noscript><!--]--></div><div id="teleports"></div><script type="application/json" id="__NUXT_DATA__" data-ssr="true">[["ShallowReactive",1],{"data":2,"state":4,"once":10,"_errors":11,"serverRendered":13,"path":14,"pinia":15},["ShallowReactive",3],{},["Reactive",5],{"$ssite-config":6},{"env":7,"name":8,"url":9},"production","Frontiers articles","https://article-pages-2024.frontiersin.org/",["Set"],["ShallowReactive",12],{},true,"/journals/neurology/articles/10.3389/fneur.2024.1465747/full",["Reactive",16],{"main":17,"user":579,"article":580,"articleHub":855,"mainHeader":859},{"ibar":18,"footer":296,"newsletterComponent":-1,"snackbarItem":378,"toggleShowSnackbar":379,"contentfulJournal":380,"graphJournal":480,"settingsFeaturesSwitchers":484,"templateToggleBanner":485,"tenantConfig":544},{"tenantLogo":19,"journalLogo":19,"aboutUs":20,"submitUrl":113,"showSubmitButton":13,"journal":114,"sectionTerm":227,"aboutJournal":228,"mainLinks":277,"journalLinks":284,"helpCenterLink":293},"",[21,38,47,71,87],{"title":22,"links":23},"Who we are",[24,29,32,35],{"text":25,"url":26,"target":27,"ariaLabel":28},"Mission and values","https://www.frontiersin.org/about/mission","_self",null,{"text":30,"url":31,"target":27,"ariaLabel":28},"History","https://www.frontiersin.org/about/history",{"text":33,"url":34,"target":27,"ariaLabel":28},"Leadership","https://www.frontiersin.org/about/leadership",{"text":36,"url":37,"target":27,"ariaLabel":28},"Awards","https://www.frontiersin.org/about/awards",{"title":39,"links":40},"Impact and progress",[41,44],{"text":42,"url":43,"target":27,"ariaLabel":28},"Frontiers' impact","https://www.frontiersin.org/about/impact",{"text":45,"url":46,"target":27,"ariaLabel":28},"Our annual reports","https://www.frontiersin.org/about/annual-reports",{"title":48,"links":49},"Publishing model",[50,53,56,59,62,65,68],{"text":51,"url":52,"target":27,"ariaLabel":28},"How we publish","https://www.frontiersin.org/about/how-we-publish",{"text":54,"url":55,"target":27,"ariaLabel":28},"Open access","https://www.frontiersin.org/about/open-access",{"text":57,"url":58,"target":27,"ariaLabel":28},"Peer review","https://www.frontiersin.org/about/peer-review",{"text":60,"url":61,"target":27,"ariaLabel":28},"Research integrity","https://www.frontiersin.org/about/research-integrity",{"text":63,"url":64,"target":27,"ariaLabel":28},"Research Topics","https://www.frontiersin.org/about/research-topics",{"text":66,"url":67,"target":27,"ariaLabel":28},"FAIR Data Management","https://www.frontiersin.org/about/fair-data-management",{"text":69,"url":70,"target":27,"ariaLabel":28},"Fee policy","https://www.frontiersin.org/about/fee-policy",{"title":72,"links":73},"Services",[74,78,81,84],{"text":75,"url":76,"target":77,"ariaLabel":28},"Societies","https://publishingpartnerships.frontiersin.org/","_blank",{"text":79,"url":80,"target":27,"ariaLabel":28},"National consortia","https://www.frontiersin.org/open-access-agreements/consortia",{"text":82,"url":83,"target":27,"ariaLabel":28},"Institutional partnerships","https://www.frontiersin.org/about/open-access-agreements",{"text":85,"url":86,"target":27,"ariaLabel":28},"Collaborators","https://www.frontiersin.org/about/collaborators",{"title":88,"links":89},"More from Frontiers",[90,94,97,101,105,109],{"text":91,"url":92,"target":77,"ariaLabel":93},"Frontiers Forum","https://forum.frontiersin.org/","this link will take you to the Frontiers Forum website",{"text":95,"url":96,"target":27,"ariaLabel":28},"Frontiers Planet Prize","https://www.frontiersin.org/about/frontiers-planet-prize",{"text":98,"url":99,"target":77,"ariaLabel":100},"Press office","https://pressoffice.frontiersin.org/","this link will take you to the Frontiers press office website",{"text":102,"url":103,"target":27,"ariaLabel":104},"Sustainability","https://www.frontiersin.org/about/sustainability","link to information about Frontiers' sustainability",{"text":106,"url":107,"target":77,"ariaLabel":108},"Career opportunities","https://careers.frontiersin.org/","this link will take you to the Frontiers careers website",{"text":110,"url":111,"target":27,"ariaLabel":112},"Contact us","https://www.frontiersin.org/about/contact","this link will take you to the help pages to contact our support team","https://www.frontiersin.org/submission/submit?domainid=2&fieldid=54&specialtyid=0&entitytype=2&entityid=141",{"id":115,"name":116,"slug":117,"sections":118},141,"Frontiers in Neurology","neurology",[119,123,127,131,135,139,143,147,151,155,159,163,167,171,175,179,183,187,191,195,199,203,207,211,215,219,223],{"id":120,"name":121,"slug":122},156,"Applied Neuroimaging","applied-neuroimaging",{"id":124,"name":125,"slug":126},3712,"Artificial Intelligence in Neurology","artificial-intelligence-in-neurology",{"id":128,"name":129,"slug":130},3023,"Autonomic Disorders","autonomic-disorders",{"id":132,"name":133,"slug":134},3740,"Cognitive and Behavioral Neurology","cognitive-and-behavioral-neurology",{"id":136,"name":137,"slug":138},1439,"Dementia and Neurodegenerative Diseases","dementia-and-neurodegenerative-diseases",{"id":140,"name":141,"slug":142},2038,"Diagnostic Neuropathology","diagnostic-neuropathology",{"id":144,"name":145,"slug":146},143,"Endovascular and Interventional Neurology","endovascular-and-interventional-neurology",{"id":148,"name":149,"slug":150},144,"Epilepsy","epilepsy",{"id":152,"name":153,"slug":154},1784,"Experimental Therapeutics","experimental-therapeutics",{"id":156,"name":157,"slug":158},153,"Headache and Neurogenic Pain","headache-and-neurogenic-pain",{"id":160,"name":161,"slug":162},145,"Movement Disorders","movement-disorders",{"id":164,"name":165,"slug":166},147,"Multiple Sclerosis and Neuroimmunology","multiple-sclerosis-and-neuroimmunology",{"id":168,"name":169,"slug":170},150,"Neuro-Oncology and Neurosurgical Oncology","neuro-oncology-and-neurosurgical-oncology",{"id":172,"name":173,"slug":174},154,"Neuro-Ophthalmology","neuro-ophthalmology",{"id":176,"name":177,"slug":178},155,"Neuro-Otology","neuro-otology",{"id":180,"name":181,"slug":182},159,"Neurocritical and Neurohospitalist Care","neurocritical-and-neurohospitalist-care",{"id":184,"name":185,"slug":186},1339,"Neuroepidemiology","neuroepidemiology",{"id":188,"name":189,"slug":190},160,"Neurogenetics","neurogenetics",{"id":192,"name":193,"slug":194},1334,"Neuroinfectious Diseases","neuroinfectious-diseases",{"id":196,"name":197,"slug":198},2345,"Neurological Biomarkers","neurological-biomarkers",{"id":200,"name":201,"slug":202},146,"Neuromuscular Disorders and Peripheral Neuropathies","neuromuscular-disorders-and-peripheral-neuropathies",{"id":204,"name":205,"slug":206},547,"Neurorehabilitation","neurorehabilitation",{"id":208,"name":209,"slug":210},3418,"Neurotechnology","neurotechnology",{"id":212,"name":213,"slug":214},163,"Neurotrauma","neurotrauma",{"id":216,"name":217,"slug":218},161,"Pediatric Neurology","pediatric-neurology",{"id":220,"name":221,"slug":222},151,"Sleep Disorders","sleep-disorders",{"id":224,"name":225,"slug":226},142,"Stroke","stroke","Sections",[229,253],{"title":230,"links":231},"Scope",[232,235,238,241,244,247,250],{"text":233,"url":234,"target":27,"ariaLabel":28},"Field chief editors","https://www.frontiersin.org/journals/neurology/about#about-editors",{"text":236,"url":237,"target":27,"ariaLabel":28},"Mission & scope","https://www.frontiersin.org/journals/neurology/about#about-scope",{"text":239,"url":240,"target":27,"ariaLabel":28},"Facts","https://www.frontiersin.org/journals/neurology/about#about-facts",{"text":242,"url":243,"target":27,"ariaLabel":28},"Journal sections","https://www.frontiersin.org/journals/neurology/about#about-submission",{"text":245,"url":246,"target":27,"ariaLabel":28},"Open access statement","https://www.frontiersin.org/journals/neurology/about#about-open",{"text":248,"url":249,"target":27,"ariaLabel":28},"Copyright statement","https://www.frontiersin.org/journals/neurology/about#copyright-statement",{"text":251,"url":252,"target":27,"ariaLabel":28},"Quality","https://www.frontiersin.org/journals/neurology/about#about-quality",{"title":254,"links":255},"For authors",[256,259,262,265,268,271,274],{"text":257,"url":258,"target":27,"ariaLabel":28},"Why submit?","https://www.frontiersin.org/journals/neurology/for-authors/why-submit",{"text":260,"url":261,"target":27,"ariaLabel":28},"Article types","https://www.frontiersin.org/journals/neurology/for-authors/article-types",{"text":263,"url":264,"target":27,"ariaLabel":28},"Author guidelines","https://www.frontiersin.org/journals/neurology/for-authors/author-guidelines",{"text":266,"url":267,"target":27,"ariaLabel":28},"Editor guidelines","https://www.frontiersin.org/journals/neurology/for-authors/editor-guidelines",{"text":269,"url":270,"target":27,"ariaLabel":28},"Publishing fees","https://www.frontiersin.org/journals/neurology/for-authors/publishing-fees",{"text":272,"url":273,"target":27,"ariaLabel":28},"Submission checklist","https://www.frontiersin.org/journals/neurology/for-authors/submission-checklist",{"text":275,"url":276,"target":27,"ariaLabel":28},"Contact editorial office","https://www.frontiersin.org/journals/neurology/for-authors/contact-editorial-office",[278,281],{"text":279,"url":280,"target":27,"ariaLabel":28},"All journals","https://www.frontiersin.org/journals",{"text":282,"url":283,"target":27,"ariaLabel":28},"All articles","https://www.frontiersin.org/articles",[285,288,290],{"text":286,"url":287,"target":27,"ariaLabel":28},"Articles","articles",{"text":63,"url":289,"target":27,"ariaLabel":28},"research-topics",{"text":291,"url":292,"target":27,"ariaLabel":28},"Editorial board","editors",{"text":294,"url":295,"target":77,"ariaLabel":294},"Help center","https://helpcenter.frontiersin.org",{"blocks":297,"socialLinks":351,"copyright":375,"termsAndConditionsUrl":376,"privacyPolicyUrl":377},[298,312,322,336],{"title":299,"links":300},"Guidelines",[301,303,306,309,311],{"text":263,"url":302,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/author-guidelines",{"text":304,"url":305,"target":27,"ariaLabel":28},"Services for authors","https://www.frontiersin.org/for-authors/author-services",{"text":307,"url":308,"target":27,"ariaLabel":28},"Policies and publication ethics","https://www.frontiersin.org/guidelines/policies-and-publication-ethics",{"text":266,"url":310,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/editor-guidelines",{"text":69,"url":70,"target":27,"ariaLabel":28},{"title":313,"links":314},"Explore",[315,316,319,321],{"text":286,"url":283,"target":27,"ariaLabel":28},{"text":317,"url":318,"target":27,"ariaLabel":28},"Research Topics ","https://www.frontiersin.org/research-topics",{"text":320,"url":280,"target":27,"ariaLabel":28},"Journals",{"text":51,"url":52,"target":27,"ariaLabel":28},{"title":323,"links":324},"Outreach",[325,328,331,335],{"text":326,"url":92,"target":77,"ariaLabel":327},"Frontiers Forum ","Frontiers Forum website",{"text":329,"url":330,"target":77,"ariaLabel":28},"Frontiers Policy Labs ","https://policylabs.frontiersin.org/",{"text":332,"url":333,"target":77,"ariaLabel":334},"Frontiers for Young Minds","https://kids.frontiersin.org/","Frontiers for Young Minds journal",{"text":95,"url":96,"target":27,"ariaLabel":28},{"title":337,"links":338},"Connect",[339,340,344,347,350],{"text":294,"url":295,"target":77,"ariaLabel":294},{"text":341,"url":342,"target":77,"ariaLabel":343},"Emails and alerts ","https://subscription-management.frontiersin.org/emails/preferences#block0","Subscribe to Frontiers emails",{"text":345,"url":111,"target":27,"ariaLabel":346},"Contact us ","Subscribe to newsletter",{"text":348,"url":349,"target":27,"ariaLabel":28},"Submit","https://www.frontiersin.org/submission/submit",{"text":106,"url":107,"target":77,"ariaLabel":28},[352,360,365,370],{"link":353,"type":356,"color":357,"icon":358,"size":359,"hiddenText":13},{"text":354,"url":355,"target":77,"ariaLabel":354},"Frontiers Facebook","https://www.facebook.com/Frontiersin","Link","Grey","Facebook","Medium",{"link":361,"type":356,"color":357,"icon":364,"size":359,"hiddenText":13},{"text":362,"url":363,"target":77,"ariaLabel":28},"Frontiers Twitter","https://twitter.com/frontiersin","Twitter",{"link":366,"type":356,"color":357,"icon":369,"size":359,"hiddenText":13},{"text":367,"url":368,"target":77,"ariaLabel":28},"Frontiers LinkedIn","https://www.linkedin.com/company/frontiers","LinkedIn",{"link":371,"type":356,"color":357,"icon":374,"size":359,"hiddenText":13},{"text":372,"url":373,"target":77,"ariaLabel":28},"Frontiers Instagram","https://www.instagram.com/frontiersin_","Instagram","Frontiers Media SA. All rights reserved.","https://www.frontiersin.org/legal/terms-and-conditions","https://www.frontiersin.org/legal/privacy-policy",{},false,{"__typename":381,"identifier":115,"name":116,"slug":117,"banner":382,"description":473,"mission":474,"palette":475,"impactFactor":476,"citeScore":477,"citations":478,"showTagline":28,"twitter":479},"Journal",[383],{"id":384,"src":385,"name":386,"tags":387,"type":432,"width":433,"height":434,"idHash":435,"archive":436,"brandId":437,"limited":436,"fileSize":438,"isPublic":439,"original":440,"copyright":19,"extension":441,"thumbnails":443,"dateCreated":451,"description":452,"orientation":453,"userCreated":454,"watermarked":436,"dateModified":451,"datePublished":455,"ecsArchiveFiles":456,"propertyOptions":457,"property_Channel":462,"property_Sub-Type":464,"property_Asset_Type":466,"activeOriginalFocusPoint":468,"property_Office_Department":471},"D315ADB2-2967-48B6-BE3B61009343D69E","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/D315ADB2-2967-48B6-BE3B61009343D69E/webimage-810A1E19-163C-4FD0-BFD3D50A4721B642.png","FNEUR_Main Visual_Cyan_Website",[388,389,390,391,392,393,394,395,396,397,398,399,400,401,402,403,404,405,406,407,408,409,410,411,412,413,414,415,416,417,418,419,420,421,422,423,424,425,426,427,428,429,117,430,431],"professional","device","medical","close up","technology","wires","brain waves","record","digital","selective focus","laboratory","brain","health","electrodes","computer","examination","electroencephalography","scan","study","oncology","examine","electroencephalogram","neurosurgery","science","doctor","diagnose","magnetic","patient","modern","electroencephalograph","equipment","office","healthcare","scanning","instrument","eeg","hospital","ct","technician","medicine","ultrasound","radiology","diagnostic","lab","image",5052,3368,"62463d527f6ddd4d",0,"22C10171-81B3-4DA6-99342F272A32E8BB",5758943,1,"https://brand.frontiersin.org/m/62463d527f6ddd4d/original/FNEUR_Main-Visual_Cyan_Website.jpg",[442],"jpg",{"mini":444,"thul":445,"webimage":385,"Guidelines":446,"WebsiteJpg_XL":447,"WebsiteWebP_L":448,"WebsiteWebP_M":449,"WebsiteWebP_XL":450},"https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/D315ADB2-2967-48B6-BE3B61009343D69E/mini-A927C1B7-02F8-4D29-94320F509270457D.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/D315ADB2-2967-48B6-BE3B61009343D69E/thul-FCD9F16D-D1A9-4535-A7E4C140224266B9.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/D315ADB2-2967-48B6-BE3B61009343D69E/84855035-8C7E-4727-AB7CEC390287243C/Guidelines-FNEUR_Main Visual_Cyan_Website.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/D315ADB2-2967-48B6-BE3B61009343D69E/84855035-8C7E-4727-AB7CEC390287243C/WebsiteJpg_XL-FNEUR_Main Visual_Cyan_Website.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/D315ADB2-2967-48B6-BE3B61009343D69E/84855035-8C7E-4727-AB7CEC390287243C/WebsiteWebP_L-FNEUR_Main Visual_Cyan_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/D315ADB2-2967-48B6-BE3B61009343D69E/84855035-8C7E-4727-AB7CEC390287243C/WebsiteWebP_M-FNEUR_Main Visual_Cyan_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/D315ADB2-2967-48B6-BE3B61009343D69E/84855035-8C7E-4727-AB7CEC390287243C/WebsiteWebP_XL-FNEUR_Main Visual_Cyan_Website.webp","2022-06-27T10:00:23Z","Charming young woman undergoing electroencephalography; Shutterstock ID 695951221; purchase_order: Main Visual; job: ; client: ; other:","landscape","Caroline Sutter","2022-06-27T06:08:46Z",[],[458,459,460,461],"414FB2D4-2283-43FD-BE14E534ECA67928","6C18119B-14BD-4951-B437696F4357BD33","7C692885-DB25-4858-B1FB4FF47B241E9B","D88C0047-EC30-4506-A7DF28A4D765E1CF",[463],"frontiersin_org",[465],"Main_Visual",[467],"Photography",{"x":469,"y":470},2526,1684,[472],"Publishing","The world's most cited clinical neurology journal, exploring the diagnosis, causes, treatment, and public health aspects of neurological illnesses to improve patient care.","\u003Cp>Frontiers in Neurology is a multidisciplinary journal that addresses all areas of neurology to better understand, treat, and prevent neurological disorders. It is indexed in PubMed Central (PMC), Scopus, and the DOAJ.\u003C/p>\n\n\u003Cp>Led by Field Chief Editor Prof. Irene Litvan (University of California, San Diego, USA), Frontiers in Neurology welcomes submissions that explore the diagnosis, nature, causes, treatment, and public health aspects of neurological disorders.\u003C/p>\n\n\u003Cp>The journal covers a wide spectrum of basic, translational, and clinical research that help improve patient care, including but not limited to:\u003C/p>\n\n\u003Cul>\n  \u003Cli>artificial intelligence in neurology\u003C/li>\n  \u003Cli>applied neuroimaging\u003C/li>\n  \u003Cli>autonomic disorders\u003C/li>\n  \u003Cli>cognitive behavioural neurology\u003C/li>\n  \u003Cli>dementia and neurodegenerative diseases\u003C/li>\n  \u003Cli>diagnostic neuropathology\u003C/li>\n  \u003Cli>endovascular and interventional neurology\u003C/li>\n  \u003Cli>epilepsy\u003C/li>\n  \u003Cli>experimental therapeutics\u003C/li>\n  \u003Cli>headache and neurogenic pain\u003C/li>\n  \u003Cli>movement disorders\u003C/li>\n  \u003Cli>multiple sclerosis and neuroimmunology\u003C/li>\n  \u003Cli>neuro-oncology and neurosurgical oncology\u003C/li>\n  \u003Cli>neuro-ophthalmology\u003C/li>\n  \u003Cli>neuro-otology\u003C/li>\n  \u003Cli>neurocritical and neurohospitalist care\u003C/li>\n  \u003Cli>neuroepidemiology\u003C/li>\n  \u003Cli>neurogenetics\u003C/li>\n  \u003Cli>neuroinfectious diseases\u003C/li>\n  \u003Cli>neurological biomarkers\u003C/li>\n  \u003Cli>neuromuscular disorders and peripheral neuropathies\u003C/li>\n  \u003Cli>neurorehabilitation\u003C/li>\n  \u003Cli>neurotechnology\u003C/li>\n  \u003Cli>neurotrauma\u003C/li>\n  \u003Cli>pediatric neurology\u003C/li>\n  \u003Cli>sleep disorders\u003C/li>\n  \u003Cli>stroke\u003C/li>\n\u003C/ul>\n\n\u003Cp>In particular, the journal welcomes submissions that support and advance the UNs \u003Ca href=https://globalgoals.org/goals/>Sustainable Development Goals\u003C/a> (SDGs), notably \u003Ca href=https://globalgoals.org/goals/3-good-health-and-well-being/>SDG 3: Good Health and Well-Being\u003C/a>.\u003C/p>\n\n\u003Cp>Manuscripts that focus solely on surgical techniques are not suitable for publication in this journal. Case Reports are only suitable for submission to our Neuro-Ophthalmology section; please see the section description for more information. Studies that do not provide significant insight into the neurological basis of disease or disorder, or those that do not contribute to the understanding of the fundamental mechanisms of neurology, diagnosis and treatment of neurological disorders are not appropriate for this journal.\u003C/p>\n\n\u003Cp>The journal no longer accepts papers concerning simple bibliometric studies. Authors are still welcome to submit Systematic Reviews using publicly available data, but these must adhere to the \u003Ca href=https://www.prisma-statement.org/>PRISMA guidelines\u003C/a> and have a conclusion related to neurological research. Studies without this primary focus will be transferred to a more applicable journal.\u003C/p>\n\n\u003Cp>Frontiers journals require that manuscripts primarily comprising computational studies of public data, such as NHANES or Mendelian Randomization studies, must include appropriate validation. Please refer to the \u003Ca href=\"https://www.frontiersin.org/guidelines/policies-and-publication-ethics#standards-for-research-methodology:~:text=complaints%20and%20allegations.-,Standards%20for%20research%20methodology,-Experiments\">Frontiers Standards for research methodology policy\u003C/a> for more information. Manuscripts not adhering to these standards will not be considered.\u003Cp>\n\n\u003Cp>Frontiers in Neurology is committed to advancing developments in the field of neurology by communicating scientific knowledge to researchers, academics, clinicians and the public worldwide, to enable the scientific breakthroughs of the future.\u003C/p>","cyan","3.4","4.8","273537","@FrontNeurol",{"id":115,"name":116,"slug":117,"abbreviation":481,"isOnline":13,"isOpenForSubmissions":13,"citeScore":482,"impactFactor":483},"fneur",5.2,2.8,{"displayTitlePillLabels":13,"displayRelatedArticlesBox":13,"showEditors":13,"showReviewers":13,"showLoopImpactLink":13,"enableFigshare":379},{"isPublic":13,"allowCompanyUsers":379,"whiteListEmails":486,"enableAllJournals":13,"whiteListJournals":508},[487,488,489,490,491,492,493,494,495,492,496,497,498,499,500,501,502,503,504,505,506,507],"Y2FybG9zLmxvcmNhQGZyb250aWVyc2luLm9yZw==","ZGFuaWVsLmx1ekBmcm9udGllcnNpbi5vcmc=","bGF1cmEudGVuYUBmcm9udGllcnNpbi5vcmc=","cmFmYWVsLnJpYW5jaG9AZnJvbnRpZXJzaW4ub3Jn","amFtZXMuc21hbGxib25lQGZyb250aWVyc2luLm9yZw==","ZnJhbi5tb3Jlbm9AZnJvbnRpZXJzaW4ub3Jn","c2FtdWVsLmZlcm5hbmRlekBmcm9udGllcnNpbi5vcmc=","YmFyYmFyYS5jYXJjYW5naXVAZnJvbnRpZXJzaW4ub3Jn","aXZhbi5zYW50YW1hcmlhQGZyb250aWVyc2luLm9yZw==","aHVlLnRyYW5AZnJvbnRpZXJzaW4ub3Jn","Z29uY2Fsby52YXJnYXNAZnJvbnRpZXJzaW4ub3Jn","bHVjaWUuc2VubkBmcm9udGllcnNpbi5vcmc=","bG9ybi5mcmFzZXJAZnJvbnRpZXJzaW4ub3Jn","ZWxzYS5jYXJyb25AZnJvbnRpZXJzaW4ub3Jn","bWFhcnRlbi52YW5kaWpja0Bmcm9udGllcnNpbi5vcmc=","YmluZGh1LmtyaXNobmFuQGZyb250aWVyc2luLm9yZw==","bWF0dGhldy5hdHR3YXRlcnNAZnJvbnRpZXJzaW4ub3Jn","Z2l1bGlhLnZhbHNlY2NoaUBmcm9udGllcnNpbi5vcmc=","ZmFiaWFuLmRlbGxhbW9ydGVAZnJvbnRpZXJzaW4ub3Jn","dmlqYXlhbi5wcEBwaXRzb2x1dGlvbnMuY29t","Z3VpbGxhdW1lLnNldXJhdEBmcm9udGllcnNpbi5vcmc=",[509,510,511,512,513,514,439,515,516,517,518,519,520,521,522,523,524,525,526,527,528,529,115,530,531,532,533,534,535,536,537,538,539,540,541,542,543],2232,1729,2357,2456,2176,2333,1843,602,106,616,310,657,3123,1468,2137,628,1566,2726,2086,1490,451,1335,2655,1238,604,698,1547,176,1440,403,1239,755,2136,609,1534,{"spaceId":439,"name":439,"availableJournalPages":545,"announcement":549},[287,292,289,546,547,548],"volumes","about","community-reviewers",{"__typename":550,"sys":551,"preHeader":42,"title":553,"description":554,"image":555,"link":577},"Announcement",{"id":552},"5ITtnTtQgAzPPGH6rX0AlM","Articles published with Frontiers have received 12 million total citations","Your research is the real superpower - learn how we maximise its impact through our leading community journals",[556],{"archive":436,"brandId":437,"copyright":28,"dateCreated":557,"dateModified":558,"datePublished":559,"description":28,"extension":560,"fileSize":562,"height":563,"id":564,"isPublic":436,"limited":436,"name":565,"orientation":453,"original":28,"thumbnails":566,"type":432,"watermarked":436,"width":573,"videoPreviewURLs":574,"tags":575,"textMetaproperties":576,"src":567},"2025-06-18T12:58:01Z","2025-06-18T14:15:34Z","2025-06-18T12:57:32Z",[561],"png",1365026,920,"7C5269C4-3C83-4591-951A74D15B95DAEA","Impact metrics banner for article pages",{"webimage":567,"thul":568,"mini":569,"WebsiteWebP_L":570,"WebsiteWebP_M":571,"Guidelines":572},"https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/thul-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/mini-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_L/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_M/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/Guidelines/Impact-metrics-banner-for-article-pages.png",1600,[],[],[],{"text":578,"url":43,"target":27,"ariaLabel":28},"Explore our impact metrics",{"loggedUserInfo":-1},{"currentArticle":581,"isPreviewPage":379,"hasSupplementalData":379,"showCrossmarkWidget":13,"articleTemplate":725,"currentArticlePageMetaInfo":726,"xmlParsedArticleContent":-1,"xmlParsingError":-1},{"id":582,"doi":583,"title":584,"acceptanceDate":585,"receptionDate":586,"publicationDate":587,"lastModifiedDate":588,"isPublished":13,"abstract":589,"researchTopic":28,"articleType":590,"stage":593,"keywords":595,"authors":603,"editors":651,"reviewers":661,"journal":680,"section":688,"impactMetrics":690,"volume":694,"articleVolume":695,"relatedArticles":696,"isPublishedV2":379,"contents":697,"files":700},1465747,"10.3389/fneur.2024.1465747","Assessing the effectiveness and safety of Patisiran and Vutrisiran in ATTRv amyloidosis with polyneuropathy: a systematic review",["Date","2024-08-16T15:35:55.000Z"],["Date","2024-07-17T16:08:11.000Z"],["Date","2024-09-02T00:00:00.000Z"],["Date","2025-11-25T02:38:38.150Z"],"Background: Hereditary transthyretin (ATTRv) amyloidosis, a multifaceted disorder affecting multiple systems, substantially diminishes patients' physical capabilities and overall quality of life.Patisiran and Vutrisiran, two Ribonucleic acid (RNA) interference therapies, target reducing both pathogenic and wild-type transthyretin (TTR) protein levels. This systematic review assesses the effectiveness and safety of these treatments in managing ATTRv. Methods: A comprehensive, thorough literature search across databases including Embase, PubMed, Web of Science, Cochrane Central, and Google Scholar yielded 858 studies. Following removing duplicate and irrelevant articles, 676 distinct studies underwent review. These studies, conducted on a global scale, encompassed a range of methodologies, including clinical trials and indirect treatment comparisons. Results: Ten studies, spanning a total population of 756 patients, were selected for in-depth analysis. Patisiran and Vutrisiran consistently demonstrated significant improvements in primary and secondary endpoints related to neuropathy, quality of life, and cardiac function. Both medications were well-tolerated, with primarily mild to moderate adverse events. Indirect treatment comparison studies indicated Vutrisiran's superiority over Tafamidis in treating ATTRv amyloidosis. Conclusion: This systematic review recommends using Patisiran and Vutrisiran to treat ATTRv amyloidosis. The findings suggest that these RNA interference therapies improve neuropathy, quality of life, and cardiac symptoms. The results indicate sustained benefits over prolonged treatment, with satisfactory safety profiles. However, potential biases, conflicts of interest in the studies, and limited follow-up periods in some trials necessitate cautious interpretation. Future research should address these limitations and provide more robust evidence for the long-term efficacy and safety of Patisiran and Vutrisiran in ATTRv treatment.",{"id":591,"name":592},136,"Systematic Review",{"id":594,"name":19},18,[596,597,598,599,600,601,602],"hereditary amyloidosis","Transthyretin-related amyloidosis","patisiran","Vutrisiran","polyneuropathy","cardiomyopathy","clinical trials",[604,613,621,628,636,644],{"id":605,"firstName":606,"middleName":19,"lastName":607,"givenNames":608,"isCorresponding":379,"isProfilePublic":13,"userId":605,"email":-1,"affiliations":609},1843942,"Mohammad Amin","Karimi","Mohammad Amin ",[610],{"organizationName":611,"countryName":612,"cityName":19,"stateName":19,"zipCode":19},"School of Medicine, Shahid Beheshti University of Medical Sciences","Iran",{"id":614,"firstName":615,"middleName":19,"lastName":616,"givenNames":617,"isCorresponding":379,"isProfilePublic":13,"userId":614,"email":-1,"affiliations":618},2064986,"Fatemeh","Esmaeilpour Moallem","Fatemeh ",[619],{"organizationName":620,"countryName":612,"cityName":19,"stateName":19,"zipCode":19},"Student Research Committee, Golestan University of Medical Sciences",{"id":622,"firstName":623,"middleName":19,"lastName":624,"givenNames":625,"isCorresponding":379,"isProfilePublic":13,"userId":622,"email":-1,"affiliations":626},2158070,"Mohammad Sadra","Gholami Chahkand","Mohammad Sadra ",[627],{"organizationName":620,"countryName":612,"cityName":19,"stateName":19,"zipCode":19},{"id":629,"firstName":630,"middleName":19,"lastName":631,"givenNames":632,"isCorresponding":379,"isProfilePublic":13,"userId":629,"email":-1,"affiliations":633},2802865,"Eftekhar","Azarm","Eftekhar ",[634],{"organizationName":635,"countryName":612,"cityName":19,"stateName":19,"zipCode":19},"School of Medicine, Isfahan University of Medical Sciences",{"id":637,"firstName":638,"middleName":19,"lastName":639,"givenNames":640,"isCorresponding":379,"isProfilePublic":13,"userId":637,"email":-1,"affiliations":641},1830091,"Mohammad Javad","Emami Kazemabad","Mohammad Javad ",[642],{"organizationName":643,"countryName":612,"cityName":19,"stateName":19,"zipCode":19},"Student Research Committee, School of Medicine, Qom University of Medical Sciences",{"id":645,"firstName":646,"middleName":19,"lastName":647,"givenNames":648,"isCorresponding":379,"isProfilePublic":13,"userId":645,"email":-1,"affiliations":649},2614325,"Parisa Alsadat","Dadkhah","Parisa Alsadat ",[650],{"organizationName":635,"countryName":612,"cityName":19,"stateName":19,"zipCode":19},[652],{"id":653,"firstName":654,"middleName":19,"lastName":655,"givenNames":656,"isCorresponding":379,"isProfilePublic":13,"userId":653,"email":-1,"affiliations":657},857342,"Vincenzo","Di Stefano","Vincenzo ",[658],{"organizationName":659,"countryName":660,"cityName":19,"stateName":19,"zipCode":19},"Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo","Italy",[662,671],{"id":663,"firstName":664,"middleName":19,"lastName":665,"givenNames":666,"isCorresponding":379,"isProfilePublic":13,"userId":663,"email":-1,"affiliations":667},1662511,"Jonas","Wixner","Jonas ",[668],{"organizationName":669,"countryName":670,"cityName":19,"stateName":19,"zipCode":19},"Faculty of Medicine, Ume University","Sweden",{"id":672,"firstName":673,"middleName":19,"lastName":674,"givenNames":675,"isCorresponding":379,"isProfilePublic":13,"userId":672,"email":-1,"affiliations":676},756275,"Koike","Haruki","Koike ",[677],{"organizationName":678,"countryName":679,"cityName":19,"stateName":19,"zipCode":19},"Saga University","Japan",{"id":115,"slug":117,"name":116,"shortName":681,"electronicISSN":682,"field":683,"specialtyId":28,"journalSectionPaths":686},"Front. Neurol.","1664-2295",{"id":684,"domainId":685},54,2,[687],{"section":688},{"id":200,"name":201,"slug":202,"specialtyId":689},756,{"views":691,"downloads":692,"citations":693},5768,2070,5,15,"Volume 15 - 2024",[],{"titleHtml":584,"fullTextHtml":698,"menuHtml":699},"\u003Cdiv class=\"JournalAbstract\"> \u003Ca id=\"h1\" name=\"h1\">\u003C/a>\n \u003Cdiv class=\"authors\">\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1843942\" class=\"user-id-1843942\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1843942/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Mohammad Amin Karimi\n&#x;\">Mohammad Amin Karimi\u003C/a>\u003Csup>1\u003C/sup>\u003Csup>\n&#x2020;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/2064986\" class=\"user-id-2064986\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2064986/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Fatemeh Esmaeilpour Moallem\n&#x;\">Fatemeh Esmaeilpour Moallem\u003C/a>\u003Csup>2\u003C/sup>\u003Csup>\n&#x2020;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/2158070\" class=\"user-id-2158070\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2158070/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Mohammad Sadra Gholami Chahkand\">Mohammad Sadra Gholami Chahkand\u003C/a>\u003Csup>2\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/2802865\" class=\"user-id-2802865\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2802865/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Eftekhar Azarm\">Eftekhar Azarm\u003C/a>\u003Csup>3\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1830091\" class=\"user-id-1830091\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1830091/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Mohammad Javad Emami Kazemabad\">Mohammad Javad Emami Kazemabad\u003C/a>\u003Csup>4\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/2614325\" class=\"user-id-2614325\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2614325/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Parisa Alsadat Dadkhah&#xA;\">Parisa Alsadat Dadkhah\u003C/a>\u003Csup>3\u003C/sup>\u003Csup>&#x0002A;\u003C/sup>\u003C/span>\u003C/div> \u003Cul class=\"notes\"> \u003Cli>\u003Cspan>\u003Csup>1\u003C/sup>\u003C/span>School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran\u003C/li> \u003Cli>\u003Cspan>\u003Csup>2\u003C/sup>\u003C/span>Student Research Committee, Golestan University of Medical Sciences, Gorgan, Iran\u003C/li> \u003Cli>\u003Cspan>\u003Csup>3\u003C/sup>\u003C/span>School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran\u003C/li> \u003Cli>\u003Cspan>\u003Csup>4\u003C/sup>\u003C/span>Student Research Committee, School of Medicine, Qom University of Medical Sciences, Qom, Iran\u003C/li> \u003C/ul>\n\u003Cp class=\"mb15\">\u003Cb>Background:\u003C/b> Hereditary transthyretin (ATTRv) amyloidosis, a multifaceted disorder affecting multiple systems, substantially diminishes patients&#x2019; physical capabilities and overall quality of life. Patisiran and Vutrisiran, two Ribonucleic acid (RNA) interference therapies, target reducing both pathogenic and wild-type transthyretin (TTR) protein levels. This systematic review assesses the effectiveness and safety of these treatments in managing ATTRv.\u003C/p>\n\u003Cp class=\"mb15\">\u003Cb>Methods:\u003C/b> A comprehensive, thorough literature search across databases including Embase, PubMed, Web of Science, Cochrane Central, and Google Scholar yielded 858 studies. Following removing duplicate and irrelevant articles, 676 distinct studies underwent review. These studies, conducted on a global scale, encompassed a range of methodologies, including clinical trials and indirect treatment comparisons.\u003C/p>\n\u003Cp class=\"mb15\">\u003Cb>Results:\u003C/b> Ten studies, spanning a total population of 756 patients, were selected for in-depth analysis. Patisiran and Vutrisiran consistently demonstrated significant improvements in primary and secondary endpoints related to neuropathy, quality of life, and cardiac function. Both medications were well-tolerated, with primarily mild to moderate adverse events. Indirect treatment comparison studies indicated Vutrisiran&#x2019;s superiority over Tafamidis in treating ATTRv amyloidosis.\u003C/p>\n\u003Cp class=\"mb0\">\u003Cb>Conclusion:\u003C/b> This systematic review recommends using Patisiran and Vutrisiran to treat ATTRv amyloidosis. The findings suggest that these RNA interference therapies improve neuropathy, quality of life, and cardiac symptoms. The results indicate sustained benefits over prolonged treatment, with satisfactory safety profiles. However, potential biases, conflicts of interest in the studies, and limited follow-up periods in some trials necessitate cautious interpretation. Future research should address these limitations and provide more robust evidence for the long-term efficacy and safety of Patisiran and Vutrisiran in ATTRv treatment.\u003C/p> \u003Cdiv class=\"clear\">\u003C/div> \u003C/div> \u003Cdiv class=\"JournalFullText\"> \u003Ca id=\"h2\" name=\"h2\">\u003C/a>\n\u003Ch2>Introduction\u003C/h2>\n\u003Cp class=\"mb15\">Hereditary transthyretin (ATTRv) amyloidosis is a disease typically manifesting in adulthood, subsequent to mutations within the transthyretin (TTR) gene. TTR protein constitutes a circulating tetramer serving as a carrier protein for thyroxine and retinol-binding proteins affiliated with vitamin A. TTR is detectable in both serum and cerebrospinal fluid, predominantly biosynthesized in hepatic tissue, with minor synthesis occurring in the eye and the brain (\u003Ca href=\"#ref1\">1\u003C/a>). Genetic mutations within the TTR gene precipitate the destabilization of its tetrameric structure, resulting in the dissociation into misfolded monomers, which aggregate within extracellular spaces, forming oligomers that eventually coalesce into amyloid fibrils typified by cross &#x03B2;-sheets (\u003Ca href=\"#ref2\">2\u003C/a>). Accumulation of mutated transthyretin primarily occurs in the heart and peripheral nervous system (PNS), with secondary involvement of various organs such as the brain, kidneys, skin, and muscles, rendering ATTRv a multisystemic disorder. Over 130 pathogenic mutations have been delineated, with the most common TTR variants being the valine-to-methionine substitution at amino acid 30 mutation (Val30Met) and the Val122Ile mutation. However, early-onset disease is not the typical phenotype in all endemic areas. Late-onset disease is more common in Sweden, and this phenotype is also present in Japan and Portugal (\u003Ca href=\"#ref3\">3\u003C/a>). Other mutations, particularly non-Val30Met variants, predominantly present with delayed manifestation characteristics (\u003Ca href=\"#ref4\">4\u003C/a>). Primary clinical manifestations of ATTRv predominantly affecting the PNS or cardiac system delineate distinct neurological or cardiac phenotypes. However, most mutations progressively manifest as a mixed phenotype involving both systems throughout the disease course (\u003Ca href=\"#ref1\">1\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">ATTRv polyneuropathy emerges due to the accumulation of TTR within the PNS, leading to the development of sensory-motor and autonomic neuropathies characterized by length-dependent patterns. Manifesting as a progressive and incapacitating condition, untreated ATTRv results in a worsening disability, ultimately culminating in wheelchair dependence, bedridden states, and eventual mortality (\u003Ca href=\"#ref5\">5\u003C/a>). Therefore, early identification of individuals affected by ATTRv is imperative, and prompt initiation of treatment is vital to enhance their quality of life (QOL) and attain favorable clinical outcomes (\u003Ca href=\"#ref6\">6\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">Therapeutic modalities for ATTRv amyloidosis encompass a range of interventions, including transthyretin tetramer stabilizers such as Tafamidis, pharmacotherapies targeting transthyretin reduction like Patisiran, and surgical interventions such as liver transplantation (\u003Ca href=\"#ref7\">7\u003C/a>, \u003Ca href=\"#ref8\">8\u003C/a>). Patisiran and Vutrisiran represent two newly approved pharmaceutical agents designed to mitigate abnormal protein levels through mechanisms involving either stabilization of protein structure or inhibition of protein production. These medications are classified as RNA interference (RNAi) therapies, explicitly targeting the TTR gene and effectively diminishing its expression within the liver (\u003Ca href=\"#ref9\">9\u003C/a>&#x2013;\u003Ca href=\"#ref12\">12\u003C/a>). Both pharmaceutical compounds have demonstrated effectiveness and safety through clinical trials involving individuals afflicted with ATTRv accompanied by polyneuropathy. These medications have obtained regulatory approval from both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) (\u003Ca href=\"#ref13\">13\u003C/a>&#x2013;\u003Ca href=\"#ref15\">15\u003C/a>). However, these drugs have differences and discrepancies regarding their mode of action, pharmacokinetics, and clinical outcomes.\u003C/p>\n\u003Cp class=\"mb15\">Medications like Inotersen and Eplontersen are anti-sense oligonucleotides and mediate RNA cleavage (\u003Ca href=\"#ref16\">16\u003C/a>, \u003Ca href=\"#ref17\">17\u003C/a>). They target the mRNA of the transthyretin gene and reduce the production of abnormal proteins that are responsible for ATTRv amyloidosis (\u003Ca href=\"#ref17\">17\u003C/a>, \u003Ca href=\"#ref18\">18\u003C/a>). Activation of RNase H by Inotersen causes cleavage of the mRNA that is responsible for transthyretin coding (\u003Ca href=\"#ref18\">18\u003C/a>). Eplontersen attaches to both normal and mutant TTR mRNA and causes their degradation. This process inhibits TTR protein production, preventing amyloid deposits (\u003Ca href=\"#ref17\">17\u003C/a>). Both Inotersen and Eplontersen have been recently approved for the treatment of polyneuropathy in patients with hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis) (\u003Ca href=\"#ref17\">17\u003C/a>, \u003Ca href=\"#ref18\">18\u003C/a>).\u003C/p>\n\u003Cp class=\"mb0\">This systematic review aims to critically examine and compare the cardiologic, neurologic, and adverse events of Patisiran and Vutrisiran on ATTRv with polyneuropathy.\u003C/p> \u003Ca id=\"h3\" name=\"h3\">\u003C/a>\n\u003Ch2>Methods\u003C/h2>\n\u003Ch3>Study protocol\u003C/h3>\n\u003Cp class=\"mb0\">Our systematic review assessed the efficacy of novel drugs for polyneuropathy in ATTRv amyloidosis (Patisiran and Vutrisiran). The current investigation followed the guidelines specified within the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) framework to conduct a thorough systematic review and meta-analysis in accordance with established protocols (\u003Ca href=\"#ref19\">19\u003C/a>). The design protocol for our study was appropriately registered in the Open Science Framework (OSF). The hyperlink supplied leads to the OSF database, which houses a unique identification number record.\u003Csup id=\"footnotesuper1\">\u003Ca id=\"xfn0001\">\u003C/a>\u003Ca class=\"footnoteanchor\" href=\"#fn0001\">1\u003C/a>\u003C/sup>\u003C/p>\n\u003Ch3>Literature search\u003C/h3>\n\u003Cp class=\"mb0\">In the initial stage, relevant keywords were determined using Medical Subject Headings (MeSH) terminology. Subsequently, a thorough inquiry was conducted till September 16, 2023. The investigation utilized the following databases: PubMed, Google Scholar, Scopus, Web of Science, and Cochrane Central. The search strategy was executed by considering the title, abstract, and pertinent keywords and tags, utilizing sophisticated search functionalities for each search engine. To enhance the accuracy of the search, the search strategy involved three primary subgroups of keywords and MeSH. One subgroup encompassed terms associated with the generic, brand, and premarketing titles of Patisiran and Vutrisiran. The second subgroup included keywords and terminology of Amyloid Neuropathies. Finally, the subgroups were merged using the &#x2018;AND&#x2019; operator. No specific limitations or restrictions were placed on the date, type of publishing, or language. The search methodology utilized in this investigation is illustrated in \u003Ca href=\"#SM1\">Supplementary Table 1\u003C/a>.\u003C/p>\n\u003Ch3>Study selection\u003C/h3>\n\u003Cp class=\"mb0\">This research is dedicated to examining the criteria for inclusion and exclusion within the research framework. The investigators utilized specific parameters to identify suitable publications. The eligibility requirements for this study were delineated as follows:\u003C/p>\n\u003Cp style=\"margin-left:1em;text-indent:-1em;margin-top:1em;margin-bottom:0em;text-align:left;\">&#x02022; 1. The study design needed to encompass observational cohort studies (both retrospective and prospective), randomized controlled trials, or early-phase clinical trials. These studies must be published in peer-reviewed journals and comprehensively analyzed.\u003C/p>\n\u003Cp style=\"margin-left:1em;text-indent:-1em;margin-top: 0em;margin-bottom:0em;text-align:left;\">&#x02022; 2. The trials under investigation must have evaluated Patisiran and Vutrisiran as interventions for Amyloidosis.\u003C/p>\n\u003Cp style=\"margin-left:1em;text-indent:-1em;margin-top: 0em;margin-bottom:0em;text-align:left;\">&#x02022; 3. The current study incorporated research inquiries that delved into the comparative efficacy of Patisiran or Vutrisiran compared to placebo, active therapies, or no intervention among adults aged 18&#x2009;years or older.\u003C/p>\n\u003Cp style=\"margin-left:1em;text-indent:-1em;margin-top:0em;margin-bottom:1em;text-align:left;\">&#x02022; 4. Our study comprised investigations documenting at least one occurrence of neurological or cardiologic outcomes or adverse events.\u003C/p>\n\u003Cp class=\"mb0\">Conversely, the exclusion criteria were defined as follows:\u003C/p>\n\u003Cp style=\"margin-left:1em;text-indent:-1em;margin-top:1em;margin-bottom:0em;text-align:left;\">&#x02022; 1. The surveyed population was confined to patients with ATTRv, excluding those with other types of Amyloidosis.\u003C/p>\n\u003Cp style=\"margin-left:1em;text-indent:-1em;margin-top: 0em;margin-bottom:0em;text-align:left;\">&#x02022; 2. Studies evaluating outcomes deemed irrelevant were excluded from the analysis.\u003C/p>\n\u003Cp style=\"margin-left:1em;text-indent:-1em;margin-top:0em;margin-bottom:1em;text-align:left;\">&#x02022; 3. Only well-designed observational cohort studies (including retrospective and prospective), randomized controlled trials, or early-phase clinical trials were considered for inclusion. Studies employing alternative methods, conducted on animal models, displaying biases, or utilizing different study designs were excluded from this analysis.\u003C/p>\n\u003Ch3>Data extraction\u003C/h3>\n\u003Cp class=\"mb0\">The present analysis focused exclusively on observational cohort studies, including retrospective and prospective designs and randomized controlled trials. Early-phase clinical trials published in peer-reviewed journals were also considered, and comprehensive evaluations were conducted. Our main aim was to thoroughly examine scholarly literature that explores the effects of Patisiran and Vutrisiran on the polyneuropathy associated with ATTRv. After an exhaustive search, eliminating duplicate entries, and retrieving relevant articles, two researchers meticulously reviewed the titles and abstracts of selected studies. In instances of inconsistencies, a third author was consulted to facilitate resolution through deliberation. Subsequently, the next phase involved thoroughly analyzing the full text of identified articles to ascertain their precise alignment with the established inclusion criteria. All studies meeting the predetermined inclusion criteria were incorporated into the analysis, and a third reviewer resolved any discrepancies. The two reviewers systematically gathered pertinent study data using a pre-established data collection table. This encompassed details such as the author&#x2019;s identification, study methodology, year of publication, sample size, duration, and characteristics of the patient groups. Additionally, the researchers collected various patient characteristics, including gender, age, dosage, follow-up duration, ethnicity, and outcomes. The screening procedure is illustrated in the 2020 PRISMA checklist, as shown in \u003Ca href=\"#SM1\">Supplementary Figure 1\u003C/a>.\u003C/p>\n\u003Ch3>Quality assessment\u003C/h3>\n\u003Cp class=\"mb0\">Three reviewers individually evaluated the full texts of the articles for suitability, employing critical appraisal instruments sourced from the website specified.\u003Csup id=\"footnotesuper2\">\u003Ca id=\"xfn0002\">\u003C/a>\u003Ca class=\"footnoteanchor\" href=\"#fn0002\">2\u003C/a>\u003C/sup> They resolved any disagreements by discussion and consultation with the corresponding author. Three reviewers independently collected the data using a predetermined template. This template encompassed the subsequent information: study title, publication year, publication journal, study characteristics (study design, participants, mean age, administered dose, follow-up duration), and primary outcomes (neurologic and cardiologic parameters and adverse events).\u003C/p> \u003Ca id=\"h4\" name=\"h4\">\u003C/a>\n\u003Ch2>Results\u003C/h2>\n\u003Ch3>Study selection and characteristics\u003C/h3>\n\u003Cp class=\"mb15\">A comprehensive search of primary literature databases encompassing Embase, PubMed, Web of Science, Cochrane Central, and Google Scholar identified 858 studies relevant to the present analysis. After removing duplicate items, the dataset was narrowed down to 676 distinct research studies. Subsequently, a meticulous review of titles and abstracts excluded 577 articles considered irrelevant to the research. Consequent analysis was applied to 99 remaining records, involving a comprehensive examination of their complete texts. Out of this group, 89 papers were excluded because they contained irrelevant or unnecessary information, resulting in a final collection of relevant studies for thorough examination. Finally, 10 articles with a total population of 756 were reviewed.\u003C/p>\n\u003Cp class=\"mb15\">Coelho et al. (\u003Ca href=\"#ref20\">20\u003C/a>) employed Phase 1 randomized, single-blind, placebo-controlled, dose-ranging trials to assess the safety and dosage response of two RNAi therapies, ALN-TTR01 and ALN-TTR02 (Patisiran). Several research centers across Portugal, Sweden, France, and the United Kingdom actively participated in this study. The recruitment process entailed including 32 patients for ALN-TTR01 and 17 patients for ALN-TTR02, with 56% being male in the former group and all participants being male in the latter group. The mean age recorded for participants in the ALN-TTR01 trial was 32&#x2009;years, whereas for those in the ALN-TTR02 trial, it was 27&#x2009;years. The dosage range for ALN-TTR01 was 0.01 to 1.0&#x2009;mg/kg, and for ALN-TTR02, it was 0.01 to 0.5&#x2009;mg/kg (\u003Ca href=\"#ref20\">20\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">The Phase 2 study by Coelho et al. (\u003Ca href=\"#ref21\">21\u003C/a>) was conducted internationally across seven countries, including the United States, Brazil, France, Germany, Portugal, Spain, and Sweden. The research comprised a cohort of 27 individuals diagnosed with ATTRv, manifesting mild-to-moderate neuropathic symptoms. The median age of the participants was 64, with 18 being male. The participants received intravenous administration of Patisiran at a dosage of 0.3&#x2009;mg/kg every 3&#x2009;weeks (Q3W) for a duration of approximately 2&#x2009;years (\u003Ca href=\"#ref21\">21\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">The study conducted by Suhr et al. (\u003Ca href=\"#ref22\">22\u003C/a>) was characterized by its multicenter and international nature, employing an open-label design focusing on multiple-dose escalation in a phase two clinical trial. A total of 29 individuals met the eligibility criteria for participation in the study. The cohort included patients from diverse nationalities, including Brazilian, French, German, Portuguese, Spanish, Swedish, and American. Notably, all enrolled patients identified as of Caucasian ethnicity, with 69% being male, and the average age of the participants was 55.6&#x2009;years. In the context of this phase 2 investigation, individuals diagnosed with familial amyloid polyneuropathy (FAP) were subjected to two intravenous infusions of Patisiran, each administered at varying doses: 0.01 (\u003Ci>n\u003C/i> =&#x2009;4), 0.05 (\u003Ci>n\u003C/i>&#x2009;=&#x2009;3), 0.15 (\u003Ci>n\u003C/i>&#x2009;=&#x2009;3), or 0.3 (\u003Ci>n\u003C/i>&#x2009;=&#x2009;7) mg/kg every 4&#x2009;weeks (Q4W). Additionally, a subset of patients received a dosage of 0.3&#x2009;mg/kg Q3W, amounting to a cohort of 12 participants (\u003Ca href=\"#ref22\">22\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">The HELIOS-A was a worldwide, open-label phase 3 clinical trial conducted by Adams et al. (\u003Ca href=\"#ref13\">13\u003C/a>). In this study cohort, 122 individuals were designated for the Vutrisiran cohort, 42 for the Patisiran reference cohort, and 77 subjects for the external placebo cohort. Notably, there was a significant male predominance observed within the HELIOS-A cohort, comprising 64.6% (\u003Ci>n\u003C/i>&#x2009;=&#x2009;106), and within the APPOLO cohort (placebo), constituting 75.3% (\u003Ci>n\u003C/i>&#x2009;=&#x2009;58). The study encompassed participants aged 18 to 85, recruited from 57 different sites across 22 countries. They were randomly assigned to receive either Vutrisiran at a dosage of 25&#x2009;mg subcutaneously every 3&#x2009;months (Q3M) or Partisan at a dosage of 0.3&#x2009;mg/kg intravenously Q3W over a period of 18&#x2009;months (\u003Ca href=\"#ref13\">13\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">Merkel et al. (\u003Ca href=\"#ref23\">23\u003C/a>) carried out a comparative study, utilizing data from phase three randomized controlled trials involving three distinct groups: the Fx-005, HELIOS-A trial, and APOLLO trial cohorts, comprising 125, 164, and 77 patients, respectively. The Fx-005 trial focused on transthyretin amyloidosis patients with polyneuropathy, and the Val30Met in the TTR variant was a multinational, multicenter, randomized, double-blinded, and placebo-controlled study. It enrolled 125 patients in an intention-to-treat (ITT) group, allocated in a 1:1 ratio to receive either 20&#x2009;mg of Tafamidis orally (\u003Ci>n\u003C/i>&#x2009;=&#x2009;64) or placebo (\u003Ci>n\u003C/i> =&#x2009;61) daily for 18&#x2009;months. The HELIOS-A trial, also a phase three study, was a randomized, worldwide, open-label investigation assessing the efficacy of Vutrisiran in patients with transthyretin amyloidosis and polyneuropathy. This trial involved 164 patients randomly assigned in a 3:1 ratio to receive either Vutrisiran (\u003Ci>n\u003C/i>&#x2009;=&#x2009;122; 25&#x2009;mg subcutaneously, Q3M) or Partisan (\u003Ci>n\u003C/i>&#x2009;=&#x2009;42; 0.3&#x2009;mg/kg intravenously, Q3W), which served as the reference comparator. The treatment duration was 18&#x2009;months, with data from the APOLLO trial, a phase 3 study of Patisiran, used as an external placebo in this investigation. The primary objectives of the study were to evaluate the improvement or stability of the Neuropathy Impairment Score in the Lower Limbs (NIS-LL) and changes in the Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN) total score following 18&#x2009;months of Fx-005 treatment. The HELIOS-A trial assessed changes in the modified Neuropathy Impairment Score&#x2009;+&#x2009;7 (mNIS +7) from the baseline measurement at either 9 or 18&#x2009;months, depending on jurisdictional requirements (\u003Ca href=\"#ref23\">23\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">The original study by Adams et al. (\u003Ca href=\"#ref24\">24\u003C/a>) was a phase 3 study conducted across multiple international centers, employing randomization, a placebo control, and a double-blind methodology. It enrolled 225 participants from 44 sites situated in 19 different countries. The study cohort comprised 167 male participants, representing 74% of the total sample, with a median age of 62. These individuals were subjected to random assignment, wherein they were allocated to receive either Patisiran or a placebo as part of a meticulously controlled clinical trial. In this study, 148 individuals were administered Patisiran intravenously at 0.3&#x2009;mg/kg, with each infusion lasting about 80&#x2009;min. This treatment regimen was administered Q3W for a total duration of 18&#x2009;months. In contrast, the remaining 77 participants were subjected to a placebo intervention (\u003Ca href=\"#ref24\">24\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">In a Phase 3b study conducted by Schmidt et al. (\u003Ca href=\"#ref25\">25\u003C/a>), 24 individuals with ATTRv amyloidosis and post-LT polyneuropathy were investigated. They were administered a 0.3&#x2009;mg/kg Patisiran intravenous infusion once every 3&#x2009;weeks for 12&#x2009;months. The multinational study encompassed participants from seven countries: France, Germany, Italy, Portugal, Spain, Sweden, and the United Kingdom. The participants had an average age of 58.1 and a mean BMI of 23.5. Males accounted for 56.5% (\u003Ci>n\u003C/i>&#x2009;=&#x2009;13) of the sample, with 95.7% identifying as white. Notably, the majority of participants identified as non-Hispanic or Latino (\u003Ca href=\"#ref25\">25\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">The original article by Bleecker et al. (\u003Ca href=\"#ref26\">26\u003C/a>) is a retrospective study conducted across six Belgian neuromuscular reference centers. The study encompassed a cohort of nine patients, with a median age of 63, who underwent treatment with Patisiran. The Partisan administration was conducted via an 80-min intravenous infusion at 300&#x2009;&#x03BC;g/kg dosage, administered in Q3W intervals as part of an Expanded Access Program (EAP) (\u003Ca href=\"#ref26\">26\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">The original study by Fontana et al. (\u003Ca href=\"#ref27\">27\u003C/a>) encompassed 32 participants diagnosed with transthyretin cardiomyopathy (ATTR-CM). The cohort was divided into two distinct groups: one designated as the treatment group consisting of 16 patients, and another identified as the control group with equal participants. The median age of subjects in the treatment group was 62&#x2009;years, with 13 male participants, while the control group exhibited a median age of 69&#x2009;years, encompassing 14 male participants. All patients were administered 0.3&#x2009;mg/kg Patisiran via infusion Q3W. Of the 16 patients, 12 were given Diflunisal, a TTR-stabilizing drug, orally at 250&#x2009;mg twice daily. The study participants underwent serial monitoring at 12&#x2009;months through cardiac magnetic resonance, cardiac biomarkers, bone scintigraphy, 6-min walk tests (6MWTs), and echocardiography (\u003Ca href=\"#ref27\">27\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">Adams et al. (\u003Ca href=\"#ref28\">28\u003C/a>) conducted an international, open-label extension (OLE) study across 43 medical facilities spanning 19 countries. This investigation enrolled individuals who had successfully concluded either the phase 3 APOLLO trial or the phase 2 OLE parent trials and could tolerate the experimental medication. The eligible participants from both the APOLLO trial (including both the patisiran and placebo cohorts) and the phase 2 OLE trial (Patisiran cohort) were included in this global extension study, receiving intravenous Patisiran at a dosage of 0.3&#x2009;mg/kg Q3W, with a planned study period of up to 5&#x2009;years. Recruitment took place between July 13, 2015, and August 21, 2017, with 211 out of 212 eligible patients enrolled, comprising 137 from the APOLLO-Partisan group, 49 from the APOLLO-placebo group, and 25 from the phase 2 OLE partisan group. As of the data cutoff on September 24, 2018, completion rates for the 12-month assessments were 92% (126 out of 137) for the APOLLO-Partisan group, 78% (38 out of 49) for the APOLLO-placebo group, and 100% (25 out of 25) for the phase 2 OLE Patisiran group (\u003Ca href=\"#ref28\">28\u003C/a>).\u003C/p>\n\u003Cp class=\"mb0\">The summary of the study&#x2019;s characteristics is presented in \u003Ca href=\"#tab1\">Table 1\u003C/a>.\u003C/p>\n\u003Cdiv class=\"DottedLine\">\u003C/div> \u003Cdiv class=\"Imageheaders\">Table 1\u003C/div> \u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t001.jpg\" name=\"table1\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t001.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t001.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t001.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t001.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t001.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t001.jpg\" alt=\"www.frontiersin.org\" id=\"tab1\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cb>Table 1\u003C/b>. Characteristics of studies.\n\u003C/p>\u003C/div> \u003Cdiv class=\"clear\">\u003C/div> \u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Ch3>Main results\u003C/h3>\n\u003Cp class=\"mb15\">Coelho et al. (\u003Ca href=\"#ref20\">20\u003C/a>) investigation focused on assessing the safety and efficacy of two RNAi therapies, ALN-TTR01 and ALN-TTR02 (Patisiran), focusing on TTR levels within individuals diagnosed with ATTRv and a control group of unaffected individuals. In the ALN-TTR01 trial involving 32 ATTRv patients, single doses of ALN-TTR01 (ranging from 0.01 to 1.0&#x2009;mg/kg) or placebo were administered. Notably, the 1.0&#x2009;mg/kg dose demonstrated a significant 38% mean TTR knockdown at day seven compared to the placebo, affecting both mutant and nonmutant TTR similarly. Infusion reactions of mild to moderate severity occurred in 20.8% of the ALN-TTR01 group. In the ALN-TTR02 Phase 1 trial with 17 healthy volunteers, single doses of ALN-TTR02 (ranging from 0.01 to 0.5&#x2009;mg/kg) or placebo were given. The study revealed potent, dose-dependent TTR lowering, with a mean 82&#x2013;87% TTR knockdown at nadir for 0.15 and 0.3&#x2009;mg/kg doses. Remarkably, a durable knockdown of 56&#x2013;67% persisted on day 28, with only one mild infusion reaction reported in the 0.5&#x2009;mg/kg group (\u003Ca href=\"#ref20\">20\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">In summary, ALN-TTR01 and ALN-TTR02 demonstrated a significant capacity to suppress TTR production via an RNAi mechanism, thereby establishing proof of concept. ALN-TTR02 exhibited notably enhanced potency compared to ALN-TTR01, and both RNAi therapies were generally well-tolerated. Additional research is crucial to assess these interventions&#x2019; clinical effectiveness and long-term safety thoroughly (\u003Ca href=\"#ref20\">20\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">Coelho et al. (\u003Ca href=\"#ref21\">21\u003C/a>) conducted research that revealed that prolonged Patisiran administration was both safe and efficacious in arresting or facilitating the advancement of polyneuropathy in individuals with ATTRv. Patisiran reduced TTR levels by approximately 82% over 24&#x2009;months, resulting in an average improvement of 6.95 points in mNIS+7 compared to baseline among 19 out of 27 patients at the end of the 24&#x2009;months. Throughout the duration of the study, assessments of motor function, autonomic symptoms, disease progression, and quality of life showed no notable changes. Likewise, no significant variations were observed in echocardiographic evaluations or cardiac biomarkers among the subgroup of patients with cardiac involvement. Reported adverse events were mainly mild to moderate severity, and none necessitated treatment discontinuation. Flushes and infusion reactions were the most common drug-related incidents, each accounting for 22% of the reported adverse events (\u003Ca href=\"#ref21\">21\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">Suhr et al. (\u003Ca href=\"#ref22\">22\u003C/a>) attempted to evaluate the tolerability, safety, pharmacokinetic (PK), and pharmacodynamic (PD) of Patisiran in patients with transthyretin-mediated FAP. The inclusion criteria for this study encompassed adult patients diagnosed with confirmed ATTRv. Baseline serum levels of TTR proteins exhibited uniformity across various dosage cohorts. TTR knockdown was identical between patients with the Val30Met and those with non-Val30Met genotypes. The reduction in TTR levels was strongly correlated with decreased circulating retinol-binding protein (RBP) and vitamin A. After the administration of Patisiran, the mean concentrations of the TTR small interfering RNAs (siRNAs) component decreased (\u003Ca href=\"#ref22\">22\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">Nevertheless, there was no buildup of siRNAs after administering the second dose. The C\u003Csub>max\u003C/sub> and AUC0-last increased proportionally with the dose for both the first and second doses. Mild-to-moderate reaction during the infusion was the main side effect associated with their study. It is worthy of note that a few cases also experienced various adverse events, including back pain, asthenia, leukocytosis, neutrophilia, cellulitis, lymphangitis, polyuria, nausea/vomiting, facial erythema, dry mouth, pyrexia, dysphagia (\u003Ca href=\"#ref22\">22\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">The study HELIOS-A was conducted by Adams et al. (\u003Ca href=\"#ref13\">13\u003C/a>), which lasted for 18&#x2009;months, and examined the safety and effectiveness of Vutrisiran for individuals with ATTRv and polyneuropathy. The investigation demonstrated that Vutrisiran exerted a favorable influence on the primary endpoint, specifically the alteration from baseline in the modified Neuropathy Impairment Score&#x2009;+&#x2009;7 (mNIS+7) at the nine-month mark (&#x02212;2.24 [Vutrisiran] and&#x2009;+&#x2009;14.76 [placebo] (\u003Ci>p\u003C/i>&#x2009;=&#x2009;3.54 &#x000D7; 10&#x2013;12)). Furthermore, the compound demonstrated favorable outcomes across various secondary efficacy measures. Vutrisiran exhibited notable advancements in Norfolk QOL-DN during the ninth month compared to the external placebo cohort. The Vutrisiran group demonstrated a 53.4% enhancement, surpassing the 23.4% improvement observed in the placebo group, as indicated by the Norfolk QOL-DN score. By the eighteenth month, these figures further accentuated the positive impact of Vutrisiran, with a 56.8% improvement observed in the Vutrisiran group, in contrast to a mere 10.4% improvement in the placebo group. The 10-meter walk test (10MWT) demonstrated significant improvements at both the nine and 18-month intervals (\u003Ca href=\"#ref13\">13\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">Additionally, the mNIS+7 results after 18&#x2009;months showed a notable difference, with a decrease of 0.46 for Vutrisiran and an increase of 28.1 for the placebo. Notably, 48.3% of Vutrisiran recipients exhibited improvement in mNIS+7, in contrast to only 3.9% in the external placebo cohort. Furthermore, favorable results were noted in the modified Body Mass Index (mBMI) and the Rasch-built Overall Disability Scale (R-ODS) after 18&#x2009;months. The majority of adverse occurrences documented exhibited mild to moderate severity and aligned with the expected course of ATTRv. Noteworthy is the absence of any occurrences necessitating cessation of drug treatment or resulting in fatalities. The research findings underscore that Vutrisiran demonstrated substantial improvements in various disease-related parameters for ATTRv compared to an external placebo while maintaining a commendable safety record (\u003Ca href=\"#ref13\">13\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">Merkel et al. (\u003Ca href=\"#ref23\">23\u003C/a>) conducted an investigation employing Indirect Treatment Comparison (ITC) methodology to evaluate the therapeutic effectiveness of Vutrisiran and Tafamidis across diverse parameters such as NIS-LL, Norfolk QOL-DN score, NIS-LL Response, and mBMI. This investigation seeks to establish the effectiveness of both Vutrisiran and Tafamidis in treating ATTRv with polyneuropathy. The empirical basis for this study is derived from the analysis of data obtained from phase three randomized controlled trials, namely HELIOS-A, APOLLO, and Fx-005 studies. These trials systematically evaluated and compared the outcomes associated with Vutrisiran and Tafamidis interventions in the context of ATTRv with polyneuropathy. The primary analysis demonstrated a statistically significant superiority of Vutrisiran compared to Tafamidis in terms of the average change from baseline at the 18-month evaluation point for two crucial outcome metrics: the NIS-LL (mean difference: &#x02212;5.3, 95% CI: &#x02212;9.4 to &#x02212;1.2, \u003Ci>p\u003C/i>&#x2009;=&#x2009;0.011) and the Norfolk QOL-DN (mean difference: &#x02212;18.3, CI 95%: &#x02212;28.6 to &#x02212;8.0, \u003Ci>p\u003C/i>&#x2009;&#x0003C;&#x2009;0.001). Additionally, Vutrisiran exhibited superior efficacy in the NIS-LL Responder outcome at the 18-month mark compared to Tafamidis NIS-LL response (odds ratio: 1.7). This ITC study concluded that Vutrisiran has higher efficacy in enhancing multiple measures of polyneuropathy impairment and health-related quality of life (HRQOL) compared to Tafamidis in patients with ATTRv amyloidosis with polyneuropathy (\u003Ca href=\"#ref23\">23\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">Adams et al. (\u003Ca href=\"#ref24\">24\u003C/a>) conducted a research study to examine the effectiveness of Patisiran in patients with ATTRv with polyneuropathy. All individuals involved in this research were of adult age and exhibited an NIS ranging from 5 to 130, along with a polyneuropathy disability score of 3b or below, and demonstrated sufficient liver and renal functionality. According to the research, Patisiran demonstrated significant enhancements in both the primary endpoint (mNIS+7) for 56% of the patients who received the treatment, as opposed to only 4% of those who received a placebo. Additionally, regarding the secondary endpoint, Norfolk QOL-DN score, 51% of the patients who received Patisiran displayed an improvement in their Norfolk QOL-DN score, compared to 10% of those who received a placebo. In the subset of individuals within the cardiac subpopulation, Patisiran demonstrated a superior impact on cardiac structural integrity and functionality compared to administering a placebo. It is noteworthy that both cohorts documented the occurrence of adverse events throughout the clinical trial (\u003Ca href=\"#ref24\">24\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">Schmidt et al. (\u003Ca href=\"#ref25\">25\u003C/a>) conducted a Phase 3b open-label trial to evaluate the efficacy and safety of Patisiran in patients with ATTRv amyloidosis who experienced polyneuropathy progression following liver transplantation. The study involved mature individuals who had received a liver transplant as a treatment for ATTRv amyloidosis at least a year before the study and had encountered the advancement of polyneuropathy after the transplant. The research findings revealed that Patisiran led to an average reduction of approximately 91% in TTR levels between Months 6 and 12. Additionally, at Month 12, improvements in neuropathy, quality of life, and autonomic symptoms were observed, with mean changes from baseline of &#x02212;3.7 (SEM 2.7) in the NIS, &#x02212;6.5 (SEM 4.9) in the Norfolk QOL-DN score, and&#x2009;&#x02212;&#x2009;5.0 (SEM 2.6) in the Composite Autonomic Symptom Score-31 (COMPASS-31). Measures of disability, assessed using the R-ODS, and nutritional status, monitored through the mBMI, remained relatively stable with mean changes from baseline of &#x02212;0.1 (SEM 1.1) and&#x2009;+&#x2009;4.4 (SEM 21.8), respectively, over the 12-month treatment period. Adverse events reported during the trial were consistent with the known safety profile of Patisiran, including diarrhea and infusion-related reactions (\u003Ca href=\"#ref25\">25\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">After an 18-month retrospective study, Bleecker et al. (\u003Ca href=\"#ref26\">26\u003C/a>) investigated 12 patients diagnosed with ATTRv who underwent Patisiran treatment. The comprehensive character of the disease is demonstrated through the manifestation of neurological and/or cardiological symptoms, as indicated by various metrics and assessments. The investigation revealed that 98.9% of the intended treatment regimens were successfully executed throughout the study (\u003Ca href=\"#ref26\">26\u003C/a>). The median durations of treatment were 551.1&#x2009;days and 700&#x2009;days, respectively, spanning from 35 to 815&#x2009;days. Among the patients, seven exhibited stage 1 polyneuropathy, while the remaining five presented stage 2. The polyneuropathy disability (PND) score varied from 1 to 3b, with a median NIS-LL score of 31. Eleven patients had abnormal Electromyography (EMG) results. The median Functional Independence Measurements (FIM) score was 115, and six patients had cardiac symptoms. Six patients had abnormal electrocardiogram (ECG) and left ventricular ejection fraction (LVEF) findings (\u003Ca href=\"#ref26\">26\u003C/a>).\u003C/p>\n\u003Cp class=\"mb0\">Fontana et al. (\u003Ca href=\"#ref27\">27\u003C/a>) investigated for 12&#x2009;months and found that Patisiran was well tolerated. The median reduction in serum TTR levels among the cohort of treated patients amounted to 86% (interquartile range [IQR]: 82 to 90%). Furthermore, it is noteworthy that 82% of the cases exhibited a TTR knockdown exceeding 80%. The administration of Patisiran therapy showed a remarkable decrease in extracellular volume (ECV), as evidenced by the adjusted mean difference between groups amounting to &#x02212;6.2% (\u003Ci>p\u003C/i>&#x2009;=&#x2009;0.001). Furthermore, there was an evident reduction in levels of N-terminal pro&#x2013;B-type natriuretic peptide (NT-proBNP) linked with Patisiran treatment, as demonstrated by the adjusted mean difference between cohorts, which amounted to &#x02212;1,342&#x2009;ng/L (\u003Ci>p\u003C/i>&#x2009;=&#x2009;0.012). Moreover, Patisiran therapy was significantly associated with better distances in the 6MWT, as indicated by adjusted mean differences between groups of 169 meters (\u003Ci>p\u003C/i>&#x2009;=&#x2009;0.004). Additionally, a median reduction of 19.6% in cardiac uptake was observed, as determined through bone scintigraphy, and expressed with an IQR of 9.8 to 27.1%. In conclusion, the investigation postulated that reductions in ECV, as discerned through cardiac magnetic resonance, offered compelling evidence of regression in ATTRv affecting the heart in select patients undergoing Patisiran treatment (\u003Ca href=\"#ref27\">27\u003C/a>). The cardiologic effects, neurologic consequences, and adverse events documented in the encompassed studies have been briefly presented in \u003Ca href=\"#tab2\">Tables 2\u003C/a>&#x2013;\u003Ca href=\"#tab4\">4\u003C/a>, respectively.\u003C/p>\n\u003Cdiv class=\"DottedLine\">\u003C/div> \u003Cdiv class=\"Imageheaders\">Table 2\u003C/div> \u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t002.jpg\" name=\"table2\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t002.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t002.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t002.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t002.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t002.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t002.jpg\" alt=\"www.frontiersin.org\" id=\"tab2\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cb>Table 2\u003C/b>. Cardiological effects.\n\u003C/p>\u003C/div> \u003Cdiv class=\"clear\">\u003C/div> \u003Cdiv class=\"DottedLine mb15\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">Table 3\u003C/div> \u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t003.jpg\" name=\"table3\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t003.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t003.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t003.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t003.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t003.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t003.jpg\" alt=\"www.frontiersin.org\" id=\"tab3\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cb>Table 3\u003C/b>. Neurological effects.\n\u003C/p>\u003C/div> \u003Cdiv class=\"clear\">\u003C/div> \u003Cdiv class=\"DottedLine mb15\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">Table 4\u003C/div> \u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t004.jpg\" name=\"table4\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t004.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t004.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t004.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t004.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t004.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t004.jpg\" alt=\"www.frontiersin.org\" id=\"tab4\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cb>Table 4\u003C/b>. Adverse events.\n\u003C/p>\u003C/div> \u003Cdiv class=\"clear\">\u003C/div> \u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cp class=\"mb0\">Adams et al. (\u003Ca href=\"#ref28\">28\u003C/a>) extended the phase 3 open-label clinical trial over 12&#x2009;months. Data were collected systematically at regular intervals, revealing persistent enhancements in polyneuropathy measures following treatment with Patisiran. The analysis also revealed improved QOL, autonomic function, disability, and nutritional condition. Nevertheless, despite a consistent enhancement in polyneuropathy, it did not revert to the baseline levels observed in prior studies. The average alteration in autonomic function demonstrated a decrease of &#x02212;3.7 following 12&#x2009;months of treatment. Furthermore, the levels of TTR exhibited a significant reduction of 78% after 6&#x2009;months of treatment. The study&#x2019;s primary objective was to evaluate the safety and tolerability of prolonged Patisiran administration. Secondary objectives included investigating disease progression, assessing quality of life, and evaluating nutritional well-being (\u003Ca href=\"#ref28\">28\u003C/a>).\u003C/p>\n\u003Ch3>Risk of bias\u003C/h3>\n\u003Cp class=\"mb15\">These investigations offer noteworthy discoveries; nonetheless, it is essential to recognize the conceivable hazards linked to conflicts of interest and biases that could have influenced the research outcomes. An identifiable source of bias in these inquiries is the sponsorship received from specific pharmaceutical companies, introducing the potential for partiality in study design, execution, and reporting. Furthermore, researchers may be inclined to disclose positive results to ensure continued financial support from these entities. To alleviate the risk of bias and conflicts of interest, researchers ought to openly divulge potential conflicts and institute measures to ensure the objectivity and impartiality of the research. The sponsor of the trials is indeed a pharmaceutical company, but this is inevitable since a pharmaceutical company initiates most phase I-III trials.\u003C/p>\n\u003Cp class=\"mb15\">In the study by Schmidt et al. (\u003Ca href=\"#ref25\">25\u003C/a>), the authors disclosed conflicts of interest, including employment and stock ownership with Alnylam Pharmaceuticals, as well as consulting fees, honoraria, and research funding from Alnylam Pharmaceuticals, Pfizer Inc., Akcea Therapeutics, Ionis Pharmaceuticals, and Eidos. Additionally, Alnylam Pharmaceuticals supported related research by Adams et al. (\u003Ca href=\"#ref13\">13\u003C/a>, \u003Ca href=\"#ref24\">24\u003C/a>, \u003Ca href=\"#ref28\">28\u003C/a>), Merckle et al. (\u003Ca href=\"#ref23\">23\u003C/a>), and Coelho et al. (\u003Ca href=\"#ref20\">20\u003C/a>, \u003Ca href=\"#ref21\">21\u003C/a>). Furthermore, Adams et al. (\u003Ca href=\"#ref28\">28\u003C/a>) also reported financial support from Pfizer, while Coelho et al. (\u003Ca href=\"#ref20\">20\u003C/a>) disclosed funding from the National Institute for Health Research (NIHR) Biomedical Research Center at Guy&#x2019;s and St. Thomas&#x2019; NHS Foundation Trust and King&#x2019;s College London, specifically allocated to Dr. Mant (\u003Ca href=\"#ref20\">20\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">The authors of the investigation by Suhr et al. (\u003Ca href=\"#ref22\">22\u003C/a>) revealed financial affiliations with pharmaceutical enterprises among the involved parties. O Suhr is actively engaged in clinical investigations in collaboration with Pfizer and Alnylam Pharmaceuticals. T Coelho&#x2019;s medical institution has received remunerations from multiple corporate entities, and Coelho personally has received financial backing from Alnylam Pharmaceuticals and Pfizer. J Buades, J Pouget, and I Conceicao are affiliated with Alnylam Pharmaceuticals, whereas J Berk and M Waddington-Cruz have received financial support from pharmaceutical corporations.\u003C/p>\n\u003Cp class=\"mb0\">In a study by Bleeker et al. (\u003Ca href=\"#ref26\">26\u003C/a>), various institutions such as Sanofi-Genzyme, CSL Behring, Pfizer, Alnylam, Biogen, Roche, and Alexion provided compensation between 2008 and 2021. On the other hand, the study by Fontana et al. (\u003Ca href=\"#ref27\">27\u003C/a>) was financially supported by the British Heart Foundation, with reference number FS/18/21/33447. Furthermore, the authors reported consulting affiliations with Alnylam, Akcea, Eidos, Intellia, Pfizer, and Alexion.\u003C/p> \u003Ca id=\"h5\" name=\"h5\">\u003C/a>\n\u003Ch2>Discussion\u003C/h2>\n\u003Cp class=\"mb15\">ATTRv causes multisystem dysfunction due to peripheral and autonomic neuropathy and/or cardiomyopathy. This significantly and progressively impacts physical functioning and QOL (\u003Ca href=\"#ref24\">24\u003C/a>, \u003Ca href=\"#ref29\">29\u003C/a>, \u003Ca href=\"#ref30\">30\u003C/a>). Vutrisiran and Patisiran represent RNAi treatments aimed at diminishing the levels of pathogenic TTR protein by suppressing the expression of the TTR gene in individuals afflicted with ATTRv (\u003Ca href=\"#ref13\">13\u003C/a>, \u003Ca href=\"#ref24\">24\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">This systematic review recommends using Vutrisiran and Patisiran in ATTRv. The recommendation is based on outcomes of the latest studies that showed notable enhancements across various disease-relevant parameters in individuals with ATTRv (\u003Ca href=\"#ref13\">13\u003C/a>, \u003Ca href=\"#ref20\">20\u003C/a>&#x2013;\u003Ca href=\"#ref24\">24\u003C/a>, \u003Ca href=\"#ref26\">26\u003C/a>&#x2013;\u003Ca href=\"#ref28\">28\u003C/a>). The results indicate that Patisiran (\u003Ca href=\"#ref20\">20\u003C/a>, \u003Ca href=\"#ref21\">21\u003C/a>, \u003Ca href=\"#ref24\">24\u003C/a>, \u003Ca href=\"#ref25\">25\u003C/a>, \u003Ca href=\"#ref28\">28\u003C/a>) and Vutrisiran (\u003Ca href=\"#ref13\">13\u003C/a>) considerably enhanced the mNIS+7 and Norfolk QOL-DN results. Vutrisiran (\u003Ca href=\"#ref13\">13\u003C/a>) also demonstrated significant enhancements in the 10MWT, mBMI, and R-ODS. At the same time, Patisiran showed substantial improvements in the NIS-LL Field (\u003Ca href=\"#ref25\">25\u003C/a>, \u003Ca href=\"#ref26\">26\u003C/a>), autonomic function, disability, and nutritional situation (\u003Ca href=\"#ref20\">20\u003C/a>, \u003Ca href=\"#ref21\">21\u003C/a>, \u003Ca href=\"#ref25\">25\u003C/a>, \u003Ca href=\"#ref28\">28\u003C/a>), as well as reduced neurofilament light (NfL) levels (\u003Ca href=\"#ref31\">31\u003C/a>). Both pharmaceutical interventions were well-tolerated among the study participants, and most adverse incidents exhibited mild to moderate severity (\u003Ca href=\"#ref13\">13\u003C/a>, \u003Ca href=\"#ref20\">20\u003C/a>&#x2013;\u003Ca href=\"#ref24\">24\u003C/a>, \u003Ca href=\"#ref28\">28\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">Merkel et al. (\u003Ca href=\"#ref23\">23\u003C/a>) conducted an analysis using phase three randomized controlled trials. They used a Bucher analysis to compare the effects of Vutrisiran and Tafamidis&#x2019; treatment. The results indicated that Vutrisiran is more effective than Tafamidis in treating symptoms associated with polyneuropathy manifestations, HRQOL, nutritional status, NIS-LL, Norfolk QOL-DN, and mBMI in patients with a diagnosis of ATTRv amyloidosis. They observed disparity in efficacy holds clinical significance, suggesting Vutrisiran&#x2019;s potential as a preferable option for maintaining physical function and enhancing the QOL in this patient population (\u003Ca href=\"#ref23\">23\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">Schmidt et al. (\u003Ca href=\"#ref25\">25\u003C/a>) demonstrated that 12&#x2009;months of Patisiran treatment led to a 91.0% median reduction in serum TTR levels. Significant improvements were observed in neuropathy (NIS), quality of life (Norfolk QOL-DN), and autonomic symptoms (COMPASS-31). Additionally, disability (R-ODS) and nutritional status (mBMI) remained stable throughout the study period. Patisiran demonstrated a favorable safety profile with no new safety concerns emerging. These findings underscore the efficacy of Patisiran in the management of polyneuropathy in patients with ATTRv following liver transplantation.\u003C/p>\n\u003Cp class=\"mb15\">Furthermore, the second interim analysis of the Global OLE study (\u003Ca href=\"#ref31\">31\u003C/a>) provides empirical evidence regarding the long-term administration of Patisiran treatment spanning 48&#x2009;months. The results demonstrate sustained enhancements in mNIS+7 and Norfolk QOL-DN scores over an additional 24&#x2009;months of Patisiran treatment, accompanied by a safety profile deemed acceptable and consistent with previous reports spanning up to 12&#x2009;months (\u003Ca href=\"#ref28\">28\u003C/a>). Additionally, analytical studies showed that, In the APOLLO and HELIOS-A trials, NfL levels significantly decreased at 4 and 18&#x2009;months in patients treated with Patisiran or Vutrisiran (\u003Ca href=\"#ref31\">31\u003C/a>, \u003Ca href=\"#ref32\">32\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">The APOLLO and phase 2 OLE investigations have demonstrated that Patisiran therapy significantly diminishes NfL concentrations and enhances neuropathy outcomes as evaluated by mNIS+7 and QOL measures in contrast to initial assessments (\u003Ca href=\"#ref21\">21\u003C/a>). The findings remained consistent throughout an additional 24-month treatment period in the Global OLE investigation, demonstrating a correlation between the impact of Patisiran on NfL levels and its clinical efficacy (\u003Ca href=\"#ref24\">24\u003C/a>). After a nine-month treatment regimen, Patisiran demonstrated notable superiority over a placebo in enhancing the QOL. By the 18-month, enhancements were evident across all QOL metrics, particularly within the predetermined cardiac subgroup, as delineated in the APOLLO study. These findings underscore the advantageous impact of Patisiran on QOL among individuals afflicted with both polyneuropathy and cardiomyopathy, conditions known to diminish overall well-being substantially (\u003Ca href=\"#ref33\">33\u003C/a>). Postural blood pressure (PBP) evaluations investigate the impact of RNAi medications such as Patisiran and Vutrisiran on autonomic functioning among individuals diagnosed with ATTRv accompanied by polyneuropathy. The observed elevation of PBP levels into symptomatic thresholds among untreated individuals underscores the importance of prompt intervention measures (\u003Ca href=\"#ref34\">34\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">Patisiran and Vutrisiran exert an influence on cardiac symptoms and findings as well. Notably, Vutrisiran therapy has demonstrated a beneficial effect on NT-ProBNP levels and echocardiographic parameters within the subset of patients with cardiac involvement. It also led to a reduction in cardiac uptake of 99mTc, suggesting a decrease in cardiac amyloid. Nevertheless, the clinical significance remains uncertain at present (\u003Ca href=\"#ref35\">35\u003C/a>). Patisiran treatment has reduced NT-proBNP (\u003Ca href=\"#ref24\">24\u003C/a>, \u003Ca href=\"#ref27\">27\u003C/a>, \u003Ca href=\"#ref28\">28\u003C/a>), TTR levels (\u003Ca href=\"#ref28\">28\u003C/a>), cardiac uptake (\u003Ca href=\"#ref27\">27\u003C/a>), and abnormal ECG (\u003Ca href=\"#ref26\">26\u003C/a>). Additionally, it demonstrated enhanced cardiac morphology and performance, evidenced by notable variances in the average thickness of the left ventricular wall and longitudinal strain (\u003Ca href=\"#ref26\">26\u003C/a>) and an increase in 6MWT distances (\u003Ca href=\"#ref27\">27\u003C/a>). Cardiac magnetic resonance (CMR) is a superior alternative for assessing myocardial tissue and estimating cardiac amyloid burden (\u003Ca href=\"#ref27\">27\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">Depending on the phenotype and country regulations, Tafamidis, Diflunisal, Patisiran, Inotersen, Vutrisiran, and Eplontersen can be used for ATTRv amyloidosis. Patisiran is administered at 0.3&#x2009;mg/kg via intravenous infusion lasting 80&#x2009;min every 3&#x2009;weeks (\u003Ca href=\"#ref24\">24\u003C/a>). In contrast, Vutrisiran is a novel therapeutic agent that operates through a similar mechanism and is administered at a dosage of 25&#x2009;mg via subcutaneous injection every 3&#x2009;months (Q3M) (\u003Ca href=\"#ref13\">13\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">Regarding cost, Vutrisiran is estimated to be more cost-effective than Patisiran due to its less frequent dosing schedule and lower administration costs. The cost savings for Vutrisiran depend on factors such as how long it takes to administer Patisiran and which healthcare professional distributes it. Considering these factors, a cost comparison suggests that Vutrisiran is more cost-effective than Patisiran and is therefore recommended (\u003Ca href=\"#ref36\">36\u003C/a>).\u003C/p>\n\u003Cp class=\"mb0\">This systematic review article acknowledges several limitations that impede a comprehensive evaluation of Patisiran and Vutrisiran&#x2019;s effects on amyloidosis polyneuropathy and myocardiopathies. Firstly, the scarcity of studies available to the researchers limits the scope of the analysis. Secondly, heterogeneity in participant numbers across studies challenges comparing results. Thirdly, most studies were funded by Anylham, a drug manufacturer, which raises the possibility of publication bias. Finally, incomplete follow-up periods in a series of studies further complicate the interpretation of findings. Given these limitations, it is recommended that large-scale studies be conducted to provide a more robust understanding of the effects of Vutrisiran and Patrisiran on these conditions.\u003C/p> \u003Ca id=\"h6\" name=\"h6\">\u003C/a>\n\u003Ch2>Conclusion\u003C/h2>\n\u003Cp class=\"mb0\">This comprehensive analysis evaluated the effectiveness and safety of RNA interference treatments, Patisiran and Vutrisiran, in managing ATTRv amyloidosis. The study consistently demonstrated favorable results, revealing that Patisiran and Vutrisiran significantly reduce pathogenic TTR protein levels. This reduction significantly improved neuropathy parameters, quality of life, and cardiac symptoms among patients with ATTRv amyloidosis. The findings strongly support using these RNA interference therapies for controlling the multisystem dysfunction associated with the disease. However, it is imperative to approach the interpretation of the results with caution due to potential biases stemming from funding sources and variations in study designs. Extended investigations with prolonged observation periods and diverse cohorts are essential to enhance our comprehensive understanding of these interventions&#x2019; enduring effectiveness and safety.\u003C/p> \u003Ca id=\"h7\" name=\"h7\">\u003C/a>\n\u003Ch2>Data availability statement\u003C/h2>\n\u003Cp class=\"mb0\">The original contributions presented in the study are included in the article/\u003Ca href=\"#SM1\">Supplementary material\u003C/a>, further inquiries can be directed to the corresponding author.\u003C/p> \u003Ca id=\"h8\" name=\"h8\">\u003C/a>\n\u003Ch2>Author contributions\u003C/h2>\n\u003Cp class=\"mb0\">MK: Writing &#x2013; original draft, Writing &#x2013; review &#x00026; editing. FE: Writing &#x2013; original draft, Writing &#x2013; review &#x00026; editing. MG: Writing &#x2013; original draft, Writing &#x2013; review &#x00026; editing. EA: Writing &#x2013; original draft, Writing &#x2013; review &#x00026; editing. ME: Writing &#x2013; original draft, Writing &#x2013; review &#x00026; editing. PD: Writing &#x2013; original draft, Writing &#x2013; review &#x00026; editing.\u003C/p> \u003Ca id=\"h9\" name=\"h9\">\u003C/a>\n\u003Ch2>Funding\u003C/h2>\n\u003Cp class=\"mb0\">The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.\u003C/p> \u003Ca id=\"h10\" name=\"h10\">\u003C/a>\n\u003Ch2>Acknowledgments\u003C/h2>\n\u003Cp class=\"mb0\">The authors would like to appreciate all the researchers whose published articles were used in this study. No organizations or associations supported this work.\u003C/p> \u003Ca id=\"h11\" name=\"h11\">\u003C/a>\n\u003Ch2>Conflict of interest\u003C/h2>\n\u003Cp class=\"mb0\">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\u003C/p> \u003Ca id=\"h12\" name=\"h12\">\u003C/a>\n\u003Ch2>Publisher&#x2019;s note\u003C/h2>\n\u003Cp class=\"mb0\">All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.\u003C/p> \u003Ca id=\"h13\" name=\"h13\">\u003C/a>\n\u003Ch2>Supplementary material\u003C/h2>\n\u003Cp class=\"mb0\" id=\"SM1\">The Supplementary material for this article can be found online at: \u003Ca href=\"https://www.frontiersin.org/articles/10.3389/fneur.2024.1465747/full#supplementary-material\">https://www.frontiersin.org/articles/10.3389/fneur.2024.1465747/full#supplementary-material\u003C/a>\u003C/p> \u003Ca id=\"h14\" name=\"h14\">\u003C/a>\n\u003Ch2>Footnotes\u003C/h2> \u003Cdiv id=\"footnotetext\" class=\"fulltextdescription\">\n\u003Cp style=\"margin-top:0em;margin-bottom:0em;margin-left:1em;text-indent:-1em;\" id=\"fn0001\">1. \u003Ca class=\"footnotetextanchor\" href=\"#xfn0001\" title=\"\">^\u003C/a>\n\u003Ca href=\"https://osf.io/evwtd\">https://osf.io/evwtd\u003C/a>\n\u003C/p>\n\u003Cp style=\"margin-top:0em;margin-bottom:0em;margin-left:1em;text-indent:-1em;\" id=\"fn0002\">2. \u003Ca class=\"footnotetextanchor\" href=\"#xfn0002\" title=\"\">^\u003C/a>\n\u003Ca href=\"https://jbi.global/critical-appraisal-tools\">https://jbi.global/critical-appraisal-tools\u003C/a>\n\u003C/p>\n\u003C/div> \u003Ca id=\"h15\" name=\"h15\">\u003C/a>\n\u003Ch2>References\u003C/h2>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref1\" id=\"ref1\">\u003C/a>1. Adams, D, Koike, H, Slama, M, and Coelho, T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. \u003Ci>Nat Rev Neurol\u003C/i>. (2019) 15:387&#x2013;404. doi: 10.1038/s41582-019-0210-4 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31209302\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/s41582-019-0210-4\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=D+Adams&#x00026;author=H+Koike&#x00026;author=M+Slama&#x00026;author=T+Coelho&#x00026;publication_year=2019&#x00026;title=Hereditary+transthyretin+amyloidosis:+a+model+of+medical+progress+for+a+fatal+disease&#x00026;journal=Nat+Rev+Neurol&#x00026;volume=15&#x00026;pages=387-404\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref2\" id=\"ref2\">\u003C/a>2. Manganelli, F, Fabrizi, GM, Luigetti, M, Mandich, P, Mazzeo, A, and Pareyson, D. Hereditary transthyretin amyloidosis overview. \u003Ci>Neurol Sci\u003C/i>. (2022) 43:595&#x2013;604. doi: 10.1007/s10072-020-04889-2\n\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1007/s10072-020-04889-2\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=F+Manganelli&#x00026;author=GM+Fabrizi&#x00026;author=M+Luigetti&#x00026;author=P+Mandich&#x00026;author=A+Mazzeo&#x00026;author=D+Pareyson&#x00026;publication_year=2022&#x00026;title=Hereditary+transthyretin+amyloidosis+overview&#x00026;journal=Neurol+Sci&#x00026;volume=43&#x00026;pages=595-604\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref3\" id=\"ref3\">\u003C/a>3. Koike, H, Misu, K-i, Ikeda, S-i, Ando, Y, Nakazato, M, Ando, E, et al. Type I (transthyretin met 30) familial amyloid polyneuropathy in Japan: early-vs late-onset form. \u003Ci>Arch Neurol\u003C/i>. (2002) 59:1771&#x2013;6. doi: 10.1001/archneur.59.11.1771\n\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1001/archneur.59.11.1771\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=H+Koike&#x00026;author=K-i+Misu&#x00026;author=S-i+Ikeda&#x00026;author=Y+Ando&#x00026;author=M+Nakazato&#x00026;author=E+Ando&#x00026;publication_year=2002&#x00026;title=Type+I+(transthyretin+met+30)+familial+amyloid+polyneuropathy+in+Japan:+early-vs+late-onset+form&#x00026;journal=Arch+Neurol&#x00026;volume=59&#x00026;pages=1771-6\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref4\" id=\"ref4\">\u003C/a>4. Carroll, A, Dyck, PJ, de Carvalho, M, Kennerson, M, Reilly, MM, Kiernan, MC, et al. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. \u003Ci>J Neurol Neurosurg Psychiatry\u003C/i>. (2022) 93:668&#x2013;78. doi: 10.1136/jnnp-2021-327909 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/35256455\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1136/jnnp-2021-327909\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A+Carroll&#x00026;author=PJ+Dyck&#x00026;author=M+de+Carvalho&#x00026;author=M+Kennerson&#x00026;author=MM+Reilly&#x00026;author=MC+Kiernan&#x00026;publication_year=2022&#x00026;title=Novel+approaches+to+diagnosis+and+management+of+hereditary+transthyretin+amyloidosis&#x00026;journal=J+Neurol+Neurosurg+Psychiatry&#x00026;volume=93&#x00026;pages=668-78\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref5\" id=\"ref5\">\u003C/a>5. Tozza, S, Severi, D, Spina, E, Iovino, A, Aruta, F, Ruggiero, L, et al. The neuropathy in hereditary transthyretin amyloidosis: a narrative review. \u003Ci>J Peripher Nerv Syst\u003C/i>. (2021) 26:155&#x2013;9. doi: 10.1111/jns.12451 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/33960565\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1111/jns.12451\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S+Tozza&#x00026;author=D+Severi&#x00026;author=E+Spina&#x00026;author=A+Iovino&#x00026;author=F+Aruta&#x00026;author=L+Ruggiero&#x00026;publication_year=2021&#x00026;title=The+neuropathy+in+hereditary+transthyretin+amyloidosis:+a+narrative+review&#x00026;journal=J+Peripher+Nerv+Syst&#x00026;volume=26&#x00026;pages=155-9\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref6\" id=\"ref6\">\u003C/a>6. Plant&#x000E9;-Bordeneuve, V, Gorram, F, Salhi, H, Nordine, T, Ayache, SS, Le Corvoisier, P, et al. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study. \u003Ci>J Neurol\u003C/i>. (2017) 264:268&#x2013;76. doi: 10.1007/s00415-016-8337-3 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/27878441\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s00415-016-8337-3\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=V+Plant&#x000E9;-Bordeneuve&#x00026;author=F+Gorram&#x00026;author=H+Salhi&#x00026;author=T+Nordine&#x00026;author=SS+Ayache&#x00026;author=P+Le+Corvoisier&#x00026;publication_year=2017&#x00026;title=Long-term+treatment+of+transthyretin+familial+amyloid+polyneuropathy+with+tafamidis:+a+clinical+and+neurophysiological+study&#x00026;journal=J+Neurol&#x00026;volume=264&#x00026;pages=268-76\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref7\" id=\"ref7\">\u003C/a>7. Hawkins, PN, Ando, Y, Dispenzeri, A, Gonzalez-Duarte, A, Adams, D, and Suhr, OB. Evolving landscape in the management of transthyretin amyloidosis. \u003Ci>Ann Med\u003C/i>. (2015) 47:625&#x2013;38. doi: 10.3109/07853890.2015.1068949 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26611723\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3109/07853890.2015.1068949\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=PN+Hawkins&#x00026;author=Y+Ando&#x00026;author=A+Dispenzeri&#x00026;author=A+Gonzalez-Duarte&#x00026;author=D+Adams&#x00026;author=OB+Suhr&#x00026;publication_year=2015&#x00026;title=Evolving+landscape+in+the+management+of+transthyretin+amyloidosis&#x00026;journal=Ann+Med&#x00026;volume=47&#x00026;pages=625-38\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref8\" id=\"ref8\">\u003C/a>8. Aimo, A, Castiglione, V, Rapezzi, C, Franzini, M, Panichella, G, Vergaro, G, et al. RNA-targeting and gene editing therapies for transthyretin amyloidosis. \u003Ci>Nat Rev Cardiol\u003C/i>. (2022) 19:655&#x2013;67. doi: 10.1038/s41569-022-00683-z \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/35322226\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/s41569-022-00683-z\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A+Aimo&#x00026;author=V+Castiglione&#x00026;author=C+Rapezzi&#x00026;author=M+Franzini&#x00026;author=G+Panichella&#x00026;author=G+Vergaro&#x00026;publication_year=2022&#x00026;title=RNA-targeting+and+gene+editing+therapies+for+transthyretin+amyloidosis&#x00026;journal=Nat+Rev+Cardiol&#x00026;volume=19&#x00026;pages=655-67\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref9\" id=\"ref9\">\u003C/a>9. Soprano, DR, Herbert, J, Soprano, K, Schon, E, and Goodman, D. Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat. \u003Ci>J Biol Chem\u003C/i>. (1985) 260:11793&#x2013;8.\n\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/4044580\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=DR+Soprano&#x00026;author=J+Herbert&#x00026;author=K+Soprano&#x00026;author=E+Schon&#x00026;author=D+Goodman&#x00026;publication_year=1985&#x00026;title=Demonstration+of+transthyretin+mRNA+in+the+brain+and+other+extrahepatic+tissues+in+the+rat&#x00026;journal=J+Biol+Chem&#x00026;volume=260&#x00026;pages=11793-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref10\" id=\"ref10\">\u003C/a>10. Holmgren, G, Steen, L, Ekstedt, J, Groth, CG, Ericzon, BG, Eriksson, S, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met 30). \u003Ci>Clin Genet\u003C/i>. (1991) 40:242&#x2013;6.\n\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/1685359\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=G+Holmgren&#x00026;author=L+Steen&#x00026;author=J+Ekstedt&#x00026;author=CG+Groth&#x00026;author=BG+Ericzon&#x00026;author=S+Eriksson&#x00026;publication_year=1991&#x00026;title=Biochemical+effect+of+liver+transplantation+in+two+Swedish+patients+with+familial+amyloidotic+polyneuropathy+(FAP-met+30)&#x00026;journal=Clin+Genet&#x00026;volume=40&#x00026;pages=242-6\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref11\" id=\"ref11\">\u003C/a>11. Nair, JK, Willoughby, JL, Chan, A, Charisse, K, Alam, MR, Wang, Q, et al. Multivalent N-acetylgalactosamine-conjugated si RNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. \u003Ci>J Am Chem Soc\u003C/i>. (2014) 136:16958&#x2013;61. doi: 10.1021/ja505986a \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25434769\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1021/ja505986a\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=JK+Nair&#x00026;author=JL+Willoughby&#x00026;author=A+Chan&#x00026;author=K+Charisse&#x00026;author=MR+Alam&#x00026;author=Q+Wang&#x00026;publication_year=2014&#x00026;title=Multivalent+N-acetylgalactosamine-conjugated+si+RNA+localizes+in+hepatocytes+and+elicits+robust+RNAi-mediated+gene+silencing&#x00026;journal=J+Am+Chem+Soc&#x00026;volume=136&#x00026;pages=16958-61\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref12\" id=\"ref12\">\u003C/a>12. Habtemariam, BA, Karsten, V, Attarwala, H, Goel, V, Melch, M, Clausen, VA, et al. Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine&#x2013;small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects. \u003Ci>Clinical Pharmacol Therapeutics\u003C/i>. (2021) 109:372&#x2013;82. doi: 10.1002/cpt.1974 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32599652\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/cpt.1974\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=BA+Habtemariam&#x00026;author=V+Karsten&#x00026;author=H+Attarwala&#x00026;author=V+Goel&#x00026;author=M+Melch&#x00026;author=VA+Clausen&#x00026;publication_year=2021&#x00026;title=Single-dose+pharmacokinetics+and+pharmacodynamics+of+transthyretin+targeting+N-acetylgalactosamine&#x2013;small+interfering+ribonucleic+acid+conjugate+vutrisiran+in+healthy+subjects&#x00026;journal=Clinical+Pharmacol+Therapeutics&#x00026;volume=109&#x00026;pages=372-82\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref13\" id=\"ref13\">\u003C/a>13. Adams, D, Tournev, IL, Taylor, MS, Coelho, T, Plant&#x000E9;-Bordeneuve, V, Berk, JL, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. \u003Ci>Amyloid\u003C/i>. (2023) 30:18&#x2013;26. doi: 10.1080/13506129.2022.2091985\n\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1080/13506129.2022.2091985\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=D+Adams&#x00026;author=IL+Tournev&#x00026;author=MS+Taylor&#x00026;author=T+Coelho&#x00026;author=V+Plant&#x000E9;-Bordeneuve&#x00026;author=JL+Berk&#x00026;publication_year=2023&#x00026;title=Efficacy+and+safety+of+vutrisiran+for+patients+with+hereditary+transthyretin-mediated+amyloidosis+with+polyneuropathy:+a+randomized+clinical+trial&#x00026;journal=Amyloid&#x00026;volume=30&#x00026;pages=18-26\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref14\" id=\"ref14\">\u003C/a>14. Center for Drug Evaluation and Research. Onpattro 2 mg/mL injectionfor intravenous use. (2023). Available from: \u003Ca href=\"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210922Orig1s000Approv.pdf\">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210922Orig1s000Approv.pdf\u003C/a> (Accessed February 25, 2024).\n\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?publication_year=2023&#x00026;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref15\" id=\"ref15\">\u003C/a>15. European Medicines Agency. Onpattro (patisiran): an overview of Onpattro and why it is authorised in the EU. (2023). Available from: \u003Ca href=\"https://www.ema.europa.eu/en/documents/overview/onpattro-epar-medicine-overview_en.pdf\">https://www.ema.europa.eu/en/documents/overview/onpattro-epar-medicine-overview_en.pdf\u003C/a> (Accessed February 25, 2024).\n\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?publication_year=2023&#x00026;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref16\" id=\"ref16\">\u003C/a>16. Brannagan, TH 3rd, Berk, JL, Gillmore, JD, Maurer, MS, Waddington-Cruz, M, Fontana, M, et al. Liver-directed drugs for transthyretin-mediated amyloidosis. \u003Ci>J Peripher Nerv Syst: JPNS\u003C/i>. (2022) 27:228&#x2013;37. doi: 10.1111/jns.12519 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/36345805\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1111/jns.12519\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=TH+Brannagan&#x00026;author=JL+Berk&#x00026;author=JD+Gillmore&#x00026;author=MS+Maurer&#x00026;author=M+Waddington-Cruz&#x00026;author=M+Fontana&#x00026;publication_year=2022&#x00026;title=Liver-directed+drugs+for+transthyretin-mediated+amyloidosis&#x00026;journal=J+Peripher+Nerv+Syst:+JPNS&#x00026;volume=27&#x00026;pages=228-37\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref17\" id=\"ref17\">\u003C/a>17. Nie, T. Eplontersen: first approval. \u003Ci>Drugs\u003C/i>. (2024) 84:473&#x2013;8. doi: 10.1007/s40265-024-02008-5 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/38413492\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s40265-024-02008-5\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=T+Nie&#x00026;publication_year=2024&#x00026;title=Eplontersen:+first+approval&#x00026;journal=Drugs&#x00026;volume=84&#x00026;pages=473-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref18\" id=\"ref18\">\u003C/a>18. Collotta, D, Bertocchi, I, Chiapello, E, and Collino, M. Antisense oligonucleotides: a novel Frontier in pharmacological strategy. \u003Ci>Front. Pharmacol\u003C/i>. 14:1304342. (2023). doi: 10.3389/fphar.2023.1304342\n\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.3389/fphar.2023.1304342\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=D+Collotta&#x00026;author=I+Bertocchi&#x00026;author=E+Chiapello&#x00026;author=M+Collino&#x00026;publication_year=2023&#x00026;title=Antisense+oligonucleotides:+a+novel+Frontier+in+pharmacological+strategy&#x00026;journal=Front.+Pharmacol&#x00026;volume=14&#x00026;pages=1304342\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref19\" id=\"ref19\">\u003C/a>19. Page, MJ, McKenzie, JE, Bossuyt, PM, Boutron, I, Hoffmann, TC, Mulrow, CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. \u003Ci>BMJ\u003C/i>. (2021) 372:n71. doi: 10.1136/bmj.n71\n\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1136/bmj.n71\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=MJ+Page&#x00026;author=JE+McKenzie&#x00026;author=PM+Bossuyt&#x00026;author=I+Boutron&#x00026;author=TC+Hoffmann&#x00026;author=CD+Mulrow&#x00026;publication_year=2021&#x00026;title=The+PRISMA+2020+statement:+an+updated+guideline+for+reporting+systematic+reviews&#x00026;journal=BMJ&#x00026;volume=372&#x00026;pages=n71\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref20\" id=\"ref20\">\u003C/a>20. Coelho, T, Adams, D, Silva, A, Lozeron, P, Hawkins, PN, Mant, T, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. \u003Ci>N Engl J Med\u003C/i>. (2013) 369:819&#x2013;29. doi: 10.1056/NEJMoa1208760 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23984729\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1056/NEJMoa1208760\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=T+Coelho&#x00026;author=D+Adams&#x00026;author=A+Silva&#x00026;author=P+Lozeron&#x00026;author=PN+Hawkins&#x00026;author=T+Mant&#x00026;publication_year=2013&#x00026;title=Safety+and+efficacy+of+RNAi+therapy+for+transthyretin+amyloidosis&#x00026;journal=N+Engl+J+Med&#x00026;volume=369&#x00026;pages=819-29\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref21\" id=\"ref21\">\u003C/a>21. Coelho, T, Adams, D, Concei&#x000E7;&#x000E3;o, I, Waddington-Cruz, M, Schmidt, HH, Buades, J, et al. A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis. \u003Ci>Orphanet J Rare Dis\u003C/i>. (2020) 15:1&#x2013;10. doi: 10.1186/s13023-020-01399-4\n\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1186/s13023-020-01399-4\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=T+Coelho&#x00026;author=D+Adams&#x00026;author=I+Concei&#x000E7;&#x000E3;o&#x00026;author=M+Waddington-Cruz&#x00026;author=HH+Schmidt&#x00026;author=J+Buades&#x00026;publication_year=2020&#x00026;title=A+phase+II+open-label+extension+study+of+long-term+patisiran+treatment+in+patients+with+hereditary+transthyretin-mediated+(hATTR)+amyloidosis&#x00026;journal=Orphanet+J+Rare+Dis&#x00026;volume=15&#x00026;pages=1-10\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref22\" id=\"ref22\">\u003C/a>22. Suhr, O, Coelho, T, Buades Pouget, J, Conceicao, I, Berk, J, and Schmidt, H. Waddington-Cruz; Campistol JM; Bettencourt BR; Vaishnaw a; Gollob J; Adams D efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase ii multi-dose study. \u003Ci>Orphanet J Rare Dis\u003C/i>. (2015) 10:1&#x2013;9. doi: 10.1186/s13023-015-0326-6\n\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1186/s13023-015-0326-6\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=O+Suhr&#x00026;author=T+Coelho&#x00026;author=J+Buades+Pouget&#x00026;author=I+Conceicao&#x00026;author=J+Berk&#x00026;author=H+Schmidt&#x00026;publication_year=2015&#x00026;title=Waddington-Cruz;+Campistol+JM;+Bettencourt+BR;+Vaishnaw+a;+Gollob+J;+Adams+D+efficacy+and+safety+of+patisiran+for+familial+amyloidotic+polyneuropathy:+a+phase+ii+multi-dose+study&#x00026;journal=Orphanet+J+Rare+Dis&#x00026;volume=10&#x00026;pages=1-9\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref23\" id=\"ref23\">\u003C/a>23. Merkel, M, Danese, D, Chen, C, Wang, J, Wu, A, Yang, H, et al. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy. \u003Ci>Expert Opin Pharmacother\u003C/i>. (2023) 24:1205&#x2013;14. doi: 10.1080/14656566.2023.2215925\n\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1080/14656566.2023.2215925\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Merkel&#x00026;author=D+Danese&#x00026;author=C+Chen&#x00026;author=J+Wang&#x00026;author=A+Wu&#x00026;author=H+Yang&#x00026;publication_year=2023&#x00026;title=Indirect+treatment+comparison+(ITC)+of+the+efficacy+of+vutrisiran+and+tafamidis+for+hereditary+transthyretin-mediated+amyloidosis+with+polyneuropathy&#x00026;journal=Expert+Opin+Pharmacother&#x00026;volume=24&#x00026;pages=1205-14\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref24\" id=\"ref24\">\u003C/a>24. Adams, D, Gonzalez-Duarte, A, O&#x2019;Riordan, WD, Yang, C-C, Ueda, M, Kristen, AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. \u003Ci>N Engl J Med\u003C/i>. (2018) 379:11&#x2013;21. doi: 10.1056/NEJMoa1716153 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29972753\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1056/NEJMoa1716153\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=D+Adams&#x00026;author=A+Gonzalez-Duarte&#x00026;author=WD+O&#x2019;Riordan&#x00026;author=C-C+Yang&#x00026;author=M+Ueda&#x00026;author=AV+Kristen&#x00026;publication_year=2018&#x00026;title=Patisiran+an+RNAi+therapeutic+for+hereditary+transthyretin+amyloidosis&#x00026;journal=N+Engl+J+Med&#x00026;volume=379&#x00026;pages=11-21\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref25\" id=\"ref25\">\u003C/a>25. Schmidt, HH, Wixner, J, Plant&#x000E9;-Bordeneuve, V, Mu&#x000F1;oz-Beamud, F, Llad&#x000F3;, L, Gillmore, JD, et al. Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation. \u003Ci>Am J Transplant\u003C/i>. (2022) 22:1646&#x2013;57. doi: 10.1111/ajt.17009 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/35213769\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1111/ajt.17009\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=HH+Schmidt&#x00026;author=J+Wixner&#x00026;author=V+Plant&#x000E9;-Bordeneuve&#x00026;author=F+Mu&#x000F1;oz-Beamud&#x00026;author=L+Llad&#x000F3;&#x00026;author=JD+Gillmore&#x00026;publication_year=2022&#x00026;title=Patisiran+treatment+in+patients+with+hereditary+transthyretin-mediated+amyloidosis+with+polyneuropathy+after+liver+transplantation&#x00026;journal=Am+J+Transplant&#x00026;volume=22&#x00026;pages=1646-57\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref26\" id=\"ref26\">\u003C/a>26. De Bleecker, JL, Claeys, KG, Delstanche, S, Van Parys, V, Baets, J, Tilleux, S, et al. A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium. \u003Ci>Acta Neurol Belg\u003C/i>. (2023). 1029&#x2013;37. doi: 10.1007/s13760-023-02188-z\n\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1007/s13760-023-02188-z\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=JL+De+Bleecker&#x00026;author=KG+Claeys&#x00026;author=S+Delstanche&#x00026;author=V+Van+Parys&#x00026;author=J+Baets&#x00026;author=S+Tilleux&#x00026;publication_year=2023&#x00026;title=A+retrospective+survey+of+patients+with+hereditary+transthyretin-mediated+(hATTR)+amyloidosis+treated+with+patisiran+in+real-world+clinical+practice+in+Belgium&#x00026;journal=Acta+Neurol+Belg&#x00026;pages=1029-37\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref27\" id=\"ref27\">\u003C/a>27. Fontana, M, Martinez-Naharro, A, Chacko, L, Rowczenio, D, Gilbertson, JA, Whelan, CJ, et al. Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression. \u003Ci>Cardiovascular Imaging\u003C/i>. (2021) 14:189&#x2013;99. doi: 10.1016/j.jcmg.2020.07.043 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/33129740\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.jcmg.2020.07.043\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Fontana&#x00026;author=A+Martinez-Naharro&#x00026;author=L+Chacko&#x00026;author=D+Rowczenio&#x00026;author=JA+Gilbertson&#x00026;author=CJ+Whelan&#x00026;publication_year=2021&#x00026;title=Reduction+in+CMR+derived+extracellular+volume+with+patisiran+indicates+cardiac+amyloid+regression&#x00026;journal=Cardiovascular+Imaging&#x00026;volume=14&#x00026;pages=189-99\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref28\" id=\"ref28\">\u003C/a>28. Adams, D, Polydefkis, M, Gonz&#x000E1;lez-Duarte, A, Wixner, J, Kristen, AV, Schmidt, HH, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. \u003Ci>Lancet Neurol\u003C/i>. (2021) 20:49&#x2013;59. doi: 10.1016/S1474-4422(20)30368-9 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/33212063\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/S1474-4422(20)30368-9\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=D+Adams&#x00026;author=M+Polydefkis&#x00026;author=A+Gonz&#x000E1;lez-Duarte&#x00026;author=J+Wixner&#x00026;author=AV+Kristen&#x00026;author=HH+Schmidt&#x00026;publication_year=2021&#x00026;title=Long-term+safety+and+efficacy+of+patisiran+for+hereditary+transthyretin-mediated+amyloidosis+with+polyneuropathy:+12-month+results+of+an+open-label+extension+study&#x00026;journal=Lancet+Neurol&#x00026;volume=20&#x00026;pages=49-59\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref29\" id=\"ref29\">\u003C/a>29. Vinik, EJ, Vinik, AI, Paulson, JF, Merkies, IS, Packman, J, Grogan, DR, et al. Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy. \u003Ci>J Peripher Nerv Syst\u003C/i>. (2014) 19:104&#x2013;14. doi: 10.1111/jns5.12059 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/24738700\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1111/jns5.12059\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=EJ+Vinik&#x00026;author=AI+Vinik&#x00026;author=JF+Paulson&#x00026;author=IS+Merkies&#x00026;author=J+Packman&#x00026;author=DR+Grogan&#x00026;publication_year=2014&#x00026;title=Norfolk+QOL-DN:+validation+of+a+patient+reported+outcome+measure+in+transthyretin+familial+amyloid+polyneuropathy&#x00026;journal=J+Peripher+Nerv+Syst&#x00026;volume=19&#x00026;pages=104-14\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref30\" id=\"ref30\">\u003C/a>30. Coelho, T, Vinik, A, Vinik, EJ, Tripp, T, Packman, J, and Grogan, DR. Clinical measures in transthyretin familial amyloid polyneuropathy. \u003Ci>Muscle Nerve\u003C/i>. (2017) 55:323&#x2013;32. doi: 10.1002/mus.25257 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/27422379\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/mus.25257\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=T+Coelho&#x00026;author=A+Vinik&#x00026;author=EJ+Vinik&#x00026;author=T+Tripp&#x00026;author=J+Packman&#x00026;author=DR+Grogan&#x00026;publication_year=2017&#x00026;title=Clinical+measures+in+transthyretin+familial+amyloid+polyneuropathy&#x00026;journal=Muscle+Nerve&#x00026;volume=55&#x00026;pages=323-32\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref31\" id=\"ref31\">\u003C/a>31. Ticau, S, Aldinc, E, Polydefkis, M, Adams, D, Coelho, T, Ueda, M, et al. Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study. \u003Ci>Amyloid\u003C/i>. (2023) 1-11. doi: 10.1080/13506129.2023.2232520\n\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1080/13506129.2023.2232520\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S+Ticau&#x00026;author=E+Aldinc&#x00026;author=M+Polydefkis&#x00026;author=D+Adams&#x00026;author=T+Coelho&#x00026;author=M+Ueda&#x00026;publication_year=2023&#x00026;title=Treatment+response+and+neurofilament+light+chain+levels+with+long-term+patisiran+in+hereditary+transthyretin-mediated+amyloidosis+with+polyneuropathy:+24-month+results+of+an+open-label+extension+study&#x00026;journal=Amyloid&#x00026;volume=1-11&#x00026;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref32\" id=\"ref32\">\u003C/a>32. Polydefkis, M, Aldinc, E, Nienhuis, H, Karam, C, Ajroud-Driss, S, Sekijima, Y, et al. \u003Ci>NfL levels significantly decrease in response to treatment with Patisiran or Vutrisiran in hATTR amyloidosis with polyneuropathy (S14. 001)\u003C/i> Switzerland: AAN Enterprises (2023).\n\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Polydefkis&#x00026;author=E+Aldinc&#x00026;author=H+Nienhuis&#x00026;author=C+Karam&#x00026;author=S+Ajroud-Driss&#x00026;author=Y+Sekijima&#x00026;publication_year=2023&#x00026;journal=NfL+levels+significantly+decrease+in+response+to+treatment+with+Patisiran+or+Vutrisiran+in+hATTR+amyloidosis+with+polyneuropathy+(S14.+001)&#x00026;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref33\" id=\"ref33\">\u003C/a>33. Obici, L, Berk, JL, Gonz&#x000E1;lez-Duarte, A, Coelho, T, Gillmore, J, Schmidt, HH-J, et al. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. \u003Ci>Amyloid\u003C/i>. (2020) 27:153&#x2013;62. doi: 10.1080/13506129.2020.1730790 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32131641\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1080/13506129.2020.1730790\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=L+Obici&#x00026;author=JL+Berk&#x00026;author=A+Gonz&#x000E1;lez-Duarte&#x00026;author=T+Coelho&#x00026;author=J+Gillmore&#x00026;author=HH-J+Schmidt&#x00026;publication_year=2020&#x00026;title=Quality+of+life+outcomes+in+APOLLO+the+phase+3+trial+of+the+RNAi+therapeutic+patisiran+in+patients+with+hereditary+transthyretin-mediated+amyloidosis&#x00026;journal=Amyloid&#x00026;volume=27&#x00026;pages=153-62\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref34\" id=\"ref34\">\u003C/a>34. Algalarrondo, V, Obici, L, Okumura, T, Slama, M, Arum, S, Hale, C, et al. Effect of RNAi therapeutics patisiran and vutrisiran on orthostatic hypotension due to dysautonomia in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. \u003Ci>Archives of Cardiovas Dis Supplements\u003C/i>. (2023) 15:37. doi: 10.1016/j.acvdsp.2022.10.065\n\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1016/j.acvdsp.2022.10.065\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=V+Algalarrondo&#x00026;author=L+Obici&#x00026;author=T+Okumura&#x00026;author=M+Slama&#x00026;author=S+Arum&#x00026;author=C+Hale&#x00026;publication_year=2023&#x00026;title=Effect+of+RNAi+therapeutics+patisiran+and+vutrisiran+on+orthostatic+hypotension+due+to+dysautonomia+in+patients+with+hereditary+transthyretin-mediated+amyloidosis+with+polyneuropathy&#x00026;journal=Archives+of+Cardiovas+Dis+Supplements&#x00026;volume=15&#x00026;pages=37\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref35\" id=\"ref35\">\u003C/a>35. Mussinelli, R, Garcia-pavia, P, Gillmore, JD, Kale, P, Berk, JL, Maurer, MS, et al. 77 HELIOS-a: 18-month exploratory cardiac results from the phase 3 study of VUTRISIRAN in patients with hereditary transthyretin-mediated amyloidosis. \u003Ci>European Heart J Supplements\u003C/i>. (2022) 24:654. doi: 10.1093/eurheartjsupp/suac121.654\n\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1093/eurheartjsupp/suac121.654\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R+Mussinelli&#x00026;author=P+Garcia-pavia&#x00026;author=JD+Gillmore&#x00026;author=P+Kale&#x00026;author=JL+Berk&#x00026;author=MS+Maurer&#x00026;publication_year=2022&#x00026;title=77+HELIOS-a:+18-month+exploratory+cardiac+results+from+the+phase+3+study+of+VUTRISIRAN+in+patients+with+hereditary+transthyretin-mediated+amyloidosis&#x00026;journal=European+Heart+J+Supplements&#x00026;volume=24&#x00026;pages=654\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref36\" id=\"ref36\">\u003C/a>36. National Insitute for Health and care Excellence (NICE). Vutrisiran for treating hereditary transthyretin-related amyloidosis. (2023). Available from: \u003Ca href=\"https://www.nice.org.uk/guidance/ta868\">https://www.nice.org.uk/guidance/ta868\u003C/a> (Accessed February 15, 2024).\n\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?publication_year=2023&#x00026;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003C/div> \u003Cdiv class=\"thinLineM20\">\u003C/div> \u003Cdiv class=\"AbstractSummary\">\n\u003Cp>\u003Cspan>Keywords:\u003C/span> hereditary amyloidosis, transthyretin-related amyloidosis, Patisiran, Vutrisiran, polyneuropathy, cardiomyopathy, clinical trials\u003C/p>\n\u003Cp>\u003Cspan>Citation:\u003C/span> Karimi MA, Esmaeilpour Moallem F, Gholami Chahkand MS, Azarm E, Emami Kazemabad MJ and Dadkhah PA (2024) Assessing the effectiveness and safety of Patisiran and Vutrisiran in ATTRv amyloidosis with polyneuropathy: a systematic review. \u003Ci>Front. Neurol\u003C/i>. 15:1465747. doi: 10.3389/fneur.2024.1465747\u003C/p>\n\u003Cp class=\"timestamps\">\u003Cspan>Received:\u003C/span> 17 July 2024; \u003Cspan>Accepted:\u003C/span> 16 August 2024;\u003Cbr> \u003Cspan>Published:\u003C/span> 02 September 2024.\u003C/p> \u003Cdiv>\n\u003Cp>Edited by:\u003C/p> \u003Ca href=\"https://loop.frontiersin.org/people/857342/overview\">Vincenzo Di Stefano\u003C/a>, University of Studies G. d&#x2019;Annunzio Chieti and Pescara, Italy\u003C/div> \u003Cdiv>\n\u003Cp>Reviewed by:\u003C/p> \u003Ca href=\"https://loop.frontiersin.org/people/756275/overview\">Koike Haruki\u003C/a>, Saga University, Japan\u003Cbr> \u003Ca href=\"https://loop.frontiersin.org/people/1662511/overview\">Jonas Wixner\u003C/a>, Ume&#x00E5; University, Sweden\u003C/div>\n\u003Cp>\u003Cspan>Copyright\u003C/span> &#x000A9; 2024 Karimi, Esmaeilpour Moallem, Gholami Chahkand, Azarm, Emami Kazemabad and Dadkhah. This is an open-access article distributed under the terms of the \u003Ca rel=\"license\" href=\"http://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">Creative Commons Attribution License (CC BY)\u003C/a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.\u003C/p>\n\u003Cp>\u003Cspan>&#x0002A;Correspondence:\u003C/span> Parisa Alsadat Dadkhah, \u003Ca id=\"encmail\">cGFyZGFkNzY5N0BnbWFpbC5jb20=\u003C/a>\u003C/p>\n\u003Cp>\u003Cspan>\u003Csup>&#x2020;\u003C/sup>\u003C/span>These authors have contributed equally to this work\u003C/p> \u003Cdiv class=\"clear\">\u003C/div> \u003C/div>","\u003Cul class=\"flyoutJournal\"> \u003Cli>\u003Ca href=\"#h1\">Abstract\u003C/a>\u003C/li> \u003Cli>\u003Ca href=\"#h2\">Introduction\u003C/a>\u003C/li> \u003Cli>\u003Ca href=\"#h3\">Methods\u003C/a>\u003C/li> \u003Cli>\u003Ca href=\"#h4\">Results\u003C/a>\u003C/li> \u003Cli>\u003Ca href=\"#h5\">Discussion\u003C/a>\u003C/li> \u003Cli>\u003Ca href=\"#h6\">Conclusion\u003C/a>\u003C/li> \u003Cli>\u003Ca href=\"#h7\">Data availability statement\u003C/a>\u003C/li> \u003Cli>\u003Ca href=\"#h8\">Author contributions\u003C/a>\u003C/li> \u003Cli>\u003Ca href=\"#h9\">Funding\u003C/a>\u003C/li> \u003Cli>\u003Ca href=\"#h10\">Acknowledgments\u003C/a>\u003C/li> \u003Cli>\u003Ca href=\"#h11\">Conflict of interest\u003C/a>\u003C/li> \u003Cli>\u003Ca href=\"#h12\">Publisher&#x2019;s note\u003C/a>\u003C/li> \u003Cli>\u003Ca href=\"#h13\">Supplementary material\u003C/a>\u003C/li> \u003Cli>\u003Ca href=\"#h14\">Footnotes\u003C/a>\u003C/li> \u003Cli>\u003Ca href=\"#h15\">References\u003C/a>\u003C/li> \u003C/ul>",[701,706,712,715,721],{"name":702,"fileServerPackageEntryId":19,"fileServerId":703,"fileServerVersionNumber":439,"type":704},"EPUB.epub","1465747/epub",{"code":705,"name":705},"EPUB",{"name":707,"fileServerPackageEntryId":708,"fileServerId":709,"fileServerVersionNumber":439,"type":710},"fneur-15-1465747.pdf","fneur-15-1465747/fneur-15-1465747.pdf","1465747/pubmed-zip",{"code":711,"name":711},"PDF",{"name":707,"fileServerPackageEntryId":19,"fileServerId":713,"fileServerVersionNumber":439,"type":714},"1465747/publishers-proof/pdf",{"code":711,"name":711},{"name":716,"fileServerPackageEntryId":717,"fileServerId":709,"fileServerVersionNumber":439,"type":718},"fneur-15-1465747.xml","fneur-15-1465747/fneur-15-1465747.xml",{"code":719,"name":720},"NLM_XML","XML",{"name":722,"fileServerPackageEntryId":19,"fileServerId":723,"fileServerVersionNumber":439,"type":724},"Provisional PDF.pdf","1465747/provisional-pdf",{"code":711,"name":711},"v3",{"title":727,"link":728,"meta":732,"script":843},"Frontiers | Assessing the effectiveness and safety of Patisiran and Vutrisiran in ATTRv amyloidosis with polyneuropathy: a systematic review",[729],{"rel":730,"href":731},"canonical","https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1465747/full",[733,736,739,741,744,748,751,755,758,761,764,766,768,770,772,774,777,780,782,785,787,789,792,795,798,801,804,808,812,815,818,821,823,826,829,832,835,838,840],{"hid":734,"property":734,"name":734,"content":735},"description","Background: Hereditary transthyretin (ATTRv) amyloidosis, a multifaceted disorder affecting multiple systems, substantially diminishes patients' physical cap...",{"hid":737,"property":737,"name":738,"content":727},"og:title","title",{"hid":740,"property":740,"name":734,"content":735},"og:description",{"hid":742,"name":742,"content":743},"keywords","hereditary amyloidosis,Transthyretin-related amyloidosis,patisiran,Vutrisiran,polyneuropathy,cardiomyopathy,clinical trials",{"hid":745,"property":745,"name":746,"content":747},"og:site_name","site_name","Frontiers",{"hid":749,"property":749,"name":432,"content":750},"og:image","https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/1465747/fneur-15-1465747-HTML/image_m/fneur-15-1465747-t001.jpg",{"hid":752,"property":752,"name":753,"content":754},"og:type","type","article",{"hid":756,"property":756,"name":757,"content":731},"og:url","url",{"hid":759,"name":759,"content":760},"twitter:card","summary_large_image",{"hid":762,"name":762,"content":763},"citation_volume","15",{"hid":765,"name":765,"content":116},"citation_journal_title",{"hid":767,"name":767,"content":747},"citation_publisher",{"hid":769,"name":769,"content":681},"citation_journal_abbrev",{"hid":771,"name":771,"content":682},"citation_issn",{"hid":773,"name":773,"content":583},"citation_doi",{"hid":775,"name":775,"content":776},"citation_firstpage","1465747",{"hid":778,"name":778,"content":779},"citation_language","English",{"hid":781,"name":781,"content":584},"citation_title",{"hid":783,"name":783,"content":784},"citation_keywords","hereditary amyloidosis; Transthyretin-related amyloidosis; patisiran; Vutrisiran; polyneuropathy; cardiomyopathy; clinical trials",{"hid":786,"name":786,"content":589},"citation_abstract",{"hid":788,"name":788,"content":592},"citation_article_type",{"hid":790,"name":790,"content":791},"citation_pdf_url","https://public-pages-files-2025.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1465747/pdf",{"hid":793,"name":793,"content":794},"citation_xml_url","https://public-pages-files-2025.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1465747/xml",{"hid":796,"name":796,"content":797},"citation_fulltext_world_readable","yes",{"hid":799,"name":799,"content":800},"citation_online_date","2024/08/16",{"hid":802,"name":802,"content":803},"citation_publication_date","2024/09/02",{"hid":805,"name":806,"content":807},"citation_author_0","citation_author","Karimi, Mohammad Amin ",{"hid":809,"name":810,"content":811},"citation_author_institution_0","citation_author_institution","School of Medicine, Shahid Beheshti University of Medical Sciences, Iran",{"hid":813,"name":806,"content":814},"citation_author_1","Esmaeilpour Moallem, Fatemeh ",{"hid":816,"name":810,"content":817},"citation_author_institution_1","Student Research Committee, Golestan University of Medical Sciences, Iran",{"hid":819,"name":806,"content":820},"citation_author_2","Gholami Chahkand, Mohammad Sadra ",{"hid":822,"name":810,"content":817},"citation_author_institution_2",{"hid":824,"name":806,"content":825},"citation_author_3","Azarm, Eftekhar ",{"hid":827,"name":810,"content":828},"citation_author_institution_3","School of Medicine, Isfahan University of Medical Sciences, Iran",{"hid":830,"name":806,"content":831},"citation_author_4","Emami Kazemabad, Mohammad Javad ",{"hid":833,"name":810,"content":834},"citation_author_institution_4","Student Research Committee, School of Medicine, Qom University of Medical Sciences, Iran",{"hid":836,"name":806,"content":837},"citation_author_5","Dadkhah, Parisa Alsadat ",{"hid":839,"name":810,"content":828},"citation_author_institution_5",{"hid":841,"name":841,"content":842},"dc.identifier","doi:10.3389/fneur.2024.1465747",[844,847,849,851,853],{"src":845,"body":13,"type":846,"async":13},"https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6","text/javascript",{"src":848,"body":13,"type":846,"async":13},"https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML",{"src":850,"body":13,"type":846,"async":13},"https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js",{"src":852,"body":13,"type":846,"async":13},"https://api.altmetric.com/v1/doi/10.3389/fneur.2024.1465747?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15",{"src":854,"body":13,"type":846,"async":13},"https://crossmark-cdn.crossref.org/widget/v2.0/widget.js",{"articleHubSlug":19,"articleHubPage":856,"articleHubArticlesList":857,"canJournalHasArticleHub":379,"articleDoiList":858},{},[],[],{"title":19,"image":-1,"breadcrumbs":860,"linksCollection":861,"metricsCollection":863},[],{"total":436,"items":862},[],{"total":436,"items":864},[]]</script>
<script>window.__NUXT__={};window.__NUXT__.config={public:{isDevMode:false,appName:"article-pages-2024",baseUrl:"https://www.frontiersin.org",domain:"frontiersin.org",loopUrl:"https://loop.frontiersin.org",ssMainDomain:"frontiersin.org",contentfulUrl:"https://graphql.contentful.com/content/v1/spaces",spaceId:1,spaceName:"Frontiers",liveSpaceId:1,tenantLogoUrl:"",frontiersGraphUrl:"https://apollo-federation-gateway.frontiersin.org",registrationApiUrl:"https://onboarding-ui.frontiersin.org",emailDigestApiUrl:"https://api-email-digest.frontiersin.org",journalFilesApiUrl:"https://files-journal-api.frontiersin.org",publicPagesFilesUrl:"https://public-pages-files-2025.frontiersin.org",searchApiUrl:"https://search-api.frontiersin.org",productionForumApiUrl:"https://production-forum-api-v2.frontiersin.org",gtmServerUrl:"https://tag-manager.frontiersin.org",gtmId:"GTM-M322FV2",gtmAuth:"owVbWxfaJr21yQv1fe1cAQ",gtmPreview:"env-1",figsharePluginUrl:"https://widgets.figshare.com/static/figshare.js",figshareApiUrl:"https://api.figshare.com/v2/collections/search",figshareTimeout:3000,crossmarkPublishedDate:"2015/08/24",googleRecaptchaSiteKey:"6LdG3i0UAAAAAOC4qUh35ubHgJotEHp_STXHgr_v",googleRecaptchaKeyName:"FrontiersRecaptchaV2",faviconSize16:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png",faviconSize32:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png",faviconSize180:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_180-tenantFavicon-Frontiers.png",faviconSize192:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_192-tenantFavicon-Frontiers.png",faviconSize512:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_512-tenantFavicon-Frontiers.png",socialMediaImg:"https://brand.frontiersin.org/m/1c8bcb536c789e11/Guidelines-Frontiers_Logo_1200x628_1-91to1.png",linkedArticleCopyText:"'{\"articleTypeCopyText\":[{\"articleTypeId\":0,\"originalArticleCopyText\":\"Part of this article's content has been mentioned in:\",\"linkedArticleCopyText\":\"This article mentions parts of:\"},{\"articleTypeId\":122,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an erratum on:\"},{\"articleTypeId\":129,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an addendum to:\"},{\"articleTypeId\":128,\"originalArticleCopyText\":\"A correction has been applied to this article in:\",\"linkedArticleCopyText\":\"This article is a correction to:\"},{\"articleTypeId\":134,\"originalArticleCopyText\":\"A retraction of this article was approved in:\",\"linkedArticleCopyText\":\"This article is a retraction of:\"},{\"articleTypeId\":29,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"},{\"articleTypeId\":30,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"}],\"articleIdCopyText\":[]}'\n",acceptedArticleExcludedJournalIds:"'[2766,979]'\n",articleTypeConfigurableLabel:"\u003C\u003Carticle-type:uppercase>> article",settingsFeaturesSwitchers:"'{\"displayTitlePillLabels\":true,\"displayRelatedArticlesBox\":true,\"showEditors\":true,\"showReviewers\":true,\"showLoopImpactLink\":true,\"enableFigshare\":false}'\n",journalsWithArticleHub:"'{\"strings\":[\"science\"]}'\n",terminologySettings:"'{\"terms\":[{\"sequenceNumber\":1,\"key\":\"frontiers\",\"tenantTerm\":\"Frontiers\",\"frontiersDefaultTerm\":\"Frontiers\",\"category\":\"Customer\"},{\"sequenceNumber\":2,\"key\":\"submission_system\",\"tenantTerm\":\"submission system\",\"frontiersDefaultTerm\":\"submission system\",\"category\":\"Product\"},{\"sequenceNumber\":3,\"key\":\"public_pages\",\"tenantTerm\":\"public pages\",\"frontiersDefaultTerm\":\"public pages\",\"category\":\"Product\"},{\"sequenceNumber\":4,\"key\":\"my_frontiers\",\"tenantTerm\":\"my frontiers\",\"frontiersDefaultTerm\":\"my frontiers\",\"category\":\"Product\"},{\"sequenceNumber\":5,\"key\":\"digital_editorial_office\",\"tenantTerm\":\"digital editorial office\",\"frontiersDefaultTerm\":\"digital editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":6,\"key\":\"deo\",\"tenantTerm\":\"DEO\",\"frontiersDefaultTerm\":\"DEO\",\"category\":\"Product\"},{\"sequenceNumber\":7,\"key\":\"digital_editorial_office_for_chiefs\",\"tenantTerm\":\"digital editorial office for chiefs\",\"frontiersDefaultTerm\":\"digital editorial office for chiefs\",\"category\":\"Product\"},{\"sequenceNumber\":8,\"key\":\"digital_editorial_office_for_eof\",\"tenantTerm\":\"digital editorial office for eof\",\"frontiersDefaultTerm\":\"digital editorial office for eof\",\"category\":\"Product\"},{\"sequenceNumber\":9,\"key\":\"editorial_office\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":10,\"key\":\"eof\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"Product\"},{\"sequenceNumber\":11,\"key\":\"research_topic_management\",\"tenantTerm\":\"research topic management\",\"frontiersDefaultTerm\":\"research topic management\",\"category\":\"Product\"},{\"sequenceNumber\":12,\"key\":\"review_forum\",\"tenantTerm\":\"review forum\",\"frontiersDefaultTerm\":\"review forum\",\"category\":\"Product\"},{\"sequenceNumber\":13,\"key\":\"accounting_office\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"Product\"},{\"sequenceNumber\":14,\"key\":\"aof\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"Product\"},{\"sequenceNumber\":15,\"key\":\"publishing_office\",\"tenantTerm\":\"publishing office\",\"frontiersDefaultTerm\":\"publishing office\",\"category\":\"Product\"},{\"sequenceNumber\":16,\"key\":\"production_office\",\"tenantTerm\":\"production office forum\",\"frontiersDefaultTerm\":\"production office forum\",\"category\":\"Product\"},{\"sequenceNumber\":17,\"key\":\"pof\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"Product\"},{\"sequenceNumber\":18,\"key\":\"book_office_forum\",\"tenantTerm\":\"book office forum\",\"frontiersDefaultTerm\":\"book office forum\",\"category\":\"Product\"},{\"sequenceNumber\":19,\"key\":\"bof\",\"tenantTerm\":\"BOF\",\"frontiersDefaultTerm\":\"BOF\",\"category\":\"Product\"},{\"sequenceNumber\":20,\"key\":\"aira\",\"tenantTerm\":\"AIRA\",\"frontiersDefaultTerm\":\"AIRA\",\"category\":\"Product\"},{\"sequenceNumber\":21,\"key\":\"editorial_board_management\",\"tenantTerm\":\"editorial board management\",\"frontiersDefaultTerm\":\"editorial board management\",\"category\":\"Product\"},{\"sequenceNumber\":22,\"key\":\"ebm\",\"tenantTerm\":\"EBM\",\"frontiersDefaultTerm\":\"EBM\",\"category\":\"Product\"},{\"sequenceNumber\":23,\"key\":\"domain\",\"tenantTerm\":\"domain\",\"frontiersDefaultTerm\":\"domain\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":24,\"key\":\"journal\",\"tenantTerm\":\"journal\",\"frontiersDefaultTerm\":\"journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":25,\"key\":\"section\",\"tenantTerm\":\"section\",\"frontiersDefaultTerm\":\"section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":26,\"key\":\"domains\",\"tenantTerm\":\"domains\",\"frontiersDefaultTerm\":\"domains\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":27,\"key\":\"specialty_section\",\"tenantTerm\":\"specialty section\",\"frontiersDefaultTerm\":\"specialty section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":28,\"key\":\"specialty_journal\",\"tenantTerm\":\"specialty journal\",\"frontiersDefaultTerm\":\"specialty journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":29,\"key\":\"journals\",\"tenantTerm\":\"journals\",\"frontiersDefaultTerm\":\"journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":30,\"key\":\"sections\",\"tenantTerm\":\"sections\",\"frontiersDefaultTerm\":\"sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":31,\"key\":\"specialty_sections\",\"tenantTerm\":\"specialty sections\",\"frontiersDefaultTerm\":\"specialty sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":32,\"key\":\"specialty_journals\",\"tenantTerm\":\"specialty journals\",\"frontiersDefaultTerm\":\"specialty journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":33,\"key\":\"manuscript\",\"tenantTerm\":\"manuscript\",\"frontiersDefaultTerm\":\"manuscript\",\"category\":\"Core\"},{\"sequenceNumber\":34,\"key\":\"manuscripts\",\"tenantTerm\":\"manuscripts\",\"frontiersDefaultTerm\":\"manuscripts\",\"category\":\"Core\"},{\"sequenceNumber\":35,\"key\":\"article\",\"tenantTerm\":\"article\",\"frontiersDefaultTerm\":\"article\",\"category\":\"Core\"},{\"sequenceNumber\":36,\"key\":\"articles\",\"tenantTerm\":\"articles\",\"frontiersDefaultTerm\":\"articles\",\"category\":\"Core\"},{\"sequenceNumber\":37,\"key\":\"article_type\",\"tenantTerm\":\"article type\",\"frontiersDefaultTerm\":\"article type\",\"category\":\"Core\"},{\"sequenceNumber\":38,\"key\":\"article_types\",\"tenantTerm\":\"article types\",\"frontiersDefaultTerm\":\"article types\",\"category\":\"Core\"},{\"sequenceNumber\":39,\"key\":\"author\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":40,\"key\":\"authors\",\"tenantTerm\":\"authors\",\"frontiersDefaultTerm\":\"authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":41,\"key\":\"authoring\",\"tenantTerm\":\"authoring\",\"frontiersDefaultTerm\":\"authoring\",\"category\":\"Core\"},{\"sequenceNumber\":42,\"key\":\"authored\",\"tenantTerm\":\"authored\",\"frontiersDefaultTerm\":\"authored\",\"category\":\"Core\"},{\"sequenceNumber\":43,\"key\":\"accept\",\"tenantTerm\":\"accept\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":44,\"key\":\"accepted\",\"tenantTerm\":\"accepted\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":45,\"key\":\"assistant_field_chief_editor\",\"tenantTerm\":\"Assistant Field Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editor\",\"description\":\"An editorial role on a Field Journal that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":46,\"key\":\"assistant_specialty_chief_editor\",\"tenantTerm\":\"Assistant Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":47,\"key\":\"assistant_specialty_chief_editors\",\"tenantTerm\":\"Assistant Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":48,\"key\":\"associate_editor\",\"tenantTerm\":\"Associate Editor\",\"frontiersDefaultTerm\":\"Associate Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":49,\"key\":\"specialty_chief_editor\",\"tenantTerm\":\"Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":50,\"key\":\"specialty_chief_editors\",\"tenantTerm\":\"Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":51,\"key\":\"chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":52,\"key\":\"chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":53,\"key\":\"call_for_participation\",\"tenantTerm\":\"call for participation\",\"frontiersDefaultTerm\":\"call for participation\",\"category\":\"Process\"},{\"sequenceNumber\":54,\"key\":\"citation\",\"tenantTerm\":\"citation\",\"frontiersDefaultTerm\":\"citation\",\"category\":\"Misc.\"},{\"sequenceNumber\":55,\"key\":\"citations\",\"tenantTerm\":\"citations\",\"frontiersDefaultTerm\":\"citations\",\"category\":\"Misc.\"},{\"sequenceNumber\":56,\"key\":\"contributor\",\"tenantTerm\":\"contributor\",\"frontiersDefaultTerm\":\"contributor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":57,\"key\":\"contributors\",\"tenantTerm\":\"contributors\",\"frontiersDefaultTerm\":\"contributors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":58,\"key\":\"corresponding_author\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":59,\"key\":\"corresponding_authors\",\"tenantTerm\":\"corresponding authors\",\"frontiersDefaultTerm\":\"corresponding authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":60,\"key\":\"decline\",\"tenantTerm\":\"decline\",\"frontiersDefaultTerm\":\"decline\",\"category\":\"Process\"},{\"sequenceNumber\":61,\"key\":\"declined\",\"tenantTerm\":\"declined\",\"frontiersDefaultTerm\":\"declined\",\"category\":\"Process\"},{\"sequenceNumber\":62,\"key\":\"reject\",\"tenantTerm\":\"reject\",\"frontiersDefaultTerm\":\"reject\",\"category\":\"Process\"},{\"sequenceNumber\":63,\"key\":\"rejected\",\"tenantTerm\":\"rejected\",\"frontiersDefaultTerm\":\"rejected\",\"category\":\"Process\"},{\"sequenceNumber\":64,\"key\":\"publish\",\"tenantTerm\":\"publish\",\"frontiersDefaultTerm\":\"publish\",\"category\":\"Core\"},{\"sequenceNumber\":65,\"key\":\"published\",\"tenantTerm\":\"published\",\"frontiersDefaultTerm\":\"published\",\"category\":\"Core\"},{\"sequenceNumber\":66,\"key\":\"publication\",\"tenantTerm\":\"publication\",\"frontiersDefaultTerm\":\"publication\",\"category\":\"Core\"},{\"sequenceNumber\":67,\"key\":\"peer_review\",\"tenantTerm\":\"peer review\",\"frontiersDefaultTerm\":\"peer review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":68,\"key\":\"peer_reviewed\",\"tenantTerm\":\"peer reviewed\",\"frontiersDefaultTerm\":\"peer reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":69,\"key\":\"initial_validation\",\"tenantTerm\":\"initial validation\",\"frontiersDefaultTerm\":\"initial validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":70,\"key\":\"editorial_assignment\",\"tenantTerm\":\"editorial assignment\",\"frontiersDefaultTerm\":\"editorial assignment\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":71,\"key\":\"independent_review\",\"tenantTerm\":\"independent review\",\"frontiersDefaultTerm\":\"independent review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":72,\"key\":\"interactive_review\",\"tenantTerm\":\"interactive review\",\"frontiersDefaultTerm\":\"interactive review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":73,\"key\":\"review\",\"tenantTerm\":\"review\",\"frontiersDefaultTerm\":\"review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":74,\"key\":\"reviewing\",\"tenantTerm\":\"reviewing\",\"frontiersDefaultTerm\":\"reviewing\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":75,\"key\":\"reviewer\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":76,\"key\":\"reviewers\",\"tenantTerm\":\"reviewers\",\"frontiersDefaultTerm\":\"reviewers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":77,\"key\":\"review_finalized\",\"tenantTerm\":\"review finalized\",\"frontiersDefaultTerm\":\"review finalized\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":78,\"key\":\"final_decision\",\"tenantTerm\":\"final decision\",\"frontiersDefaultTerm\":\"final decision\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":79,\"key\":\"final_validation\",\"tenantTerm\":\"final validation\",\"frontiersDefaultTerm\":\"final validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":80,\"key\":\"ae_accept_manuscript\",\"tenantTerm\":\"recommend to accept manuscript\",\"frontiersDefaultTerm\":\"accept manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":81,\"key\":\"fee\",\"tenantTerm\":\"fee\",\"frontiersDefaultTerm\":\"fee\",\"category\":\"Accounting\"},{\"sequenceNumber\":82,\"key\":\"fees\",\"tenantTerm\":\"fees\",\"frontiersDefaultTerm\":\"fees\",\"category\":\"Accounting\"},{\"sequenceNumber\":83,\"key\":\"guest_associate_editor\",\"tenantTerm\":\"Guest Associate Editor\",\"frontiersDefaultTerm\":\"Guest Associate Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":84,\"key\":\"guest_associate_editors\",\"tenantTerm\":\"Guest Associate Editors\",\"frontiersDefaultTerm\":\"Guest Associate Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":85,\"key\":\"in_review\",\"tenantTerm\":\"in review\",\"frontiersDefaultTerm\":\"in review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":86,\"key\":\"institutional_member\",\"tenantTerm\":\"institutional partner\",\"frontiersDefaultTerm\":\"institutional partner\",\"category\":\"Accounting\"},{\"sequenceNumber\":87,\"key\":\"institutional_membership\",\"tenantTerm\":\"institutional partnership\",\"frontiersDefaultTerm\":\"institutional partnership\",\"category\":\"Accounting\"},{\"sequenceNumber\":88,\"key\":\"article_processing_charge\",\"tenantTerm\":\"article processing charge\",\"frontiersDefaultTerm\":\"article processing charge\",\"category\":\"Accounting\"},{\"sequenceNumber\":89,\"key\":\"article_processing_charges\",\"tenantTerm\":\"article processing charges\",\"frontiersDefaultTerm\":\"article processing charges\",\"category\":\"Accounting\"},{\"sequenceNumber\":90,\"key\":\"apcs\",\"tenantTerm\":\"APCs\",\"frontiersDefaultTerm\":\"APCs\",\"category\":\"Accounting\"},{\"sequenceNumber\":91,\"key\":\"apc\",\"tenantTerm\":\"APC\",\"frontiersDefaultTerm\":\"APC\",\"category\":\"Accounting\"},{\"sequenceNumber\":92,\"key\":\"received\",\"tenantTerm\":\"received\",\"frontiersDefaultTerm\":\"received\",\"description\":\"Date manuscript was received on.\",\"category\":\"Core\"},{\"sequenceNumber\":93,\"key\":\"transferred\",\"tenantTerm\":\"transferred\",\"frontiersDefaultTerm\":\"transferred\",\"category\":\"Core\"},{\"sequenceNumber\":94,\"key\":\"transfer\",\"tenantTerm\":\"transfer\",\"frontiersDefaultTerm\":\"transfer\",\"category\":\"Core\"},{\"sequenceNumber\":95,\"key\":\"research_topic\",\"tenantTerm\":\"research topic\",\"frontiersDefaultTerm\":\"research topic\",\"category\":\"Core\"},{\"sequenceNumber\":96,\"key\":\"research_topics\",\"tenantTerm\":\"research topics\",\"frontiersDefaultTerm\":\"research topics\",\"category\":\"Core\"},{\"sequenceNumber\":97,\"key\":\"topic_editor\",\"tenantTerm\":\"Topic Editor\",\"frontiersDefaultTerm\":\"Topic Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":98,\"key\":\"review_editor\",\"tenantTerm\":\"Community Reviewer\",\"frontiersDefaultTerm\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":99,\"key\":\"title\",\"tenantTerm\":\"title\",\"frontiersDefaultTerm\":\"title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":100,\"key\":\"running_title\",\"tenantTerm\":\"running title\",\"frontiersDefaultTerm\":\"running title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":101,\"key\":\"submit\",\"tenantTerm\":\"submit\",\"frontiersDefaultTerm\":\"submit\",\"category\":\"Process\"},{\"sequenceNumber\":102,\"key\":\"submitted\",\"tenantTerm\":\"submitted\",\"frontiersDefaultTerm\":\"submitted\",\"category\":\"Process\"},{\"sequenceNumber\":103,\"key\":\"submitting\",\"tenantTerm\":\"submitting\",\"frontiersDefaultTerm\":\"submitting\",\"category\":\"Process\"},{\"sequenceNumber\":104,\"key\":\"t_e\",\"tenantTerm\":\"TE\",\"frontiersDefaultTerm\":\"TE\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":105,\"key\":\"topic\",\"tenantTerm\":\"topic\",\"frontiersDefaultTerm\":\"topic\",\"category\":\"Process\"},{\"sequenceNumber\":106,\"key\":\"topic_summary\",\"tenantTerm\":\"topic summary\",\"frontiersDefaultTerm\":\"topic summary\",\"category\":\"Process\"},{\"sequenceNumber\":107,\"key\":\"figure\",\"tenantTerm\":\"figure\",\"frontiersDefaultTerm\":\"figure\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":108,\"key\":\"figures\",\"tenantTerm\":\"figures\",\"frontiersDefaultTerm\":\"figures\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":109,\"key\":\"editorial_file\",\"tenantTerm\":\"editorial file\",\"frontiersDefaultTerm\":\"editorial file\",\"category\":\"Core\"},{\"sequenceNumber\":110,\"key\":\"editorial_files\",\"tenantTerm\":\"editorial files\",\"frontiersDefaultTerm\":\"editorial files\",\"category\":\"Core\"},{\"sequenceNumber\":111,\"key\":\"e_book\",\"tenantTerm\":\"e-book\",\"frontiersDefaultTerm\":\"e-book\",\"category\":\"Core\"},{\"sequenceNumber\":112,\"key\":\"organization\",\"tenantTerm\":\"organization\",\"frontiersDefaultTerm\":\"organization\",\"category\":\"Core\"},{\"sequenceNumber\":113,\"key\":\"institution\",\"tenantTerm\":\"institution\",\"frontiersDefaultTerm\":\"institution\",\"category\":\"Core\"},{\"sequenceNumber\":114,\"key\":\"reference\",\"tenantTerm\":\"reference\",\"frontiersDefaultTerm\":\"reference\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":115,\"key\":\"references\",\"tenantTerm\":\"references\",\"frontiersDefaultTerm\":\"references\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":116,\"key\":\"sce\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"description\":\"Abbreviation for Specialty Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":117,\"key\":\"submission\",\"tenantTerm\":\"submission\",\"frontiersDefaultTerm\":\"submission\",\"category\":\"Process\"},{\"sequenceNumber\":118,\"key\":\"submissions\",\"tenantTerm\":\"submissions\",\"frontiersDefaultTerm\":\"submissions\",\"category\":\"Process\"},{\"sequenceNumber\":119,\"key\":\"editing\",\"tenantTerm\":\"editing\",\"frontiersDefaultTerm\":\"editing\",\"category\":\"Process\"},{\"sequenceNumber\":120,\"key\":\"in_preparation\",\"tenantTerm\":\"in preparation\",\"frontiersDefaultTerm\":\"in preparation\",\"category\":\"Process\"},{\"sequenceNumber\":121,\"key\":\"country_region\",\"tenantTerm\":\"country/region\",\"frontiersDefaultTerm\":\"country/region\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":122,\"key\":\"countries_regions\",\"tenantTerm\":\"countries/regions\",\"frontiersDefaultTerm\":\"countries/regions\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":123,\"key\":\"specialty\",\"tenantTerm\":\"specialty\",\"frontiersDefaultTerm\":\"specialty\",\"category\":\"Core\"},{\"sequenceNumber\":124,\"key\":\"specialties\",\"tenantTerm\":\"specialties\",\"frontiersDefaultTerm\":\"specialties\",\"category\":\"Core\"},{\"sequenceNumber\":125,\"key\":\"associate_editors\",\"tenantTerm\":\"Associate Editors\",\"frontiersDefaultTerm\":\"Associate Editors\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":126,\"key\":\"reviewed\",\"tenantTerm\":\"reviewed\",\"frontiersDefaultTerm\":\"reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":127,\"key\":\"institutional_members\",\"tenantTerm\":\"institutional partners\",\"frontiersDefaultTerm\":\"institutional partners\",\"category\":\"Accounting\"},{\"sequenceNumber\":128,\"key\":\"institutional_memberships\",\"tenantTerm\":\"institutional partnerships\",\"frontiersDefaultTerm\":\"institutional partnerships\",\"category\":\"Accounting\"},{\"sequenceNumber\":129,\"key\":\"assistant_field_chief_editors\",\"tenantTerm\":\"Assistant Field Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":130,\"key\":\"publications\",\"tenantTerm\":\"publications\",\"frontiersDefaultTerm\":\"publications\",\"category\":\"Process\"},{\"sequenceNumber\":131,\"key\":\"ae_accepted\",\"tenantTerm\":\"recommended acceptance\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":132,\"key\":\"field_journal\",\"tenantTerm\":\"field journal\",\"frontiersDefaultTerm\":\"field journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":133,\"key\":\"field_journals\",\"tenantTerm\":\"field journals\",\"frontiersDefaultTerm\":\"field journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":134,\"key\":\"program_manager\",\"tenantTerm\":\"program manager\",\"frontiersDefaultTerm\":\"program manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":135,\"key\":\"journal_manager\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":136,\"key\":\"journal_specialist\",\"tenantTerm\":\"journal specialist\",\"frontiersDefaultTerm\":\"journal specialist\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":137,\"key\":\"program_managers\",\"tenantTerm\":\"program managers\",\"frontiersDefaultTerm\":\"program managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":138,\"key\":\"journal_managers\",\"tenantTerm\":\"journal managers\",\"frontiersDefaultTerm\":\"journal managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":139,\"key\":\"journal_specialists\",\"tenantTerm\":\"journal specialists\",\"frontiersDefaultTerm\":\"journal specialists\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":140,\"key\":\"cover_letter\",\"tenantTerm\":\"manuscript contribution to the field\",\"frontiersDefaultTerm\":\"manuscript contribution to the field\",\"category\":\"Process\"},{\"sequenceNumber\":141,\"key\":\"ae_accepted_manuscript\",\"tenantTerm\":\"recommended to accept manuscript\",\"frontiersDefaultTerm\":\"accepted manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":142,\"key\":\"recommend_for_rejection\",\"tenantTerm\":\"recommend for rejection\",\"frontiersDefaultTerm\":\"recommend for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":143,\"key\":\"recommended_for_rejection\",\"tenantTerm\":\"recommended for rejection\",\"frontiersDefaultTerm\":\"recommended for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":144,\"key\":\"ae\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"description\":\"Associate Editor - board member\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":145,\"key\":\"re\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"description\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":146,\"key\":\"rev\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"description\":\"Reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":147,\"key\":\"aut\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"description\":\"Author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":148,\"key\":\"coraut\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"description\":\"Corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":149,\"key\":\"saut\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"description\":\"Submitting author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":150,\"key\":\"coaut\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"description\":\"co-author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":151,\"key\":\"tsof\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"description\":\"Typesetter\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":152,\"key\":\"typesetting_office\",\"tenantTerm\":\"typesetting office\",\"frontiersDefaultTerm\":\"typesetting office\",\"category\":\"Product\"},{\"sequenceNumber\":153,\"key\":\"config\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"description\":\"Configuration office role\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":154,\"key\":\"jm\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"description\":\"Journal Manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":155,\"key\":\"rte\",\"tenantTerm\":\"RTE\",\"frontiersDefaultTerm\":\"RTE\",\"description\":\"Research topic editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":156,\"key\":\"organizations\",\"tenantTerm\":\"organizations\",\"frontiersDefaultTerm\":\"organizations\",\"category\":\"Core\"},{\"sequenceNumber\":157,\"key\":\"publishing\",\"tenantTerm\":\"publishing\",\"frontiersDefaultTerm\":\"publishing\",\"category\":\"Core\"},{\"sequenceNumber\":158,\"key\":\"acceptance\",\"tenantTerm\":\"acceptance\",\"frontiersDefaultTerm\":\"acceptance\",\"category\":\"Process\"},{\"sequenceNumber\":159,\"key\":\"preferred_associate_editor\",\"tenantTerm\":\"preferred associate editor\",\"frontiersDefaultTerm\":\"preferred associate editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":160,\"key\":\"topic_editors\",\"tenantTerm\":\"Topic Editors\",\"frontiersDefaultTerm\":\"Topic Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":161,\"key\":\"institutions\",\"tenantTerm\":\"institutions\",\"frontiersDefaultTerm\":\"institutions\",\"category\":\"Core\"},{\"sequenceNumber\":162,\"key\":\"author(s)\",\"tenantTerm\":\"author(s)\",\"frontiersDefaultTerm\":\"author(s)\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":163,\"key\":\"figure(s)\",\"tenantTerm\":\"figure(s)\",\"frontiersDefaultTerm\":\"figure(s)\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":164,\"key\":\"co-authors\",\"tenantTerm\":\"co-authors\",\"frontiersDefaultTerm\":\"co-authors\",\"description\":\"co-authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":165,\"key\":\"editorial_board_members\",\"tenantTerm\":\"editorial board members\",\"frontiersDefaultTerm\":\"editorial board members\",\"description\":\"editorial board members\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":166,\"key\":\"editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"editorial board\",\"category\":\"Product\"},{\"sequenceNumber\":167,\"key\":\"co-authorship\",\"tenantTerm\":\"co-authorship\",\"frontiersDefaultTerm\":\"co-authorship\",\"description\":\"co-authorship\",\"category\":\"Misc.\"},{\"sequenceNumber\":168,\"key\":\"role_id_1\",\"tenantTerm\":\"registration office\",\"frontiersDefaultTerm\":\"registration office\",\"category\":\"User Role\"},{\"sequenceNumber\":169,\"key\":\"role_id_2\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"User Role\"},{\"sequenceNumber\":170,\"key\":\"role_id_7\",\"tenantTerm\":\"field chief editor\",\"frontiersDefaultTerm\":\"field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":171,\"key\":\"role_id_8\",\"tenantTerm\":\"assistant field chief editor\",\"frontiersDefaultTerm\":\"assistant field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":172,\"key\":\"role_id_9\",\"tenantTerm\":\"specialty chief editor\",\"frontiersDefaultTerm\":\"specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":173,\"key\":\"role_id_10\",\"tenantTerm\":\"assistant specialty chief editor\",\"frontiersDefaultTerm\":\"assistant specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":174,\"key\":\"role_id_11\",\"tenantTerm\":\"associate editor\",\"frontiersDefaultTerm\":\"associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":175,\"key\":\"role_id_12\",\"tenantTerm\":\"guest associate editor\",\"frontiersDefaultTerm\":\"guest associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":176,\"key\":\"role_id_13\",\"tenantTerm\":\"review editor\",\"frontiersDefaultTerm\":\"review editor\",\"category\":\"User Role\"},{\"sequenceNumber\":177,\"key\":\"role_id_14\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":178,\"key\":\"role_id_15\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"User Role\"},{\"sequenceNumber\":179,\"key\":\"role_id_16\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"User Role\"},{\"sequenceNumber\":180,\"key\":\"role_id_17\",\"tenantTerm\":\"submitting author\",\"frontiersDefaultTerm\":\"submitting author\",\"category\":\"User Role\"},{\"sequenceNumber\":181,\"key\":\"role_id_18\",\"tenantTerm\":\"co-author\",\"frontiersDefaultTerm\":\"co-author\",\"category\":\"User Role\"},{\"sequenceNumber\":182,\"key\":\"role_id_20\",\"tenantTerm\":\"production office\",\"frontiersDefaultTerm\":\"production office\",\"category\":\"User Role\"},{\"sequenceNumber\":183,\"key\":\"role_id_22\",\"tenantTerm\":\"typesetting office (typesetter)\",\"frontiersDefaultTerm\":\"typesetting office (typesetter)\",\"category\":\"User Role\"},{\"sequenceNumber\":184,\"key\":\"role_id_24\",\"tenantTerm\":\"registered user\",\"frontiersDefaultTerm\":\"registered user\",\"category\":\"User Role\"},{\"sequenceNumber\":185,\"key\":\"role_id_35\",\"tenantTerm\":\"job office\",\"frontiersDefaultTerm\":\"job office\",\"category\":\"User Role\"},{\"sequenceNumber\":186,\"key\":\"role_id_41\",\"tenantTerm\":\"special event administrator\",\"frontiersDefaultTerm\":\"special event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":187,\"key\":\"role_id_42\",\"tenantTerm\":\"special event reviewer\",\"frontiersDefaultTerm\":\"special event reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":188,\"key\":\"role_id_43\",\"tenantTerm\":\"submit abstract\",\"frontiersDefaultTerm\":\"submit abstract\",\"category\":\"User Role\"},{\"sequenceNumber\":189,\"key\":\"role_id_52\",\"tenantTerm\":\"events office\",\"frontiersDefaultTerm\":\"events office\",\"category\":\"User Role\"},{\"sequenceNumber\":190,\"key\":\"role_id_53\",\"tenantTerm\":\"event administrator\",\"frontiersDefaultTerm\":\"event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":191,\"key\":\"role_id_89\",\"tenantTerm\":\"content management office\",\"frontiersDefaultTerm\":\"content management office\",\"category\":\"User Role\"},{\"sequenceNumber\":192,\"key\":\"role_id_98\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"User Role\"},{\"sequenceNumber\":193,\"key\":\"role_id_99\",\"tenantTerm\":\"projects\",\"frontiersDefaultTerm\":\"projects\",\"category\":\"User Role\"},{\"sequenceNumber\":194,\"key\":\"role_id_103\",\"tenantTerm\":\"configuration office\",\"frontiersDefaultTerm\":\"configuration office\",\"category\":\"User Role\"},{\"sequenceNumber\":195,\"key\":\"role_id_104\",\"tenantTerm\":\"beta user\",\"frontiersDefaultTerm\":\"beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":196,\"key\":\"role_id_106\",\"tenantTerm\":\"wfconf\",\"frontiersDefaultTerm\":\"wfconf\",\"category\":\"User Role\"},{\"sequenceNumber\":197,\"key\":\"role_id_107\",\"tenantTerm\":\"rt management beta user\",\"frontiersDefaultTerm\":\"rt management beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":198,\"key\":\"role_id_108\",\"tenantTerm\":\"deo beta user\",\"frontiersDefaultTerm\":\"deo beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":199,\"key\":\"role_id_109\",\"tenantTerm\":\"search beta user\",\"frontiersDefaultTerm\":\"search beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":200,\"key\":\"role_id_110\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"User Role\"},{\"sequenceNumber\":201,\"key\":\"role_id_111\",\"tenantTerm\":\"myfrontiers beta user\",\"frontiersDefaultTerm\":\"myfrontiers beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":202,\"key\":\"role_id_21\",\"tenantTerm\":\"copy editor\",\"frontiersDefaultTerm\":\"copy editor\",\"category\":\"User Role\"},{\"sequenceNumber\":203,\"key\":\"role_id_1_abr\",\"tenantTerm\":\"ROF\",\"frontiersDefaultTerm\":\"ROF\",\"category\":\"User Role\"},{\"sequenceNumber\":204,\"key\":\"role_id_2_abr\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"User Role\"},{\"sequenceNumber\":205,\"key\":\"role_id_7_abr\",\"tenantTerm\":\"FCE\",\"frontiersDefaultTerm\":\"FCE\",\"category\":\"User Role\"},{\"sequenceNumber\":206,\"key\":\"role_id_8_abr\",\"tenantTerm\":\"AFCE\",\"frontiersDefaultTerm\":\"AFCE\",\"category\":\"User Role\"},{\"sequenceNumber\":207,\"key\":\"role_id_9_abr\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"category\":\"User Role\"},{\"sequenceNumber\":208,\"key\":\"role_id_10_abr\",\"tenantTerm\":\"ASCE\",\"frontiersDefaultTerm\":\"ASCE\",\"category\":\"User Role\"},{\"sequenceNumber\":209,\"key\":\"role_id_11_abr\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"category\":\"User Role\"},{\"sequenceNumber\":210,\"key\":\"role_id_12_abr\",\"tenantTerm\":\"GAE\",\"frontiersDefaultTerm\":\"GAE\",\"category\":\"User Role\"},{\"sequenceNumber\":211,\"key\":\"role_id_13_abr\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"category\":\"User Role\"},{\"sequenceNumber\":212,\"key\":\"role_id_14_abr\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"category\":\"User Role\"},{\"sequenceNumber\":213,\"key\":\"role_id_15_abr\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":214,\"key\":\"role_id_16_abr\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":215,\"key\":\"role_id_17_abr\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":216,\"key\":\"role_id_18_abr\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":217,\"key\":\"role_id_20_abr\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"User Role\"},{\"sequenceNumber\":218,\"key\":\"role_id_22_abr\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"category\":\"User Role\"},{\"sequenceNumber\":219,\"key\":\"role_id_24_abr\",\"tenantTerm\":\"RU\",\"frontiersDefaultTerm\":\"RU\",\"category\":\"User Role\"},{\"sequenceNumber\":220,\"key\":\"role_id_35_abr\",\"tenantTerm\":\"JOF\",\"frontiersDefaultTerm\":\"JOF\",\"category\":\"User Role\"},{\"sequenceNumber\":221,\"key\":\"role_id_41_abr\",\"tenantTerm\":\"SE-ADM\",\"frontiersDefaultTerm\":\"SE-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":222,\"key\":\"role_id_42_abr\",\"tenantTerm\":\"SE-REV\",\"frontiersDefaultTerm\":\"SE-REV\",\"category\":\"User Role\"},{\"sequenceNumber\":223,\"key\":\"role_id_43_abr\",\"tenantTerm\":\"SE-AUT\",\"frontiersDefaultTerm\":\"SE-AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":224,\"key\":\"role_id_52_abr\",\"tenantTerm\":\"EVOF\",\"frontiersDefaultTerm\":\"EVOF\",\"category\":\"User Role\"},{\"sequenceNumber\":225,\"key\":\"role_id_53_abr\",\"tenantTerm\":\"EV-ADM\",\"frontiersDefaultTerm\":\"EV-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":226,\"key\":\"role_id_89_abr\",\"tenantTerm\":\"COMOF\",\"frontiersDefaultTerm\":\"COMOF\",\"category\":\"User Role\"},{\"sequenceNumber\":227,\"key\":\"role_id_98_abr\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"User Role\"},{\"sequenceNumber\":228,\"key\":\"role_id_99_abr\",\"tenantTerm\":\"Projects\",\"frontiersDefaultTerm\":\"Projects\",\"category\":\"User Role\"},{\"sequenceNumber\":229,\"key\":\"role_id_103_abr\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"category\":\"User Role\"},{\"sequenceNumber\":230,\"key\":\"role_id_104_abr\",\"tenantTerm\":\"BETA\",\"frontiersDefaultTerm\":\"BETA\",\"category\":\"User Role\"},{\"sequenceNumber\":231,\"key\":\"role_id_106_abr\",\"tenantTerm\":\"WFCONF\",\"frontiersDefaultTerm\":\"WFCONF\",\"category\":\"User Role\"},{\"sequenceNumber\":232,\"key\":\"role_id_107_abr\",\"tenantTerm\":\"RTBETA\",\"frontiersDefaultTerm\":\"RTBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":233,\"key\":\"role_id_108_abr\",\"tenantTerm\":\"DEOBETA\",\"frontiersDefaultTerm\":\"DEOBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":234,\"key\":\"role_id_109_abr\",\"tenantTerm\":\"SEARCHBETA\",\"frontiersDefaultTerm\":\"SEARCHBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":235,\"key\":\"role_id_110_abr\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"category\":\"User Role\"},{\"sequenceNumber\":236,\"key\":\"role_id_111_abr\",\"tenantTerm\":\"MFBETA\",\"frontiersDefaultTerm\":\"MFBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":237,\"key\":\"role_id_21_abr\",\"tenantTerm\":\"COPED\",\"frontiersDefaultTerm\":\"COPED\",\"category\":\"User Role\"},{\"sequenceNumber\":238,\"key\":\"reviewer_editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"This is the label for the review editorial board\",\"category\":\"Label\"},{\"sequenceNumber\":239,\"key\":\"field_chief_editor\",\"tenantTerm\":\"Field Chief Editor\",\"frontiersDefaultTerm\":\"Field Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":240,\"key\":\"field_chief_editors\",\"tenantTerm\":\"Field Chief Editors\",\"frontiersDefaultTerm\":\"Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":241,\"key\":\"editor\",\"tenantTerm\":\"editor\",\"frontiersDefaultTerm\":\"editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":242,\"key\":\"editors\",\"tenantTerm\":\"editors\",\"frontiersDefaultTerm\":\"editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":243,\"key\":\"board\",\"tenantTerm\":\"board\",\"frontiersDefaultTerm\":\"board\",\"category\":\"Label\"},{\"sequenceNumber\":244,\"key\":\"boards\",\"tenantTerm\":\"boards\",\"frontiersDefaultTerm\":\"boards\",\"category\":\"Label\"},{\"sequenceNumber\":245,\"key\":\"article_collection\",\"tenantTerm\":\"article collection\",\"frontiersDefaultTerm\":\"article collection\",\"category\":\"Label\"},{\"sequenceNumber\":246,\"key\":\"article_collections\",\"tenantTerm\":\"article collections\",\"frontiersDefaultTerm\":\"article collections\",\"category\":\"Label\"},{\"sequenceNumber\":247,\"key\":\"handling_editor\",\"tenantTerm\":\"handling editor\",\"frontiersDefaultTerm\":\"associate editor\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":248,\"key\":\"handling_editors\",\"tenantTerm\":\"handling editors\",\"frontiersDefaultTerm\":\"associate editors\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":249,\"key\":\"ae_accept\",\"tenantTerm\":\"recommend acceptance\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":250,\"key\":\"rtm\",\"tenantTerm\":\"RTM\",\"frontiersDefaultTerm\":\"RTM\",\"category\":\"Product\"},{\"sequenceNumber\":251,\"key\":\"frontiers_media_sa\",\"tenantTerm\":\"Frontiers Media S.A\",\"frontiersDefaultTerm\":\"Frontiers Media S.A\",\"category\":\"Customer\"},{\"sequenceNumber\":252,\"key\":\"review_editors\",\"tenantTerm\":\"Community Reviewers\",\"frontiersDefaultTerm\":\"Review Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":253,\"key\":\"journal_card_chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":254,\"key\":\"journal_card_chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":255,\"key\":\"call_for_papers\",\"tenantTerm\":\"Call for papers\",\"frontiersDefaultTerm\":\"Call for papers\",\"category\":\"Label\"},{\"sequenceNumber\":256,\"key\":\"calls_for_papers\",\"tenantTerm\":\"Calls for papers\",\"frontiersDefaultTerm\":\"Calls for papers\",\"category\":\"Label\"},{\"sequenceNumber\":257,\"key\":\"supervising_editor\",\"tenantTerm\":\"Supervising Editor\",\"frontiersDefaultTerm\":\"Supervising Editor\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editor\"},{\"sequenceNumber\":258,\"key\":\"supervising_editors\",\"tenantTerm\":\"Supervising Editors\",\"frontiersDefaultTerm\":\"Supervising Editors\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editors\"},{\"sequenceNumber\":259,\"key\":\"reviewer_endorse\",\"tenantTerm\":\"endorse\",\"frontiersDefaultTerm\":\"endorse\",\"category\":\"Label\"},{\"sequenceNumber\":260,\"key\":\"reviewer_endorsed\",\"tenantTerm\":\"endorsed\",\"frontiersDefaultTerm\":\"endorsed\",\"category\":\"Label\"},{\"sequenceNumber\":261,\"key\":\"reviewer_endorse_publication\",\"tenantTerm\":\"endorse publication\",\"frontiersDefaultTerm\":\"endorse publication\",\"category\":\"Label\"},{\"sequenceNumber\":262,\"key\":\"reviewer_endorsed_publication\",\"tenantTerm\":\"endorsed publication\",\"frontiersDefaultTerm\":\"endorsed publication\",\"category\":\"Label\"},{\"sequenceNumber\":263,\"key\":\"editor_role\",\"tenantTerm\":\"editor role\",\"frontiersDefaultTerm\":\"Editor Role\",\"category\":\"Label\"},{\"sequenceNumber\":264,\"key\":\"editor_roles\",\"tenantTerm\":\"editor roles\",\"frontiersDefaultTerm\":\"Editor Roles\",\"category\":\"Label\"},{\"sequenceNumber\":265,\"key\":\"editorial_role\",\"tenantTerm\":\"editorial role\",\"frontiersDefaultTerm\":\"Editorial Role\",\"category\":\"Label\"},{\"sequenceNumber\":266,\"key\":\"editorial_roles\",\"tenantTerm\":\"editorial roles\",\"frontiersDefaultTerm\":\"Editorial Roles\",\"category\":\"Label\"},{\"sequenceNumber\":267,\"key\":\"call_for_paper\",\"tenantTerm\":\"Call for paper\",\"frontiersDefaultTerm\":\"Call for paper\",\"category\":\"Label\"},{\"sequenceNumber\":268,\"key\":\"research_topic_abstract\",\"tenantTerm\":\"manuscript summary\",\"frontiersDefaultTerm\":\"manuscript summary\",\"category\":\"Process\"},{\"sequenceNumber\":269,\"key\":\"research_topic_abstracts\",\"tenantTerm\":\"manuscript summaries\",\"frontiersDefaultTerm\":\"manuscript summaries\",\"category\":\"Process\"},{\"sequenceNumber\":270,\"key\":\"submissions_team_manager\",\"tenantTerm\":\"Journal Manager\",\"frontiersDefaultTerm\":\"Content Manager\",\"category\":\"Process\"},{\"sequenceNumber\":271,\"key\":\"submissions_team\",\"tenantTerm\":\"Journal Team\",\"frontiersDefaultTerm\":\"Content Team\",\"category\":\"Process\"},{\"sequenceNumber\":272,\"key\":\"topic_coordinator\",\"tenantTerm\":\"topic coordinator\",\"frontiersDefaultTerm\":\"topic coordinator\",\"category\":\"Process\"},{\"sequenceNumber\":273,\"key\":\"topic_coordinators\",\"tenantTerm\":\"topic coordinators\",\"frontiersDefaultTerm\":\"topic coordinators\",\"category\":\"Process\"},{\"sequenceNumber\":274,\"key\":\"frontiers_journal_team\",\"tenantTerm\":\"frontiers journal team\",\"frontiersDefaultTerm\":\"frontiers journal team\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":275,\"key\":\"research_topic_ic_submission\",\"tenantTerm\":\"RT:IC Submission\",\"frontiersDefaultTerm\":\"RT:IC Submission\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":276,\"key\":\"research_topic_ic_submission_participant\",\"tenantTerm\":\"RT:IC Submission participant\",\"frontiersDefaultTerm\":\"RT:IC Submission participant\",\"category\":\"Label (Role)\"}]}'\n",impactGtmId:"GTM-NJF2ML9B",impactGtmAuth:"fYo-7NoDm9w37QgFMs03SA",impactGtmPreview:"env-1",impactGoogleMapsApiKey:"AIzaSyCTEhX2EU8PWfi86GW9FI00FTcyKk6Ifr8",qualtricsV4ToV3:"'{\"enabled\":true,\"interceptId\":\"SI_er0E2ze69Oz8Yn4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsUmux:"'{\"enabled\":false,\"interceptId\":\"SI_89fPHY3eTxQBwtU\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsContinuousBrand:"'{\"enabled\":true,\"interceptId\":\"SI_9ZuT94UT81FcRh4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",defaultArticleTemplate:"v3"},app:{baseURL:"/",buildId:"ed555f16-85f7-4f41-8f2f-451827c59120",buildAssetsDir:"ap-2024/_nuxt",cdnURL:""}}</script>
<script src="https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6" type="text/javascript" async></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML" type="text/javascript" async></script>
<script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js" type="text/javascript" async></script>
<script src="https://api.altmetric.com/v1/doi/10.3389/fneur.2024.1465747?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15" type="text/javascript" async></script>
<script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript" async></script></body></html>